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1 TRANSPLANTATION GENERAL   
The act of transplantation provides the opportunity to replace a failing organ or tis-
sue that may result in normal health. In the last 50 years transplantation has 
moved from an experimental concept, fueled by Alexiss Carrel’s (1912) Nobel Prize-
winning description of anastomic technique and experimental organ transplantation, 
to a clinical routine in the treatment of an array of diseases.  
Recognition of the immunological origin of transplantation rejection and the discov-
ery of pharmaceuticals that prevent these immunological mechanisms contributed in 
a large part to current success in transplantation medicine. The immunological ori-
gin of transplantation was established by two major discoveries; the characteriza-
tion of the Major Histocompatibility antigens (MHC) and the description of immu-
nological effector mechanisms. In 1936, Gorer described blood group antigens in 
mice 1, which appeared to be involved in the rejection of allogeneic tumor grafts 2. 
In the 1940’s Medawar and Gibson, reported that rejection of a human skin trans-
plants in burned patients is based on immunologic factors 3, and later demonstrated 
that rejection is a systemic process governed by lymphocytes. Medawar continued 
CHAPTER 1
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studying the grafting process in rabbits and hypothetically ascribed this process to 
the antigens found by Gorer 4. The latter appeared to be the fact, the existence of 
murine Major Histocompatibility antigens (MHC) was established in 1948 based on 
the work of Gorer and Snell 5. Human MHC, the Human Leucocyte antigens (HLA) 
were identified in the 1950s by Dauset, Paine en van Rood 6-8. The natural function 
of MHC, next to being implicated as transplantation antigens, remained unknown 
until the 1960s when investigations by McDevitt and colleagues revealed that he 
products encoded by the MHC regulate immune responsiveness to foreign antigens 
by T and B cells 9,10.  
It was not until the discovery of the fungal metabolite cyclosporine and its clinical 
application in 1970s that the modern era of transplantation was launched 11,12. The 
availability of immunosuppressive drugs has enabled the transplantation of cells 
and organs to become a rapidly evolving therapeutic modality. However, patients 
have to comply and need to administer these drugs life-long, and they are at risk to 
develop harmful side effects such as cancer, vulnerability to infections and many 
other adverse effects. Given too much immunosuppression, the patient is at risk of 
infection or malignancy. Given too little, the patient may reject the graft. Hence, 
there are many and varied problems and potential solutions in transplant immuno-
biology. Understanding the immune response to an allograft and how to control it 
remain works in progress, despite the clear success of clinical transplantation cur-
rently being performed in hundreds of centers worldwide. 
The transplantation discipline would profit if one could exploit tolerance mecha-
nisms normally used by the immune system for clinical therapy, reducing the need 
for these drugs.  
Hence it is not surprising that the major focus of current research in transplantation 
is the development of strategies to induce specific immunological tolerance to the 
transplanted organ or tissue, and to eliminate the need for life long non-specific 
immunosuppression. The immunological mechanisms responsible for transplantation 
tolerance are varied and still only partially understood.  Exploring these mechanism 
and translation to experimental protocols might provide clues leading to clinical 
transplantation tolerance. 
 
1.1 TRANSPLANTATION IMMUNOBIOLOGY 
1.1.1 Alloreactive CD4+ T cells play a central role in transplantation 
immunobiology 
Graft rejection is the consequence of multiple immune effector pathways that in-
clude CD4+ and CD8+ T cells, macrophages and alloantibodies 13,14. T cells are the 
principal mediators of transplant immunity 15-17, especially CD4+ T cells fulfill a 
dominant role in the coordination of allograft rejection 18-20 (Figure 1). Recognition 
of allogeneic MHC class-II molecules by the T cell receptor present on CD4+ T cells 
results in activation and subsequent production of cytokines that are necessary to 
initiate allograft immunity. These cytokines act in an autocrine manner on the CD4+ 
GENERAL  INTRODUCTION 
 
 
11 
T cells themselves and in a paracrine way on other cells, such as CD8+ T cells, 
macrophages, and B cells. Activation of CD8+ T cells by MHC class I molecules pre-
sent on the donor cells results in cytolysis of the donor cells. However, to perform 
their function properly the CD8+ T cells need help from the CD4+ T cells via cyto-
kines and cell-to-cell interactions mediated via the CD40L-CD40 costimulatory 
pathway 21-23. 
F I G U R E  1  
Central role for CD4+ T cells in the recognition of allogeneic MHC- molecules and 
provoking allograft rejection 
Graft rejection is often initiated by recipient 
CD4+ T cells that recognize donor MHC 
(+peptide). These T cells become activated, 
proliferate and differentiate to effector cells 
that provide help in the activation of other T 
cell and B cell subsets and macrophages. 
Some of the cells will differentiate into 
memory cells, providing a backup for rapid 
recall responses. Under normal conditions 
the immune responses are terminated by the 
induction of apoptosis and/or immunoregula-
tion for example by regulatory immunosup-
pressive T cells (See text). 
Allogeneic
‘donor’ APC
Recipient
CD4+ T cell
Activated
CD4+ T cell
Macrophages
Cytokines
Delayed-type hypersensitivity
Effector CD4+ T cells
B cell
Allo antibodies Cytokines
Cell-cell interactions
CD4+ or CD8+
Memory T cells
CD8+T cells
MHC
TCR
Costimulation
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Activated macrophages and CD4+ T cells contribute to graft rejection by a delayed-
type hypersensitivity response involving soluble mediators like cytokines such as 
TNFα and reactive oxygen intermediates. This response is sufficient to cause graft 
loss even in the absence of CD8 T cells 18. B-cells do not directly participate in 
acute rejection when the recipient has not been exposed to the alloantigens in 
question. However, alloantibodies sensitization by a previous blood transfusion or 
transplantation might cause hyper-acute and accelerated graft rejection 24. The risk 
of hyper-acute rejections is minimized due to antigen typing procedures by the tis-
sue typing laboratory that precede clinical organ transplantation. Delayed-type hy-
persensitivity reactions, the generation of alloantibodies and memory T cells may 
have a role in the process of chronic rejection 24 
 
1.1.2 Costimulation 
Roughly 5-10% of the peripheral T cells react to foreign MHC molecules 25. These 
so-called alloreactive T cells are key orchestrators of the immune response against 
transplanted tissues. The T cell receptor of these alloreactive T cells recognizes in-
tact MHC molecules on donor antigen presenting cells (APC) directly, or indirectly 
via processing and presentation of donor MHC on autologous APC 26-28(Figure 2). 
This first TCR-MHC triggering step is generally referred to as signal 1. To ensure 
complete activation of T cells a second positive costimulatory signal is required that 
is delivered by APC 29,30 (Figure 3). The costimulatory molecules CD28 and CD40L 
on the T cell are triggered by CD80/CD86 and CD40 on the APC, these surface 
molecules belong to the B7 and tumor necrosis factor receptor families respectively 
(Figure 4) 31. Upon adequate costimulation the T cell will subsequently receive auto 
or paracrine T cell growth factors (TCGF) and start to proliferate. Next, the cells are 
subject to a number of fates 14,32 (Figure 3), the first is differentiation to an effec-
tor cell, which coordinates the immune response against the target antigen. Some 
of the cells will differentiate into memory cell, creating an immune backup that will 
provide a rapid recall response upon antigenic restimulation. In order to maintain 
homeostasis the effector T cell response needs to be terminated either by negative 
regulation mediated via inhibitory receptors such as CTLA-4 33-35 or PD1 36, the in-
duction of T cell death 37,38 or by immunosuppressive regulatory T cells 39.  
In the early 1970s, Gershon and colleagues 40 were the first to recognize T cell 
regulation mediated by suppressor cells. A role for suppressor cells in transplanta-
tion was identified in 1975 41.  It is only since the last decade that the role of regu-
latory T cells in transplantation, as well as in autoimmunity, became firmly re-
established 42-46.  
Immunosuppressive regulatory T cells are the main subject described in this thesis, 
and they will be discussed in more detail in the latter part of this introduction.  
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1.1.3 Inhibition of alloreactive T cells to prevent graft rejection  
Given the central role of alloreactive T cells transplantation, they have been of par-
ticular interest to transplant immunobiologists and clinicians alike. Most of the im-
munosuppressive drugs that are currently used or under development target T cells 
47,48. The majority of successfully used immunosuppressive drugs act in the early 
phase of T cell activation. For example, cyclosporine A (CsA) and FK506 each pre-
vent T cells from producing cytokines, such as IL-2, that are critical for T cell pro-
liferation 49. Rapamycin blocks signal transduction of the common γ chain receptor 
cytokine receptors like IL-2 50 also leading to the inhibition of T cell proliferation. In 
addition, rapamycin facilitates activation induced cell death resulting in reduction of 
the alloreactive T cell pool 38. Azathioprine and mycophenolate, both inhibitors of 
purine synthesis, also result in cell cycle arrest 51. Although the advent of these 
drugs led to considerable improvement in survival rates for both patients and 
grafts, at least two major problems are accompanied with their use. First, these 
immunosuppressive drugs act in a nonspecific way. Patients taking them have a 
substantial risk of opportunistic infections and cancer. Moreover numerous side ef-
fects not associated with their immunosuppressive actions, such as nephrotoxic ef-
fects of cyclosporine and tacrolimus, have been reported. Second, these drugs sup-
press the immune response to allografts and generally do not act to induce 
transplantation tolerance towards the graft. Therefore, patients have to continue to 
receive these drugs for life. 
F I G U R E  2   
Direct and indirect recognition of donor MHC  
Recipient alloreactive T cells recognize donor 
MHC antigens either directly by recognition 
of MHC+peptide on the donor APC or indi-
rectly after processing and presentation of 
donor MHC molecules on the recipients ‘self’’ 
APC
. 
Allogeneic APC Syngeneic (self) APC
Allo-MHC
TcR
Co-stimulation
Recipient CD4+ T cell Recipient CD4+ T cell
Auto-MHC
Allo peptide
Co-stimulation
Direct pathway Indirect pathway
TCR
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An immunological tolerant state is often associated with regulatory mechanisms 
that actively control immune responses against allografts 46,52. Currently used im-
munosuppressive drugs, while preventing acute rejection, may inadvertently result 
in the inhibition of regulatory mechanisms that are crucial in the maintenance of 
tolerance 38,46,53. Ongoing sub-clinical graft injury, occurring as result of the failure 
to induce tolerance, may ultimately lead to chronic rejection and graft loss 54.  Un-
derstanding tolerance mechanisms that are normally used by the immune system 
and development of tools or strategies that mimic these mechanisms might result in 
donor antigen-specific immunosuppression and accordingly a more judicious use, or 
the complete absence of, conventional immunosuppressive drugs 55. New immuno-
modulatory strategies that exploit normal tolerance mechanisms to self-antigens, 
such as the need for costimulatory signals in T cell activation 56, may permit the 
development of immunological transplantation tolerance 57,58.  
F I G U R E  3  
T cell costimulation is required for full activation of T cells  
Complete activation of T cells is a 3-step 
process. The triggering ‘signal-1’ is delivered 
by the interaction between the T cell recep-
tor (TcR) on the T cell and MHC+peptide on 
the antigen presenting cell (APC). Signal-2 is 
provided by costimulatory interactions 
(CD28-CD80/CD86 (B7) and/or 
CD40L(CD154)-CD40) between T cell and 
APC This results in full activation of the T 
cell. Signal-3 is the consequence of 
autocrine growth factors (e.g. IL-2 produc-
tion by the activated T cell). Resting APC 
express CD40, when activated T cells ex-
press CD40L and signal to CD40, the expres-
sion of CD80/CD86 on the APC is up regu-
lated and stimulation of CD28 will occur.
CD40
CD40L
MHC
TCR
CD80 / CD86
peptide
CD28
APC
T cell
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F I G U R E  4   
Costimulatory molecules and their ligands 
Many costimulatory molecules belong to the 
CD28:B7 and tumor necrosis factor : tumor 
necrosis factor receptor (TNF:TNFR) families 
and have either positive or inhibitory effects 
on signaling in T cells. [Adapted from D.M. Roth-
stein and M.H. Sayegh, Immunological Reviews 
2003;196]
 
1.2 TRANSPLANTATION TOLERANCE 
 
1.2.1 Tolerance general 
Immunologic tolerance may be defined as a state in which (a) the immune system 
does not mount a pathologic response against a specific antigen, (b) there is no re-
quirement for exogenous immunosuppression, and (c) responses to other antigens 
are maintained 59-61. 
A milestone in transplantation was the discovery of neonatal transplant tolerance, 
which has been credited to Owen who studied the inheritance of red blood cell anti-
gens in cattle. In 1945 he described that dizygotic bovine twins usually posses a 
mixture of their own blood cells and of their twin partner due to a fusion of their 
placenta during embryonic life 62. He recognized the exchange of hematopoietic 
cells during embryonic life. Such calves did not develop alloantibodies to their twin 
suggesting a state of immunological tolerance. In the same era Burnett recognized 
the importance of Owen’s findings and postulated that during embryonic develop-
ment a process of self-recognition takes place through which tolerance is acquired 
CD40
4-1BBL (CD137L)
OX-40L (CD134L)
CD70
CD40L (CD154)
4-1BB (CD137)
OX-40L (CD134)
CD27
CTLA4 (CD152)
CD28
ICOS
PD-1
CD80 / CD86
B7h (ICOS-L)
PD-L1 / PD-L2
CD80 / CD86
TNF-R Family
B7 Family
TNF Family
T cellAPC
CD28 Family
TCRMHC + Peptide
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by fetal exposure to non-self constituents 63. These observations ultimately resulted 
in the self-non-self hypothesis in immune development and the clonal selection the-
ory 64. Medawar and Billingham provided direct support for the concept of neona-
tally acquired transplantation tolerance by successful exchange of skin grafts be-
tween dizygotic twin calves 65. Subsequent experiments demonstrated that 
neonatally acquired donor specific tolerance could be achieved in mice by admini-
stration of allogeneic donor cells in utero or in the perinatal period 66. 
Dorscher and Roser were the first to report an active role for the immune system in 
the maintenance of neonatally transplantation tolerance by demonstrated that re-
circulating CD4+ suppressor T cells could adoptively transfer this tolerant state to a 
new host 67,68. Over the years, numerous strategies especially in rodents have 
claimed tolerance induction after graft survival of more than 100 days, with accep-
tance of second graft from the original donor and rejection of third party grafts, the 
latter being a critical measure of donor-specific hyporesponsiveness,(reviewed in 
60,61). It is hard to translate these criteria to the longevity of human transplants, 
although in a few rare cases immunological tolerance in human kidney transplanta-
tion has been accomplished 69. Most current clinical trials focus on the reduction of 
steroid and calcineurin inhibitor use to achieve tolerance 69. Accurate methods to 
detect a tolerant state in humans are required so that we are able to reveal its in-
duction as well as its possible breakdown 32,70.  
 
1.2.2 Mechanisms of transplantation tolerance  
Although the precise mechanisms involved in the induction and maintenance of 
transplantation tolerance are still incompletely understood, two major categories of 
tolerance are discerned, peripheral, and central tolerance 4. 
Central tolerance induction occurs in the thymus. Central tolerance to a solid organ 
allograft requires the long-lived presence of donor bone marrow derived cells in the 
thymus. This might be reached by bone marrow transplantation and myeloablative 
conditioning prior to organ transplantation. The success of this approach is based 
on the formation of mixed hematopoietic chimera with cell of all lineages from both 
donor and host. T cells that develop in the thymus under these circumstance results 
in a T cell repertoire lacking reactivity against donor antigens 58. A major obstacle 
for routine clinical implication of this kind of therapy in solid organ transplantation 
is the high morbidity risk of the conditioning regimen, which is required for bone 
marrow engraftment, and deletion of pre-existing alloreactive T cells. Successful 
reduced toxic conditioning regimens including costimulation blockade have been de-
scribed in rodents 57 and await further investigation in nonhuman primates and in 
clinical trails.  
Peripheral tolerance as opposed to central tolerance takes place upon antigen en-
counter in the peripheral compartments including lymph nodes and spleen. The in-
duction of peripheral tolerance is an actively regulated multi-step process employ-
ing several non-mutually exclusive and complementary mechanisms (as described 
GENERAL  INTRODUCTION 
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below) 46,59,61,71. Several immune interventions have been shown to induce periph-
eral tolerance in animal models 32,57,58,72.  Thus, to establish transplantation toler-
ance, alloreactive effector T cells need to be eliminated, inactivated, or converted 
to an immunosuppressive alloreactive T cell. Immunological mechanisms that are 
classically considered to be involved in central and/or peripheral tolerance induction 
are; deletion, anergy, immunoregulation, clonal exhaustion, and ignorance of al-
loreactive T cells. 
Deletion of donor-alloantigens might be achieved in the periphery or centrally in the 
thymus. Infusion of donor cells in a recipient who has been conditioned by non-
myeloablative irradiation or immunotherapy might result in access of donor cells 
into the thymus and trigger the deletion of maturing thymocytes 73. In the periph-
ery deletion of alloreactive T cell might be triggered under suboptimal stimulation, 
such as costimulation blockade 37 or by depleting mAb such as anti-CD3 74 and 
CAMPATH-1H 75 
T cell anergy is defined as the functional inactivation of alloreactive T cells upon 
restimulation with (allo)antigen 76. T cell anergy was first described in T cell clones 
by the work of Schwarz and Jenkins as consequence of disturbed costimulation 77 
which resulted in impaired signaling in T cells 76. T cell anergy has been observed 
both in vitro and in vivo transplantation models and is often linked to immunoregu-
latory capacity 78,79 Distinct levels of anergy might arise depending on the induction 
protocol or Treg subset studied 80.  
Immunoregulation is an active process where regulatory T cells (or perhaps net-
works of Treg) control the response of various populations of cells of the immune 
system. In transplantation distinct lymphocyte populations of both the innate and 
the adaptive were shown to regulate the immune responses against alloantigens 
43,45,81. Currently, in transplantation, autoimmunity, and allergy many attention fo-
cuses on the eminent role naturally occurring CD4+CD25+ regulatory T cells 43,46. 
Of all mechanisms that have been indicated to play a role in transplantation toler-
ance, active regulation has emerged as being crucial for both induction and mainte-
nance of specific immunological unresponsiveness to donor alloantigens in vivo 46. 
Clonal exhaustion may occur as a result of chronic administration of alloantigens 
under suboptimal conditions. This will lead to functional inactivation (other than an-
ergy induction) or deletion of alloantigen reactive cells. Clonal exhaustion was ob-
served after liver transplantation, high doses of APC migrated from the liver to the 
draining lymph nodes and led to tolerance via clonal exhaustion 82. 
Ignorance is not likely to play a major role in organ transplantation, as it is unlikely 
that the immune system is not energized by the presence of antigens. Teleologi-
cally, ignorance might occur after transplantation of a completely MHC matched or-
gan, given that immune responses directed against minor antigens are lacking.  
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1.2.3 Costimulation blockade to induce transplantation tolerance 
The concept of B7-CD28 and CD40-CD40L costimulatory pathway blockade as a 
therapeutic target in the prevention of transplant rejection and eventually trans-
plantation tolerance was kindled by two findings. First, it was recognized that full T 
cell stimulation required specific stimulation through the TCR and additional 
costimulatory signals 83,84. Jenkins and Schwartz showed that lack of costimulation, 
which appeared to be mediated via CD28 on the T cell and B7 molecules 
(CD80/CD86) on the APC 30, led to T cell nonresponsiveness in vitro and in vivo 85. 
The nonresponsive state of the T cells could be rescued by antigens specific TCR 
stimulation in the presence of exogenous IL-2, this phenomenon was referred tot as 
T cell anergy 76,86. Anergy might be viewed as tolerance on a single cell level in vi-
tro 56. Second, stimulation of CD40 on the APC results in up regulation of CD80 and 
CD86 costimulatory molecules 87 and evoked a strong proliferative response of al-
logeneic T cells 88. CD40 interacts with CD40L (CD154) on activated T cells 87. Inhi-
bition of this costimulatory pathway in MLC reduces the proliferative response to 
some degree  
Blockade of the costimulatory pathways CD80/CD86–CD28 and/or CD40–CD40 by 
mAb directed against these molecule or CTLA4-Ig, a fusion protein which prevents 
binding of CD28 to CD80 and CD86, indeed provided an attractive target for immu-
nosuppressive therapy and appeared very effective in prolonging organ and tissue 
allograft survival in various animal including rodents and non human primates 54,57. 
Interference in costimulation pathways might results in various tolerance inducing 
mechanisms, such as immunoregulation, anergy and deletion. Clearly, the net im-
mune response obtained by therapeutic intervention, such as costimulation block-
ade depends on a delicate balance between effector and immunoregulatory T cells, 
and this will determine either tolerance of rejection to occur 39,61,89. 
In the absence of “danger signals”, APC remain quiescent and lack expression of 
sufficient costimulatory ligands, and hence will not activate effector T cells. Conse-
quenctly the allograft will be unaffected in a sense reminiscent to ignorance 90. This 
kind of a situation is hard to envisage in case of transplantation, the surgical 
trauma will provide a myriad of danger signals that sensitize the APC, lead to up-
regulation of costimulatory molecules, which results in costimulation (signal 2) and 
hence in activation of alloreactive T cells. Thus, it is important to prevent danger 
signals by reducing the surgical transplantation trauma and/or inhibition of the con-
sequent inflammatory response. A second line of defense against danger induced 
sensitization of APC is the blockade of costimulatory molecules such that alloreac-
tive T cells are incompletely activated which might result in immunoregulation, T 
cell anergy or deletion of alloreactive T cells 57.  
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2 REGULATORY T CELLS  IN  TRANSPLANTATION TOLERANCE 
 
2.1 REGULATORY “SUPPRESSOR” T CELLS 
Immunosuppressive regulatory T cells (Treg) are of crucial importance in the induc-
tion and maintenance of transplantation tolerance. In 1971, Gershon and Kondo 91 
were the first to recognize the importance of suppressor T cells. The first evidence 
for immunosuppressive Treg in allo-responses was obtained in the mid 1970s 
41,67,68. In 1985 Hall demonstrated specific suppressor cells in rat allograft recipi-
ents that were treated with cyclosporine 92, five years thereafter the suppressor 
cells were characterized as CD4+ T cells 93. Since then, CD4+ suppressive regula-
tory T cells were demonstrated in a wide range of models of transplantation toler-
ance, induced by a variety of tolerance induction protocols, across both minor and 
major MHC barriers 52,94-96. Currently, there is emerging consensus in both humans 
and animal models that immunoregulatory activity for donor antigens is enriched in 
the CD4+ T cell population 43,46. However immunoregulation in transplantation is by 
no means exclusively restricted to CD4+ T cells, also CD8+ 97,98, CD8+CD28- 99, 
NKT cells 100-102 CD4-CD8- double negative T cells 103. In fact, it might very well be 
that regulatory mechanisms of both the innate and adaptive systems will contribute 
to the overall outcome of transplantation 46. This thesis focuses on CD4+ regulatory 
T cells. 
 
Induced CD4+ Treg and naturally occurring CD4+CD25+ Treg 
CD4+ regulatory T cells might be divided into two classes, the naturally in vivo oc-
curring Treg, and the in vitro and in vivo induced or adapted Treg 44,104. In addition 
there is accumulating evidence that naturally occurring CD4+CD25+ Treg contribute 
to the generation of induced Treg, which might be indicative for the existence of 
regulatory T cell networks such as already proposed in the early 1980s by Gershon 
105. Mouse CD25+CD4+ naturally occurring immunoregulatory T cells facilitate the 
induction of T cell anergy 106 and are necessary to induce Treg via costimulatory 
blockade in mice and humans (107 and this thesis). Apparently, naturally occurring 
CD4+CD25+ cells facilitate a proper environment resulting in the generation of an-
ergic regulatory CD4+ T cells. 
 
2.2 INDUCED REGULATORY “SUPPRESSOR” T CELLS 
Induced Treg subsets reveal heterogeneity at multiple levels. 
The family of induced CD4+ Treg subsets is ever growing. The various described 
CD4+ induced Treg subsets are heterogeneous with respect to the mechanism of 
suppression, cytokine production profile, growth characteristics, expression of in-
tracellular or surface markers and the way they are induced. As many aspects of 
Treg biology were clarified in autoimmune models the following Treg subsets are 
not necessarily implicated in transplantation but might be more specifically associ-
ated with autoimmunity. 
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Th3 cells, Treg induced in vivo following oral induction of tolerance 
Th3 cells are CD4+ T cells that are characteristically generated following oral ad-
ministration of myelin basic protein (as antigen) to mice, so-called oral induction of 
tolerance 108. Th3 characteristically produce TGFβ with various amounts of IL-4 and 
IL-10 108,109. Whether Th3 cells are unresponsive to TCR- triggering is not reported  
110. Th3 cells suppress autoimmune disease in vivo 109 and proliferated upon anti-
gen-specific stimulation in vitro 109. Anti-TGFβ antibodies abrogated the suppressive 
effect 108. Human Th3 cells were identified following oral myelin administration in 
clinical trails of multiple sclerosis patients 109. Addition of TGFβ to cultures of mur-
ine T cell precursors promotes the induction of Th3 cells, expansion of Th3 cells is 
enhanced by IL-4 and IL-10 111. 
 
Tr1 cells, Treg induced by culture in the presence of IL-10 
Tr1 cells were generated in vitro by culturing mouse or human CD4+ T cells in the 
presence of antigen and IL-10, these Tr1 cells predominantly secrete IL-10, have 
low proliferative potential which suppress antigen-specific T cell responses in vitro 
and autoimmune disease in vivo 112. The suppressive effects of Tr1 cells was re-
versed by the addition of anti-IL-10 mAb 112,113 which indicates a predominant role 
for IL-10 in the suppression by Tr1.  Combined in vitro administration of IFNα and 
IL-10 acted synergistically in facilitating the generation of human Tr1 cells 114. Su-
pernatants of activated Tr1 cells reduce the stimulatory potential of DC to induce T 
cell proliferation 113. In addition, stimulation of resting human CD4+ T cells with 
mAb directed against CD3 and CD46 also resulted in Treg with a Tr1 phenotype 115 
 
Treg induced by culture in the presence of TGFβ 
Stimulation of naïve CD45RA+ CD45RO- CD4+ T cells with alloantigen in the pres-
ence of TGFβ resulted in regulatory T cells that suppressed the proliferation of 
CD8+ T cells to alloantigens as well as the induction of alloreactive cytotoxic CD8+ 
T cells 116. Even after expansion these TGFβ generated Treg retained their function. 
 
Treg induced by immature DC 
Treg were induced by repetitive stimulation of naïve cord-blood derived T cells by 
allogeneic immature dendritic cells (DC) in vitro 117,118. These Treg showed cell-
contact dependent suppression primarily produced IL-10 and poor growth potential. 
These cells are different from Tr1 cells in that they do not require IL-10 for their 
generation, immature DC do not produce IL-10.  
In vivo, treatment with an active form of vitamin D3 and the immunosuppressive 
agent mycophenolate mofetil (MMF) resulted in Treg and subsequent transplanta-
tion tolerance 119. In the tolerant mice high numbers of CD25+CD4+ Treg were de-
tected in the spleen and lymph nodes, transfer of these cells to naïve mice resulted 
in transfer of tolerance. Treatment with vitamin D3 and MMF impairs the maturation 
and function of DC 120. Immature DC lack high levels of costimulatory molecules 121, 
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this might be one of the prime reasons for the generation of Treg by these cells. In 
addition, pulmonary DC induce IL-10 producing Treg via a process that required 
ICOS-ICOS ligand interactions, these Treg suppressed allergen-induced airway hy-
per reactivity in mice in an antigen-specific way 122.  
Depending on the maturation state and microenvironment DC were shown to induce 
several types of Treg and tolerogeneic DC are of particular interest of therapy in 
preventing allograft rejection 81,118,123. 
 
Treg induced by the lack of costimulation 
Costimulation via the costimulatory ligands CD86/CD80 and CD40 is essential for 
full activation of T cells. Lack of costimulation via CD28-CD86/CD80 and 
CD40L(CD154)-CD40 has been shown to induce human anergic immunoregulatory 
CD4+ T cells (this thesis).  Activation of suppression by these Treg was induced in 
an antigen-specific way 79. Treg induced by costimulation blockade do not necessar-
ily produce IL-10 79,124. The CD4+ regulatory cells generated by costimulation 
blockade appeared not related to Th3 or Tr1 cells. In vivo costimulation blockade 
resulted in immunosuppressive regulatory T cells and transplantation tolerance 125. 
 
2.3 NATURALLY  OCCURRING TREG 
Naturally occurring CD4+CD25+ Treg were first identified in mice by Sakaguchi and 
co-workers in the 1990s 126,127. The suppressive capacity was demonstrated by the 
occurrence of spontaneous induction of autoimmunity in mice that were thymec-
tomized at day 3 of life or following inoculation with CD4+ T cells that were de-
pleted of CD25+ T cells 127. 
Subsequently, human naturally occurring Treg were identified in peripheral blood 
128-130, thymus 131, tonsils, spleens 132 and cord blood 130. In human peripheral 
blood, CD4+CD25+ naturally occurring Treg comprise 5-10% of CD4+ T cells 128-130, 
and like their murine counterpart, they are anergic and suppressed other T cells 
when stimulated via the T cell receptor (TcR) 128-130,133. The human CD4+CD25+ 
Treg population displays a polyclonal TCR-Vβ repertoire 134,135 suggesting that a 
broad variety of antigens might be recognized. 
 
2.3.1 Thymic and peripheral generation of CD4+CD25+ Treg 
CD4+CD25+ Treg undergo positive selection within the thymus and appear to enter 
the periphery as committed regulatory T cell 136-138. This thymic development of 
CD4+CD25+ Treg requires high affinity interactions between the TCR and MHC-
peptide complex 136,138-140, and this interaction might result in deletion by negative 
selection of highly auto reactive T cells 139,141. The presence of thymic CD4+CD25+ 
regulatory T cells (~10%) was also demonstrated in humans 131.  
CD4+CD25+ Treg might also be generated in the periphery from CD4+CD25- pre-
cursors. Evidence for peripheral generation of CD4+CD25+ Treg came from studies 
C H A P T E R  1  
 
 
22
that demonstrated the generation of CD4+CD25+ regulatory T cells from 
CD4+CD25- T cells in both autoimmune and alloantigen models 127,142. 
 
2.3.2 Phenotype of naturally occurring CD4+CD25+ Treg  
Freshly isolated human naturally occurring CD4+CD25+ Treg show intracellular 
CTLA-4 expression and surface expression of CD45RO, CD27 CD62L, CD122 
(128,129,143 and this thesis). The integrin members α4β1 and α4β7 are differentially 
expressed on human naturally occurring CD4+CD25+ and might sub classify human 
CD4+CD25+ Treg  104,144. However, the majority of the markers mentioned above 
are not selective for CD4+CD25+ naturally occurring CD4+CD25+ Treg as they 
might also be expressed on resting or activated effector T cells. Recently, the tran-
scription factor FOXP3, has been described to be selectively expressed in mouse 
and human resting CD4+CD25+ Treg 145-147. In addition, CD4+CD25+ Treg in mice 
were shown to selectively express the TNF family member GITR 148,149, CD134 149 
and Toll-like receptors 150. Unique subsets of mouse CD4+CD25+ Treg with high 
suppressive potential were identified by the expression of the integrin family mem-
ber αEβ7 151,152. Of note, no unique surface marker is known for Treg, the best way 
to characterize these cells is by demonstrating their dose-dependent effector-
suppressor function. 
 
2.3.3 The transcription factor FOXP3 and CD4+CD25+ Treg 
The transcription factor FOXP3 plays a crucial role in the function and development 
of CD4+CD25+ Treg in the thymus and periphery in mice 145,146,153. Also in resting 
human CD4+CD25+ Treg FOXP3 was selectively expressed 147. FOXP3 appears to be 
a master switch in the development of regulatory CD4+CD25+ T cells 145, which 
perhaps functions in a similar manner as the signaling and transcription factors 
STAT4 and T-bet or STAT6 and GATA in the development of Th1 and Th2 T cell sub-
sets, respectively 154,155.  
FOXP3 was characterized as result of studies in scurfy mice; CD4+ T cells isolated 
from these animals were hyper-responsive to stimulation and upon adoptive trans-
fer of these cells to nu/nu or SCID mice they induced a wasting disease 156. These 
findings were reminiscent of autoimmune and inflammatory symptoms such as in-
duced in mice by the removal of naturally occurring CD4+CD25+ Treg. Similar ob-
servations were made in the human recessive disease IPEX (immune dysregulation 
polyendocrinopathy enteropathy X-linked) 157,158.  The genetic defects of patients 
with IPEX and scurfy mice occurred in common conserved gene, FOXP3, which en-
codes a member of the forkhead/winged helix family of transcriptional repressors, 
known as scurfin 159. 
It remains to be studied how suppression by the FOXP3 encoded product exerts its 
suppressive effect. Recently it was shown that inhibition of conventional mouse T 
cells by CD4+CD25+ Treg was paralleled by an increase expression of FOXP3 in the 
suppressed T cell 160. Also, in human Treg induced by naturally occurring 
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CD4+CD25+ Treg the expression of FOXP3 was detected 161. Thus, induced subsets 
of Treg might very well be the result of FOXP3 induction into effector CD4+CD25- T 
cells such as was shown upon retroviral transfer of FOXP3 to CD4+CD25- T cells 
which as a consequence converted into suppressive regulatory T cells 145.  
 
2.3.4 Subpopulations in CD4+CD25+ naturally occurring Treg 
Information on sub populations in naturally occurring CD4+CD25+ Treg is still lim-
ited. Within naturally occurring CD4+CD25+ Treg in mice, subpopulations were iso-
lated that expressed the αEβ7 integrin (CD103) that were preferentially able to con-
trol inflammatory bowel disease 151,152 CD103 mediates adhesion to epithelial cell 
through its binding to E-cadherin which is selectively expressed on epithelial cells 
162. CD103+CD4+CD25+ are preferentially located in gut-associated lymph nodes 
and concentrated the capacity to control wasting disease and effector T cell expan-
sion 152 The CD103+ subset, as compared to the CD103- Treg subset, showed an 
increased suppressive potential both in vitro and in the prevention of intestinal pa-
thology induced by cytopathic effector T cells 151. Suppression appeared contact de-
pendent and independent of TGFβ or IL-10 151,152.  
In this thesis we describe heterogeneity within human naturally occurring 
CD4+CD25+Treg that is marked by the expression of CD27. Ex vivo stimulation of 
freshly isolated naturally occurring CD4+CD25+ Treg with alloantigen and TCGF re-
vealed the presence of two functionally and phenotypically distinct immunosuppres-
sive subtypes. We believe its is crucial to recognize the heterogeneity within the 
naturally occurring CD4+CD25+ Treg population as it enables the ex vivo genera-
tion and selection of antigen-specific-Treg subsets with a particular function to be 
used for adoptive Treg therapy. A detailed description follows in chapter 7.  
In addition, recently it has been proposed that differential expression of the in-
tegrin members α4β1 and α4β7 might also sub classify human CD4+CD25+ Treg 104. 
These α4β1 and α4β7 family members are homing receptor of cellular migration of T 
cells to inflamed tissues and non-pulmonary mucosal sites, respectively 163. 
CD4+CD25+α4β1+ Treg were proposed to induce TGFβ producing Th3 like cells, 
whereas α4β7 expressing CD4+CD25+ induced IL-10 producing Tr1 cells. Upon ex-
trapolating these observations to an in vivo situation, distinct subsets of human 
CD4+CD25+ Treg might be predestined to migrate to a particular site that is de-
termined by the expression of integrins on the Treg and its matching tissue ligand. 
Upon TCR activation the CD4+CD25+ Treg will suppress auto reactive T cell re-
sponse in a cell-cell dependent manner and promote the generation of Tr1 or Th3, 
which might help to sustain the suppressive effect 104. 
 
2.3.5 Interrelationship between naturally occurring and induced Treg 
Mouse CD4+CD25+ naturally occurring immunoregulatory T cells facilitate the in-
duction of T cell anergy 106 and are necessary to induce a tolerant state via 
costimulatory blockade in mice and humans 107,164. Depletion of naturally occurring 
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CD4+CD25+ T cells prior to the induction of regulatory anergic T cells by costimula-
tion blockade, prevented the generation of suppressive CD4+ Treg. Human natu-
rally occurring CD4+CD25+ Treg were a prerequisite in the generation of new Treg 
cells from CD4+CD25- T cells 161. TGFβ appeared a crucial player in this process 
161,165. TGFβ resulted in a Treg phenotype by inducing FOXP3 expression in 
CD4+CD25- T cells 161,165. Of interest, experiments in tolerant transplant recipients 
suggest de novo induction of FOXP3 expressing Treg within the graft that was me-
diated via a TGFβ dependent mechanism 166.  
Human naturally occurring CD4+CD25+ Treg induced suppressor capacity in 
CD4+CD25- T cells via cell-cell contact 167,168. Suppression by these induced Treg 
appeared cell-cell contact independent. Of interest, naturally occurring CD4+CD25+ 
Treg were reported to induce either TGFβ producing suppressive Treg 168 or IL-10 
producing suppressor Treg 167, and thus resulted in Treg that are similar to Tr1 and 
Th3 cells respectively. This discrepancy might be explained by the recent descrip-
tion of two distinct α4-integrin family members expressing subsets within the natu-
rally occurring CD4+CD25+ Treg pool; α4β7+ expressing CD4+CD25+ Treg induce 
IL-10 producing Tr1 like Treg, whereas α4β1+ producing CD4+CD25+ Treg led to the 
generation of TGFβ producing Th3 like cells 145. These observations might partially 
explain the inconsistency on the role of IL-10 and TGFβ. 
 
2.4 MECHANISM OF  SUPPRESSION BY TREG 
Naturally occurring human CD4+CD25+ were shown to suppress the proliferative 
capacity of naïve CD4+ and CD8+ T cells, and the induction of cytotoxic T cells in 
vitro 116,128,129. Cell contact between the Treg and the effector cells was required to 
activate suppression 128,128-130,143,169. Figure 5 summarizes the suppressive mecha-
nisms by Treg. Once suppression by the CD4+CD25+ naturally occurring Treg is ac-
tivated, both T cells with the same antigen-specificity and other antigen-specificity 
were suppressed 169, a phenomenon known as “bystander suppression”. It is likely 
that the cell-cell interaction is occurring directly between the Treg and the effector 
T cell, as suppression was also demonstrated in APC free culture systems using mAb 
against CD3 and /or CD28 for stimulation 106,170. On the other hand, in vitro it was 
demonstrated that CD4+CD25+ Treg suppressed the function of APC by down-
regulation of costimulatory molecules 171. In this way tolerogeneic DC might be ca-
pable of inducing new regulatory T cells in naïve CD4+ T cells and thus perpetuate 
the tolerogeneic state. 
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F I G U R E  5  
Effector mechanisms of regulatory T cells. 
Regulatory T cells mediate their immunosup-
pressive effect either by directly targeting 
effector T cells, or indirectly by decommis-
sioning the APC function (see text). Also 
mechanisms that protect effector T cells 
from suppression by Treg have been re-
ported (see text). 
 
2.4.1 Interactions via membrane bound molecules 
There are several indications that membrane bound cell-cell interactions are impor-
tant for Treg mediated suppression. Possible candidates are CTLA-4 and membrane 
bound TGFβ 116,172-174. CTLA-4 was found in the majority of naturally occurring Treg 
in mice 172,173 and humans 128,129,175, however only in a few studies a role for CTLA-
4 in suppression was demonstrated in vitro 173,176 or in vivo 174,177. 
Membrane-bound TGFβ, was first demonstrated in mice Treg; there it appeared im-
portant in the suppression of effector cells 116. Also on human CD4+CD25+ Treg 
surface bound TGFβ was found, but it did not correlate with a suppressor function 
168. Other investigators were unable to provide evidence for surface bound TGFβ on 
alloantigen-specific CD4+CD25+ Treg that were induced in vivo by donor specific 
transfusion under the cover of anti-CD4 mAb therapy 45,174. 
CD30-CD30 ligand interaction appeared critical in CD4+CD25+ Treg mediated sup-
pression of allograft rejection induced by memory CD8+ T cells in mice 178. 
 
Regulatory T cell
Effector T cellAPC
Indirect effects on APC
Costimulatory molecules ↓
MHC class-II expression ↓
Inhibitory receptors ↑
Inflammatory cytokines ↓
IL-10 production ↑
Conversion into tolerogeneic APC
Direct effects on Teff
IL-2 mRNA ↓
Proliferation↓
Cytokine production↓
Induction of cell death
Conversion to anergic Treg
Induction of FOXP3
Cell-Cell contact
or 
Soluble mediators
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2.4. Immuno suppressive cytokines 
Cytokines most associated with Treg suppressor function are TGFβ and IL-10.  
IL-10 appeared to be required in the induction 174 and maintenance 179 phase of 
transplantation tolerance mediated by Treg in a mouse model. Blockade of IL-10 
abrogated suppression of allograft rejection by Treg. A critical role for TGFβ in car-
diac allograft tolerance was observed in a rat model 180. TGFβ expression levels 
were increased in tolerant rats, and treatment with anti-TGFβ mAb led to graft re-
jection. 
In vitro studies examining the role of IL-10 or TGFβ are less persuasive. There are 
several lines of in vitro evidence showing that mouse and human CD4+CD25+ Treg 
produce IL-10 or TGFβ following stimulation 129,175, although others were unable 
demonstrate this 181. Some, but far from all 130,131,133,175,181, studies indicated a role 
for IL-10 and TGFβ 108,110,112,174 as the mechanism of immunosuppression. Thus the 
role for these cytokines as a mechanism remains controversial. 
In vitro, IL-2 consumption by Treg at the expense of IL-2 availability for effector T 
cells has been proposed as a mechanism of suppression 129,130,182. However, the fact 
that CD4+ Treg remained suppressive in the presence of full-blown recall T cell re-
sponses (i.e. cytokine production of IL-2, IFNγ and TNFα, and proliferation) indi-
cates that cytokine deprivation is not a major mechanism of suppression 164.  
 
2.4.3 Indirect suppression by regulating APC function 
Treg were shown to affect effector T cells indirectly by impediment of the APC func-
tion. 
In vitro mice studies indicated that Treg affected expression of costimulatory mole-
cules such as CD80 and CD86 on the APC 171. Anergic T cells functionally impaired 
the antigen presenting potential of rat APC 183. Anergic human T cells reduced both 
MHC and costimulatory molecule expression by immature DC 184. Human CD8-CD28- 
Treg render DC tolerogenic by up regulation of the inhibitory receptors immu-
noglobulin-like transcripts (ILT) ILT3 and ILT4 185. Moreover, the presence of CD8-
CD28- correlated with the absence acute rejections in cardiac transplant patients 
186. 
 
2.4.4 The outcome Treg suppression on T effector cells 
It is well established that both in vitro and in vivo the function of suppressive Treg 
depends on their ability to inhibit the proliferation of effector T cell populations. 
Upon activation Treg were shown to inhibit IL-2 mRNA in effector T cells, conse-
quently IL-2 production and concomitant proliferation were inhibited 133,181. How-
ever, effector T cells that were inhibited by Treg showed overt signs of initial T cell 
activation, such as early activation antigen up-regulation, blast formation, and 
CD25 expression (164,169 and chapter 4). Taken together, this indicates that sup-
pression is not merely the result of effector T cells elimination but rather active 
control of effector T cell expansion. In fact, these cell cycle arrested effector T cells 
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might in turn be converted to a new a generation of regulatory T cells, such as was 
recently demonstrated in case of human T cells in vitro 117,167. In addition, it ap-
peared that conventional murine T cells that were suppressed by Treg showed an 
increased expression of the Treg associated transcription factor FOXP3 160. 
 
2.4.5 Contra suppression, inhibition of Treg suppressor function 
Role for Toll-like receptors on APC 
It is not precisely known how Treg activity is regulated to allow effective immune 
response against pathogens without evoking self-reactive T cell mediated autoim-
munity. A recent study indicates that upon microbial infection and consequent in-
flammation the suppressor activity of CD4+CD25+ naturally occurring Treg was ab-
rogated in order to enhance effector T cell responses 187.  It appeared that DC 
control the suppressor activity of CD4+CD25+ Treg via Toll-like receptor (TLR) 
pathogen recognition by the DC 187. Blockade of the Treg activity requires the pro-
duction of IL-6 by DC, although other unidentified TLR induced factors are needed 
in addition. These factors act on the responder effector T cell population making 
them refractory to suppression by Treg. These experiments clearly support an im-
portant role for the innate immune components (DC) in fine-tuning the adaptive 
immune system. Pathogen recognition by APC might not always be stimulatory as 
bacterial products were shown to suppress the immune response 188,189. 
  
GITR stimulation prevents immune suppression by Treg 
Glucocorticoid induced tumor necrosis factor receptor (GITR), family related gene 
TNFRSF18 a member of the TNFR family, is highly expressed by murine CD4+CD25+ 
Treg 148,149,190, and it was shown on human Tr1 clones 191. Stimulation of GITR by a 
GITR specific mAb or the natural ligand for GITR abrogated the suppression of poly-
clonal and antigen-specific isolated murine CD4+CD25+ Treg in vitro following 
stimulation with anti-CD3 mAb 148,149,192. In addition, in vivo treatment with the 
same mAb led to autoimmune gastritis 148. Activation of conventional CD4+ and 
CD8+ T cells in mice resulted in expression of GITR 193, and in vivo, GITR activation 
also stimulated effector T cell activation 46,149. From these data it is likely that at 
least in mice the function of GITR is not limited to the regulation of CD4+CD25+ 
Treg. On freshly isolated human CD4+CD25+ Treg we were unable to detect GITR 
expression, whereas after stimulation with antigen and T cell growth factors (TCGF) 
stimulation the expression of GITR was observed on both CD4+CD25+ Treg and 
CD4+CD25- effector T cells (Chapter 4). Although GITR expression was observed on 
human Tr1 clones, the activation of GITR did not lead to abrogation of suppression 
191. Hence, a specific role for GITR in the function of Treg is controversial. 
Another member of the TNFR superfamily OX40 opposed Treg-mediated suppres-
sion; mouse CD4+CD25- T cells became insensitive to Treg-mediated suppression 
when they were stimulated via OX40 194. 
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3 THE ROLE  OF  TREG IN  TRANSPLANTATION TOLERANCE 
 
3.1 MAINTENANCE OF  TRANSPLANTATION TOLERANCE 
Several diverse mechanisms contribute to the induction transplantation tolerance, 
such as discussed in the previous part. Once induced it is crucial to maintain the 
tolerant state. Although the conditions that enable the maintenance of transplanta-
tion tolerance are still under investigation, immunoregulatory mechanism like linked 
suppression and infectious tolerance contribute in a large part to maintenance of 
transplantation tolerance (Figure 6).  
  
3.1.1 Linked recognition an linked suppression, 
Exposure to a single donor alloantigen is sufficient to induce specific unresponsive-
ness to a fully allogeneic graft, which provides evidence for linked recognition 195. 
This linked unresponsiveness is a powerful mechanism in transplantation, which 
plays a role in perpetuating the specific unresponsiveness ones it has been initiated 
196. Linked unresponsiveness was shown in vivo after alloantigen administration 
alone or in combination with various induction therapies including costimulation 
blockade 96,197,198 as well and in vitro following induction of anergic Treg by 
costimulation blockade 79. It is likely that linked suppression is localized phenome-
non taking place in the draining lymph nodes or the transplanted tissue itself 199 
 
3.1.2 Infectious tolerance. 
Clearly, CD4+ Treg suppress naïve effector cells, but next to that, these suppressor 
cells have been shown to convert naïve effector T cells into a new generation of tol-
erant cells by a process known as infectious tolerance 52,91,167,168. Once infectious 
tolerance is initiated, it can operate over several new generations of naïve recipi-
ents, eventually leading to dominant suppressor Treg 52,94,200.     
When this kind of immunoregulation is dominant after transplantation, any new T 
cell that enters the repertoire after transplantation will be converted into a regula-
tory T cell, thereby spreading the tolerant state throughout the post transplantation 
period. For this kind of suppression to take place, the antigen should be presented 
in the neighborhood of a Treg such that the regulatory function is transferred by 
linked recognition of the donor antigen. This correlates with the finding that once 
CD4+CD25+ Treg are activated they will suppress other effector T cells responding 
to different antigens present on the APC. Infectious tolerance has been demon-
strated in vivo 52 and in vitro 167,168. Infectious tolerance has also been described 
after mAb blockade of the CD40l-CD40 costimulatory pathway in vivo 125. Infectious 
tolerance might offer the best explanation of how a graft may be maintained long 
term even with continuous emergence of alloreactive T cells from the thymus 43. 
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In addition, culture of Treg with DC progenitors resulted in tolerogeneic DC that in 
turn induced the expansion/generation of Treg 201. In this way a self-maintaining 
regulatory loop is induced that might control the maintenance of allograft tolerance. 
Notably, the continuous presence of donor graft antigens appeared a prerequisite in 
the maintenance of allograft tolerance 202, emphasizing the need of antigen in pe-
ripheral tolerance mechanisms.  
F I G U R E  6  
Maintenance of transplantation tolerance by linked recognition/suppression and in-
fectious tolerance 
Following the induction of transplantation 
tolerance, maintenance of the tolerant state 
by regulatory T cells is crucial. Antigen spe-
cific engagement of a regulatory T cell on an 
APC activates the suppressor potential in 
this cell. When an effector T cell recognizes 
antigen on the same APC (linked recognition) 
it will be suppressed by the suppressor T cell 
(linked suppression). This newly induced 
regulatory T cell might convey its regulatory 
state to another effector T cell (infectious 
tolerance) resulting in a self-perpetuating 
system that controls the maintenance of 
transplantation tolerance. The possible sup-
pressive mechanisms used are indicated in 
figure 5. [Adapted from H.Waldmann, Immunity 
2001;40]
 
3.2 BALANCE BETWEEN AGGRESSIVE  AND SUPPRESSIVE.  
The balance between aggressive and protective T cells, (i.e. the pool size model) is 
crucial in homeostasis of immunity and critically dictates the outcome the immune 
response 39,59,61 (Figure 7). Too many aggressive T cell might result in autoimmu-
nity, transplant rejection and allergy, too many regulatory T cells will dampen im-
mune response against tumors 203. In the case of tolerance to transplantation or 
auto antigens it is of eminent importance that regulatory cells with antigen-
specificity keep the allo or auto-aggressive T cells in control. Generally such a con-
dition might be reached by selectively reducing the pool size of aggressive T cells 
and/or by increasing the number of regulatory T cells, leading to dominant trans-
plantation tolerance 55. In case of the latter, infusion of ex vivo generated antigen-
specific suppressive regulatory T cells might be the ultimate choice of therapy Al-
ternatively an immunomodulatory approach, of combined administration of rapamy-
Effector T cell
Regulatory T cell
APC Effector T cell
Regulatory T cell
APC
Etc.
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cin and agonist IL-2- and antagonist IL-15-related cytolytic fusion proteins, that 
selectively targets activated aggressive T cells while preserving the immunoregula-
tory network is also of potential interest 89.  
In recent years, various animal studies have indicated that immunotherapy by ex 
vivo induced regulatory T cells or ex vivo manipulated naturally occurring immu-
noregulatory suppressive T cells might serve this goal 204-210. One of the practical 
hurdles for future therapy by human immunoregulatory T cells is the generation, 
selection and expansion of antigen-specific  immunosuppressive regulatory T cells 
while preserving their suppressive potential. 
F I G U R E  7  
The balance between the number of Treg and effector T cell is important in the out-
come of transplant survival. 
Therapeutic approaches aimed at inducing 
transplantation tolerance, should ideally shift 
the balance towards Treg. A balance shift 
might be reached by immunotherapy with 
ex-vivo generated donor specific Treg and / 
or by the inhibition of effector T cell expan-
sion, for example by costimulation blockade.
 
3.2.2 Alloantigen-specific Treg expansion 
For clinical Treg immunotherapy, it is likely that high numbers of cells will be 
needed. Importantly, it is currently recognized that Treg are particularly effective 
when they have specificity for their target antigen(s) 207,211-214. Hence, the avail-
ability of antigen-specific Treg is advantageous, as it not only appears highly effec-
tive, but also reduces the number of cells needed for immunotherapy. Peripheral 
blood contains limited numbers of naturally occurring CD4+CD25+ Treg that show 
broad antigen reactivity. Hence, for antigen-specific immunotherapy with 
CD4+CD25+ Treg, the induction, expansion, and selection of target antigen-specific 
Treg is necessary.  
Most Treg described are anergic in vitro, which implies that the cells are hypore-
sponsive upon TCR stimulation but are forced to proliferate if in addition exogenous 
Treg pool
T effector pool
Transplant
rejection
Transplant
tolerance
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IL-2 is added. Successful ex vivo expansion of human and mouse naturally occur-
ring CD4+CD25+ Treg and induced CD4+ Treg by TCR stimulation in the presence 
of T cell growth factors like IL-2, IL-7 and/or IL-15 has been achieved 
79,128,129,164,206,207,215(Chapters 2,4 and 7). These expanded cells retained their sup-
pressor function both in vitro 79,130,164,175,216 (Chapters 2,4 and 7) and in vivo 206-
208. Especially IL-15, alone or combined with IL-2, is of particular interest for stimu-
lating proliferation of ex vivo generated human donor-specific Treg (164 and chapter 
7).  Large-scale ex vivo expansion of human CD4+CD25+ Treg by stimulation with 
anti-CD3 and anti-CD28 mAb coated beads and high dose IL-2 (100 U/ml or more) 
has successfully been established 135,217. This polyclonal, non-antigen-specific, ex-
pansion increases the total number of Treg, but leaves the frequency of putative 
antigen-reactive Treg unaltered 135. We developed a CD27/CFSE based purification 
protocol an ex vivo protocol for induction, selection, and expansion of antigen-
specific Treg from ex vivo cultures conducted with freshly isolated CD4+CD25+ 
Treg (Chapter 7).  
Recently, alternative expansion approaches for naturally occurring CD4+CD25+ 
mice Treg were described that were not based on the addition of exogenous TCGF. 
For example, high numbers of dendritic cells, in contrast to macrophages and B 
cells, were able to drive proliferation of freshly isolated CD4+CD25+ naturally oc-
curring Treg 218. After several cell cycles the Treg cells still retained their suppres-
sor function. LPS stimulation of the Toll-like receptor TLR 4, which is specifically 
expressed in murine CD4+CD25+ Treg, resulted in enhanced survival and prolifera-
tion of CD4+CD25+ Treg and in addition it promoted their suppressive potential 150. 
Likewise enhanced survival of CD4+CD25+ Treg cells was demonstrated by TLR2 
agonists 219. In general, in vitro activation of Treg promotes the suppressor poten-
tial Treg 169,217. It is likely that LPS stimulation like CD3+CD28 stimulation will not 
results in enrichment of antigen specific Treg but results polyclonal Treg expansion. 
 
3.3 IMMUNOSUPPRESSIVE  DRUGS AND TREG 
Future clinical adoptive Treg therapy with ex vivo generated antigen-specific Treg 
will in all likelihood occur under the cover of currently used conventional immuno-
suppressive drugs. These drugs might include Rapamycin and/or the calcineurin in-
hibitors CsA and Tacrolimus. Rapamycin prevents common γ-chain mediated signal-
ing of the cytokine TCGF receptors like IL-2 and IL15 220,221 whereas calcineurin 
inhibitors prevent TCR mediated IL-2 production 49,222,223. In addition, Rapamycin 
facilitates activation induced cell death (38 and chapter 5). The effects of different 
drugs were studied in a variety of transplantation tolerance induction models in ani-
mals and the outcomes were divers and disputed (Table1,Chapter 8). Some studies 
indicated the importance of delaying the administration of conventional immuno-
suppressive drugs 75,224 on the success of clinical kidney graft transplantation. In 
this way a window for immunological engagement (WOFIE) is generated which al-
lows for activation alloantigen-specific Treg. Of notion, transplantation tolerance 
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depends on both the reduction of aggressive alloantigen-specific effector T cells and 
promotion of the immunosuppressive alloantigen-specific Treg pool 59,61. Conven-
tional drugs might facilitate one or both of the processes. Ideally they should tip 
the balance towards immunoregulation. In case of clinical adoptive Treg therapy we 
believe it is crucial to first reduce the alloreactive T cell pool and then start the en-
hancement of Treg. Hence, selection of drugs that will not affect the function of ad-
optively transferred Treg is crucial importance in the success of this therapeutic 
modality. 
 
SCOPE AND AIM OF  THESIS 
Although there is a high degree of consensus that immunoregulation has an impor-
tant role in both the induction and maintenance of transplantation, many issues es-
pecially with respect to ex vivo manipulation of human regulatory T cells remain 
controversial and as a result they are under intensive investigation. This includes 
the development of ex vivo expansion and selection protocols for alloantigen-
specific Treg, identification of specific cell markers and mechanism of suppression. 
As we consider donor-specific Treg immunotherapy a major step in establishing 
transplantation tolerance, we addressed the question of whether we could induce, 
select, expand, and characterize alloantigen-specific Treg ex-vivo. In this thesis, we 
describe two distinct ex vivo generation and expansion protocols both resulting in 
alloantigen-specific Treg (subsets); one protocol is based on antigen-specific adap-
tation of naturally occurring CD4+CD25+Treg, and in the other protocol costimula-
tion blockade of CD40 and CD86 was used to induce Treg in polyclonal T cell popu-
lations. The former protocol resulted in two distinct subsets of Treg that were 
marked by differential CD27 expression. 
The ex vivo generated antigen-specific Treg subsets described in this thesis are of 
potential interest for antigen-specific Treg based immunotherapy. The infusion of 
these Treg is expected to shift the balance between aggressive and suppressor al-
loreactive T cells towards the latter. This shift in balance is crucial in the induction 
and maintenance of transplantation tolerance. Since, costimulation blockade, next 
to its Treg inducing potential, results in a balance shift towards alloreactive Treg, 
its clinical therapeutic use will likely facilitate the induction of transplantation toler-
ance. As new immunotherapeutic modalities will most likely be clinically imple-
mented under the cover of currently used conventional immunosuppressive drugs, 
we studied the effect of these agents on the induction of anergic Treg by costimula-
tion blockade. 
Donor-specific Treg such as described in this thesis are of great potential for immu-
notherapy and offer a potential route to permanent graft survival or autoimmune 
therapy without the need for life-long non-specific immunosuppression. 
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ABSTRACT 
The generation of immunoregulatory T-cells by blocking the B7(CD86/CD80)-CD28 
and/or CD40-CD154 costimulatory pathways has great potential for the induction of 
long term transplantation tolerance. In a human polyclonal in vitro model we show 
that combined mAb blocking of the costimulatory ligands CD40 and CD86 leads to 
allo-specific T-cell anergy that can not be reversed by antigenic rechallenge in the 
presence of IL-2. Although antigenic restimulation with IL-2 restored the prolifera-
tive response, subsequent antigenic restimulation of the restored anergic cells in a 
tertiary MLC still resulted in nonresponsiveness Importantly, these anergic T-cells 
suppress the response of naive alloreactive T-cells in an antigen specific way via 
linked recognition. Suppression may partially depend on local IL-10 production, 
while TGFβ played no role. Irrespective of the mAb combination used, blast forma-
tion occurred in a subset of CD4+ cells. These cells were characterized by a sus-
tained CD45RA expression, increased TcR density and a lower level of CD4 expres-
sion. A reduced number CD45RO+/CD8+ T-cells was observed whenever anti-CD86 
was combined with anti-CD40, which was reflected by an even more attenuated cy-
totoxic T-cell function indicating the importance of CD40-CD154 in the generation of 
cytotoxic T-cells in this transplantation model. We hypothesize that in our model 
anergy is induced in the CD4+ T-cell subset, whereby CD8+ cytotoxic effector func-
tion is impaired by the lack of both CD40-CD154 signaling and cytokine mediated 
help. This costimulatory ligand directed mAb approach might well be used for the ex 
vivo generation of antigen specific immunoregulatory T-cells applicable in adoptive 
immunotherapy. 
[BLOOD 2000; 95 (10):3153] 
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INTRODUCTION 
Several regulatory mechanisms are responsible for controlling homeostasis of im-
munological responses and maintenance of tolerance 1. In an attempt to prevent 
allograft rejection in an antigen-specific way, many different studies deliberately 
evoked these naturally occurring mechanisms to induce and maintain allo-specific 
T-cell tolerance. Although the mechanisms responsible for tolerance induction in 
mature peripheral T-cells are not completely clear, multiple non-mutually exclusive 
phenomena have been indicated in the context of transplantation 2. These include 
immunological ignorance 3,4, induction of nonresponsiveness or anergy 5, deletion 
6,7 and immunoregulation 8-13. Immunoregulatory T-cells have been proposed to act 
via intercellular interactions 9,13 that are based on competition for APC surface anti-
gens and/or locally produced cytokines 9,14. Maintenance of the tolerant state by 
immunoregulatory T-cells might be of clinical importance for long-term graft sur-
vival 15,16 An important aspect of this type of regulation with regard to the mitiga-
tion of allo-responses in a polyclonal situation, is that alloreactive T-cell clones that 
are made tolerant towards a specific allo-antigen can potentially down-regulate the 
response of another T-cell which is directed against a distinct second allo-antigen 
provided the antigen is co-expressed on the same APC as the tolerance inducing 
antigen. This phenomenon, called linked suppression 17,18 might in fact be one of 
the first steps in a self-sustaining form of tolerance known as infectious tolerance 
12,19.  
Activation of mature T-lymphocytes is a multi-step phenomenon 20 requiring anti-
gen-specific triggering of the T-cell receptor (TcR) complex on the T-cell and addi-
tional signaling via costimulation 21. A key costimulatory signal results from the 
binding of CD28 receptor on T-cells with CD86 (B7-2/B70) and CD80 (B7-1/BB1) 
ligands on the antigen presenting cell (APC) 22-26. Inhibition of this pathway in the 
presence of antigenic stimulation results in T-cell anergy 20.  More recently, the 
CD40-CD154 (CD40L) pathway was shown to attribute to the regulation of T-cell 
activation, both by independently co-stimulating T-cells and at least in part by up-
regulating CD80/CD86 molecules on APC 27,28.  
Successful use of this knowledge has been made in animal models where allograft 
rejection was prevented by blocking of CD86 and/or CD80 29,30, leading to long-
term graft survival 25,31. Others showed the effectiveness of blocking the CD40-
CD154 (CD40L) pathway in this respect 32-36. Combined inhibition of both the B7 
and CD40 pathways showed a synergistic effect on graft survival in both rodent and 
primate transplant models 4,32,37,38. 
Human in vitro studies have shown the efficacy of blocking the costimulatory 
ligands in the induction of T-cell anergy in both allo-responses 24,39,40 and memory 
T-cell responses 41.  
In the present study we elaborate on antigen-specificity, immunoregulatory fea-
tures, maintenanance of anergy as well as the phenotype of human alloreactive T-
cells, made anergic by mAb-blocking of the CD86 and CD40 costimulatory ligands. 
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The anergic T-cells were able to suppress the response of polyclonal alloreactive T-
cells in an antigen-specific way via linked recognition, which was mediated partially 
via IL-10. Importantly, the anergic state was maintained even after restoration of 
the hyporesponsiveness indicating a profound anergy inducing protocol. Collec-
tively, these data support the therapeutic potential of anergic T-cells generated by 
mAb blocking of CD86 and CD40 in the polyclonal primary human MLC. 
 
MATERIALS  & METHODS 
Cells  
For all experiments, peripheral blood mononuclear cells (PBMC) were isolated by 
density gradient centrifugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) 
from buffy coats obtained from healthy blood donors. Cells were frozen and stored 
in liquid nitrogen until use. After thawing, viability of the cells was determined by 
trypan blue exclusion. All donors were HLA typed and mixed lymphocyte cultures 
were set-up exploiting different degrees of matching.  
 
HLA-typing  
Serological HLA-A, HLA-B, HLA-DR and HLA-DQ phenotyping (broad specificities and 
splits)  was performed using the standard microcytoxicity assay. Additional class I 
and II (sub)typing was performed by molecular methods.  Preparation of genomic 
DNA was performed using the QIA-Amp Blood Kit (QIAGEN, Germany). HLA A, B, DR 
and DQ low to intermediate resolution typing was by a PCR-SSP technique (Pel-
Freeze Clinical Systems, Deerbrook Trail, USA). HLA-DRB and DQB  subtyping was 
performed using a PCR-SSP technique (Dynal DRB1*, B3*, B4*, B5* and DQB sub-
typing kits, Oslo, Norway).  
 
MLC  
Primary one-way Mixed Lymphocyte Cultures (MLC) were performed by culturing 
1.105 30 Gy γ-irradiated stimulator PBMC with 1.105 responder PBMC in 96 wells 
round bottom plates (Greiner, Frickenhausen, Germany) in 200 µl culture medium 
(RPMI-1640 with glutamax supplemented with pyruvate (0.02mM), 100 U/ml peni-
cillin, 100 µg/ml streptomycin, (all from Gibco, Paisley, UK) and 10% heat inacti-
vated pooled human serum) at 370C, 95% humidity and 5% CO2 . Proliferation was 
analysed by 3H-thymidine incorporation at day 6 of the culture; 1 µCi 3H-thymidine 
(ICN Pharmaceuticals, Irvine, CA, USA; specific activity 2.0 Ci/mmol) was present 
during the last 18 hours. 3H-thymidine incorporation was analysed by a Gas Scintil-
lation Counter (Canberra Packard, Matrix 96 Beta counter, Meriden, U.S.A.). The 
3H-incorporation is expressed as mean counts per 5 minutes and standard deviation 
of at least quadruplicate measurements. Counts per 5 minutes by gas scintilation 
analysis resemble counts per 1 minute as measured by liquid scintilation analysis. 
For cytokine measurements, culture supernatants were harvested on days 3 and 6. 
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To study the secondary response of allo-MHC primed T-cells, first bulk primary MLC 
were performed by culturing 1.106 γ-irradiated (30 Gy) stimulator PBMC and 1.106 
responder PBMC for 7 days in 24 well culture plates (Greiner, Frickenhausen, Ger-
many) in 2 ml culture medium. Cells were harvested, washed and allowed to recu-
perate for two days.  Dead cells were removed by density gradient centrifugation 
(Lymphoprep, Oslo, Norway). Subsequently, 2.104 recovered viable cells were res-
timulated with 1.105 γ-irradiated (30 Gy) stimulator PBMC in 96 well round bottom 
plates. The proliferative response of the secondary MLC was examined on day 3, 
which appeared to be the optimal time-point 42. Antigen-specificity was examined 
by using completely HLA mismatched or partially HLA matched third party PBMC. 
For cytokine measurements, culture supernatants were harvested after 48 or 72 
hours. 
To investigate the tertiary response, first bulk secondary MLC were performed in 24 
well culture plates; 2.105 responder cells from a bulk primary MLC (see above) and 
1.106 γ-irradiated stimulator PBMC were cultured for 5 days with or without IL-2 
(12.5 U/ml, Proleukine, Eurocetus, The Netherlands). Responder cells were washed, 
allowed to recuperated for 2 days and subsequently 2.104 responder cells were res-
timulated with 1.105 irradiated stimulator PBMC in 96 well round bottom plates. 3H-
incorporation was examined at day 3.  
 
Induction of allo-specific tolerance in the primary MLC 
To generate allo-specific anergic T-cells in a primary MLC, mAb directed against 
CD40 (5D12; 500ng/ml), CD80 (M24; 1000ng/ml) and/or CD86 (1G10; 500ng/ml) 
were added at the start of the bulk primary MLC. For each of the individual mAb 
dose-response titrations were performed and the optimal inhibitory concentration 
was selected. Anti-CD80 and anti-CD86 mAb were a generous gift from Dr. K. Lorré 
(N.V. Innogenetics, Ghent, Belgium), and the blocking anti-CD40 mAb (5D12; 
Tanox Pharma B.V., Amsterdam, The Netherlands) was kindly provided by Dr. M. de 
Boer. In vitro tolerance was defined as, hyporesponsiveness after antigen-specific 
restimulation and the reduced capacity to perform a specific cytotoxic response. 
 
Co-cultures to determine suppressor potential of anergic T-cells 
The regulatory capacity of anergic T-cells was analysed in an in vitro co-culture 
MLC; anergic cells (or control cells) from a primary MLC were added to a newly set-
up MLC.  Previously we showed that both concentration and functional state (e.g. 
irradiated vs. living) of the added (regulatory) cells are critical components in as-
sessing the immunoregulatory capacity 42. Co-cultures were performed in 96 wells 
round-bottom plates; 5x103 γ-irradiated (30 Gy) anergic cells or control cells were 
added to a newly-setup MLC consisting of both original responder PBMC (5.104) and 
γ-irradiated stimulator PBMC (2.5, 5 or 10.104). All tests were performed in quadru-
plicate. Antigen-specificity of the regulatory phenomenon was examined in co-
cultures performed with third party stimulator PBMC that were either completely 
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HLA mismatched or partially HLA matched (with an isolated class I or class II mis-
match) to investigate the possibility of suppression via linked recognition.  Neutral-
izing antibodies (5µg/ml) against IL-10 (MAB217) and TGFβ (MAB1835) (both 
RNDsystems)  were added during the co-culture to study the role of these cyto-
kines. Irrelevant isotype matched antibodies were used to control for specificity, 
these antibodies never abbogated suppression. 
To exclude that bystander occurred  the effect of anergic T-cells on self-restricted 
recall responses against Tetanus toxoid (RIVM, Bilthoven, The Netherlands) and 
Candida albicans extract (ARTHU Biologicals N.V., The Netherlands) were  exam-
ined. 2.105 PBMC were cultured with antigen (10 µg/ml) in the absence or presence 
of 5000 (30Gy γ-irradiated) anergic or control cells, the proliferative response was 
examined on day 5. 
 
Cytokine assays 
Cytokines were measured in culture supernatants; IFNγ, IL-4 and IL-10 production 
were analysed by ELISA (Pelikine-compact ELISA kit; CLB, Amsterdam, The Nether-
lands) and biological active IL-2 was determined by the CTLL-2 bioassay 43. The 
production of TGFβ was measured in culture supernatants of cells that were cultured 
in Serum free medium (Stem Cell technologies, Vancouver, B.C. Canada). Briefly, 
soluble type-II TGFβ receptor (RNDsystems) was used to capture bioactive TGFβ. A 
standard curve of TGFβ (RNDsystems; 10-2500 pg/ml) was used. Detection took 
place by anti-TGFβ1 antibody (RNDsystems) with biotinylated anti-chicken IgY 
(Jackson Immunoresearch). Colour reaction was performed by standard HRPO 
method (streptavidin polyHRP mAb; CLB, Amsterdam, The Netherlands). 
 
Cytotoxicity by 51Cr-release assay 
The cytotoxic capacity of primed alloreactive T-cells was examined by  51Cr-release 
of labelled PHA-blasts. Briefly, to generate PHA-blasts, PBMC were first cultured 
with PHA-M (Boehringer Mannheim, Mannheim, Germany) and subsequently with IL-
2 (50U IL-2/ml).  2.106 target-cells were labelled with 100 µCi 51Cr (Amersham, UK) 
and used as target at 1000 cells/well. Different effector/target (E/T) ratios were 
tested in quadruplicate. Culture supernatants were examined for released  51Cr on a 
γ-irradiation counter (Wallac 1470 γ-counter, Turku, Finland). Cytotoxic capacity is 
shown as percentage specific lysis calculated according to the following equation: 
(CPM sample release - CPM spontanous release)
(CPM total release - CPM spontanous release)Percentage specific lysis =
X 100%
 
 
Flowcytometry 
Cells were phenotypically analysed by a 2-step double labelling procedure. Briefly, 
cells were washed twice with FACS buffer (PBS containing 0.5% BSA) and labelled 
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first with unconjugated specific antibody, followed by conjugate binding (GAM-PE or 
GAM-FITC; DAKO, Glostrup, Denmark), thereafter the cells were labelled with either 
CD4 or CD8 (FITC or PE conjugated) antibodies. All incubations were for 30 minutes 
on ice and thereafter the cells were washed twice. The samples were run on a XL-
Epics (Coulter Electronics) and 5000 or 10.000 events were collected based on live 
lymphocyte cell gating as indicated by Propidium Iodide (5µg/ml) staining. Isotype 
matched antibodies were used to define marker settings, isotype matched controls 
were usually below background staining. Data were analysed by Coulter XL-2 and/or 
WINMDI software. CD4 and CD8 positive T-cells in the live lymphocyte gate were 
analysed by the following mAb: CD3-FITC/PE (Clone UCHT1.7), CD4-PE (MT310), 
CD8-PE (DK25), CD14-FITC (TUK4), CD19-PE (HD37(7mAb)), CD25 (ACT-1), 
CD45RA (4KB5) , CD45RO (OPD4(1)) (all from DAKO, Glostrup, Denmark), WT31 
(anti-TcR, Dr. W.Tax, Nijmegen, The Netherlands) and L243 (anti-HLA DRα, ATCC).  
 
RESULTS 
Anti-CD86 mAb is a powerful inhibitor of the primary MLC but addi-
tional CD40-blocking attenuates the cytotoxic response 
Monoclonal antibodies directed against CD40, CD80 and CD86 ligands were tested 
in the polyclonal primary MLC to study their applicability in the induction of anergy. 
In this study 6 distinct responder-stimulator combinations were studied; 5 combina-
tions were mismatched for a single HLA haplotype (i.e.1A,1B,1DR,1DQ mismatch) 
and one combination was completely HLA mismatched. Especially mAb combinations 
that included the anti-CD86 mAb led to a strong inhibition of proliferation (Fig 1A) 
and a concordant reduction in IL-2 and IFN-γ production (Fig 1B). 
Figure 1c shows the cytotoxic response of T-cells primed either in the absence (con-
trol) or presence of different mAb combinations. Clearly, mAb-blocking of CD86 in 
the primary MLC reduces the potential to generate a profound antigen-specific cyto-
toxic effector response. Notably, although the cytotoxic potential was decreased 
with all mAb combinations, the presence of anti-CD40 led to an additional reduction 
of the killing capacity. 
Thus, alloreactivity in heterogeneous polyclonal T-cell populations depends merely 
on the interaction with the CD86 costimulatory ligand, since blocking of this ligand 
led to a strong reduction of proliferation, cytokine production and the induction of 
cytotoxic effector function. This was found in all HLA combinations tested irrespec-
tive of the degree of HLA mismatch.  
CD40/CD86 BLOCKADE  INDUCES  ALLO-SPECIF IC  ANERGIC  REGULATORY  T CELLS 
 
 
53 
F I G U R E  1  
Especially mAb-blocking of CD86 inhibits the primary MLC by but additional CD40 
blocking results in a declined cytotoxic response.  
Indicated mAb were added at the start of the 
MLC. A. The proliferative response was de-
termined by 3H-incorporation at day 6 of the 
cultures. B. The presence of IL-2 (day 3) 
and IFNγ (day 6) was analyzed in culture 
supernatants. C. Percentage specific lysis of 
allogeneic target cells is shown at different 
effector to target cells (E/T) ratios in the 
absence of mAb. Effector cells were derived 
from control of mAb-blocked primary MLC. 
Standard deviations were  < 10%. Results 
are expressed as means and standard error 
of quadruplicate (A,C) and duplicate (B) 
measurements. Representative experiments 
are shown.
 
Allo-antigen priming in the presence of mAb against CD86 and CD40 
and/or CD80 induces anergic T-cells 
Primary MLC were performed in the absence (control) or presence of mAb combina-
tions directed against CD86+CD40, CD86+CD80 and CD86+CD40+CD80. Viable 
cells were harvested and restimulated with the original stimulator cells without mAb 
(Fig 2A,B). Control T-cells responded with secondary proliferative kinetics (i.e. max. 
response at day 3, waning in time) while T-cell from the mAb-blocked MLC were hy-
poresponsive (Fig 2C).The failure to proliferate, was accompanied by a seriously 
impaired IL-2 and IFNγ production (Fig 2B), while  IL-4 and IL-10 concentrations 
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were around detection level for both control and hyporesponsive cells. TGFβ levels 
were below detection level. 
Lack of priming during the primary MLC, due to the presence of mAb, might explain 
the hyporesponsiveness. To exclude this possibility, time response kinetics of the 
secondary MLC were performed (Fig 2C). If the T-cells had been neglected during 
the primary MLC, restimulation would have led to proliferation with primary kinetics 
(i.e. optimal proliferation at day 6). Restimulation of  T-cells from a mAb-treated 
MLC neither showed a secondary nor a primary response. Hyporesponsiveness was 
neither the result of deletion, since antigenic restimulation in the presence of exo-
genously added IL-2 led to comparable response of control and tolerized T-cells (Fig 
3A). 
Thus, combined mAb-blocking of the costimulatory ligands in the primary polyclonal 
MLC induces genuine T-cell hyporesponsiveness or anergy, which was not the result 
of ignorance or cell dead.  
The three distinct mAb combinations led to a similar state of hyporesponsiveness. 
F I G U R E  2  
Priming in the presence of mAb induces hyporesponsiveness 
Primary MLC were performed for 7 days ei-
ther in the absence (control) or presence of 
mAb. Primed cells (2.104) were restimulated 
with the original allogeneic stimulator PBMC 
(1.105). A. Proliferative response at day 3 of 
culture by 3H-incorporation. B. IFNγ and IL-2 
production were analyzed in the culture su-
pernatants. C. Proliferation kinetics of sec-
ondary response of control and hyporespon-
sive T-cells. Results are expressed as means 
and standard error of quadruplicate (A,C) 
and duplicate (B) measurements. Represen-
tative experiments are shown. 
 
Reversal of T-cell hyporesponsiveness by exogenous IL-2 and anti-
gen does not result in anergy reversal  
Various studies have described the potential of exogenously added IL-2 in recover-
ing the proliferative response of anergic T-cells in vitro 24,44-47. After tolerance in-
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duction we consequently analyzed the antigenic restimulation in the presence of 
added IL-2. Fig 3A shows the proliferative response of anergic T-cells after anti-
genic restimulation either in the absence or presence of exogenously added IL- 2 
and the response to IL-2 alone. The presence of both IL-2 and alloantigen resulted 
in reversal of the hyporesponsive state, while only a residual response was ob-
served with either antigen or IL-2 alone. This indicates that hyporesponsiveness can 
be restored only if antigen and IL-2 are present at the same time. Next, we ad-
dressed the tertiary proliferative response (second restimulation) of anergic T-cells 
that were first restored with antigen and IL-2 in a secondary MLC (Fig 3B). Surpris-
ingly, these restored anergic T-cells were still nonresponsive upon a subsequent 
encounter with antigen in a tertiary MLC, indicating that anergy reversal did not oc-
cur.  Collectively, these data show that anergy is maintained even after reversal of 
hyporesponsiveness by antigenic restimulation in the presence of IL-2. 
F I G U R E  3  
Restored hyporesponsive T-cells remain anergic  
A. Primed control or hyporesponsive T-cells  
(2.104), induced by different mAb combina-
tions, were restimulated with the original 
stimulator PBMC (1.105) in the presence of 
exogenous IL-2 (12.5 U/ml). The prolifera-
tive response was examined on day 3. B. 
Control and hyporesponsive T-cells derived 
from a primary MLC were recovered with an-
tigen in the presence (+ IL-2) or absence 
(no IL-2) of exogenously added IL-2 and 
subsequently restimulated for the second 
time in a tertiary MLC. The 3H-incorporation 
of this first restimulation is shown in the ta-
ble (standard error<10%). Next, 2.104 re-
covered cells were restimulated for a second 
time with 1.105 stimulator PBMC in the ab-
sence of IL-2. The proliferative response was 
examined on day 3. Results are expressed as 
means and standard error of quadruplicate 
measurements. Representative experiments 
are shown.
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The anergic state is allo-antigen specific and not dependent on the 
original APC source 
Antigen-specificity of the anergic T-cells was studied by restimulation experiments 
using third party stimulator PBMC that were either fully HLA mismatched or partially 
matched (either a HLA class I (B) or class II (DR) match) with the stimulator PBMC 
originally used for priming. Primed control cells proliferated solely when restimu  
F I G U R E  4  
Anergic T-cells are allo-antigen specific 
A. Control or hyporesponsive T-cells (2.104) 
were restimulated with specific or third party 
stimulator PBMC (1.105) that were either 
completely mismatched or partially matched  
(in this case DRB1*0401 (DR4) and B*4901 
(B49)). B. IL-2 restored the proliferative 
response of anergic T-cells solely when anti-
genic restimulation was performed with the 
specific stimulator PBMC or third party 
stimulator PBMC with a shared DR type. Re-
sults show mean 3H-incorporation and stan-
dard error of quadruplicate measurements on 
day 3 of culture. C. The cytotoxic response 
is HLA class I specific. Specific lysis (E/T= 
100) is shown against allogeneic target-cells, 
which are either completely mismatched 
(white bars) or shared MHC antigens 
(crossed bars) against which the responder 
cells were generated (here B49 and DR4).  
Results are expressed as percentage specific 
lysis. Representative experiments are shown.
 
lated with the original PBMC or third party PBMC that shared a HLA class II (DR) 
antigen with the original stimulators (Fig 4a). No antigen-specific reaction was 
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found against third parties that were either completely HLA mismatched or shared 
only a class I (B) locus antigen with the original stimulator cells. As expected, the 
anergic T-cells did not respond irrespective of the third party HLA type. To prove 
the antigen specificity of the anergic T-cells they were antigenically restimulated in 
the presence of exogenous IL-2 (Fig 4B) as described above. Hyporesponsiveness 
was restored solely when antigenic restimulation, in the presence of IL-2, was per-
formed with either the original or third party stimulator PBMC with a shared HLA 
class II type. Thus, anergic T-cells were shown to be allo-antigen specific by res-
timulation with selected third party stimulator PBMC expressing the appropriate 
target HLA antigen in the presence of IL-2. The responsiveness of T-cells towards 
third party stimulator cells that share antigenic determinants with the original 
stimulator cell is known as linked recognition 11,12,17,18. The fact that this phenome-
non was only observed for the DR, but not for the B locus match, supports the no-
tion that proliferative and cytokine responses in a MLC are mainly class II driven 48.  
Whereas HLA class II mismatches play a major role in proliferation and cytokine 
production in our experimental setup, the generation of cytotoxic effector T-cells 
appeared to be exclusively induced against HLA class-I mismatched antigens, no 
cytotoxic response against isolated HLA class-II molecules was observed (data not 
shown). To elucidate the antigen specificity of tolerized cytotoxic T-cells they were 
tested for their ability to kill third party target cells which were either completely 
mismatched or partially matched for HLA class I antigens. HLA class I matched tar-
get-cells were lysed by the allo-primed control T-cells, while effector T-cells from a 
mAb-blocked MLC left them untouched. Completely mismatched third party targets 
were neither affected by control nor by tolerized cells (Fig 4C). Together these cy-
totoxicity data indicate that priming in the presence of mAb-blocking results in dis-
abled HLA class-I specific cytotoxic T-cell function. 
 
Immunoregulation of anergic T cells via linked recognition 
The capacity of anergic T-cells to affect a specific allo-immune response was stud-
ied in an in vitro co-culture MLC; anergic cells were cultured together with a newly 
setup primary MLC. Previously, we have reported on the kinetics of co-cultures and 
showed that this type of co-cultures have to be performed with low numbers of ir-
radiated anergic cells 42. Furthermore, relative suppression was compared to co-
cultures of irradiated primed control cells. Figure 5A shows the effect of co-
culturing anergic cells. The relative suppressive effect in the co-cultures evoked by 
the anergic cells was compared to that of co-cultures with added irradiated control 
cells (Table 1). Although different levels in suppression were found, sometimes up 
to 60 % of inhibition was found at responder PBMC : stimulator PBMC : anergic T-
cell ratios of  5:5:0.5 or 5:2.5:0.5. In general, the suppressive effect became more 
apparent when the number of stimulator cells was decreased suggesting the  
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F I G U R E  5  
Allo-specific anergic T-cells suppress naive alloreactive T-cells via linked recognition 
mediated partially by IL-10 and do not confer bystander suppression.  
A. Anergic T-cells suppress their specific 
primary MLC, three different representative 
experiments of are shown. T-cell anergy was 
induced by mAb-blocking in the primary MLC 
(see legends). Next, 5.103 irradiated anergic 
T-cells were co-cultured with a newly setup 
MLC, using 5.104 responder PBMC and 2.5-
5.104 (Exp.I and Exp.II) or 5-10.104 
(Exp.III) stimulator PBMC. Control co-
cultures were performed with control cells 
that were primed and processed in a similar 
way as the anergic cells but in the absence 
of mAb. B. Anergic T-cells mediate suppres-
sion via linked recognition. 5.103 γ-irradiated 
anergic T-cells were co-cultured with a newly 
set up MLC consisting of 5.104 responder 
PBMC and 2,5.104 γ-irradiated stimulator 
PBMC. The stimulator PBMC were either allo-
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specific (left) or third party PBMC being 
completely HLA mismatched (middle) or par-
tially HLA class II matched (right) with the 
original stimulator cells. C. Anergic cells do 
not confer bystander suppression. Co-
cultures were performed by adding 5.103 
anergic or control cells to a culture of 2.105 
responder PBMC in the presence of 10µg/ml 
Tetanus Toxoid or C.albicans (right). As a 
control these anergic and control cells were 
co-cultured with a newly set up MLC consist-
ing of 5.104 responder PBMC and 5.104 γ-
irradiated stimulator PBMC (left) D. Suppres-
sion partially depends on IL-10. Cocultures 
consisting of 5.103 anergic or control cells, 
1.105 responder PBMC and 5.104 γ-irradiated 
stimulator PBMC were performed in the pres-
ence of TGFβ and/or IL-10 neutralizing anti-
bodies or isotype matched antibody (5 
µg/ml). Anergic T-cells used in the experi-
ments under (C) and (D) were generated by 
blocking CD40 and CD86. In all figures the 
proliferative response is shown as mean 3H-
incorporation and standard error of quadru-
plicate measurements on day 6 (except for 
recall responses, which were analyzed on 
day 5) of the co-cultures. 
 
importance of competition between anergic T-cells and the responder T-cells for an-
tigenic determinants. Antigen-specificity of this suppressive phenomenon, was in-
vestigated in co-cultures using original responder cells and third party stimulator 
cells that were either completely HLA mismatched or shared HLA antigens with the 
original stimulator PBMC (anergy inducing antigens). Figure 5B shows that only the 
partially  
matched third party MLC were suppressed to a similar level as the original specific 
MLC, whereas the completely mismatched third party MLC were hardly affected. In 
the described polyclonal system this implies, that recognition of the specific target-
antigen on the surface of a third party APC by these anergic T-cells enables them to 
suppress the primary reaction of neighboring T-cells recognizing distinct allo-
antigens, provided that these are present on the same APC as the anergy inducing 
antigen. This mechanism of immunoregulation has been referred to as linked sup-
pression 11,12,17,18. To exclude that bystander suppression occurred, recall responses 
against tetanus toxoid and C.albicans were studied in the presence of either anergic 
or control T-cells. The proliferative response against these antigens was left unaf-
fected by the anergic T-cells (Fig 5C). This indicates that anergic allo-specific T-
cells, do not interfere in a non-specific manner in self-MHC restricted T-cell re-
sponses.Previously, IL-10 and TGFβ have been indicated as important immunosup-
pressive cytokines (345,346, 91). To elucidate the role of these cytokines, neutral-
izing antibodies against IL-10 and/or TGFβ were added to the cocultures of naive 
allo-reactive cells, stimulator PBMC and anergic or control T-cells. In contrast to 
anti-TGFβ, anti-IL-10 antibodies partially prevented suppression by the anergic T-
cells (fig 5d). The addition of anti-TGFβ together with anti-IL10 antibodies did not 
affect the level of suppression caused by IL-10 alone (Fig 5D). This indicates that 
IL-10, but not TGFβ might play a role in the suppression by the anergic T-cells. In 
some control experiments anti-IL-10, anti-TGFβ+IL-10 or isotype matched control 
antibodies themselves led to a small reduction of the proliferative response. 
Collectively, these co-culture data show that anergic T-cells generated in the pri-
mary polyclonal MLC by mAb blocking of costimulatory ligands are able to suppress 
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alloreactive T-cell responses directed to multiple allo-antigens, provided these anti-
gens are co-expressed on the same APC as the anergy inducing antigen. Suppres-
sion was at least partially mediated by IL-10 and nonspecific bystander suppression 
was not observed. The distinct mAb-tolerizing regimens yielded T-cells with compa-
rable suppressive capacity, as measured in our system. 
 
T A B L E  1   
Relative suppressionA of alloreactive T-cells by anergic T-cells 
 Stimulator Anergic cells derived from MLC blocked for ligands 
ExpB PBMC Nr.  CD40 86 CD80 86 CD40 80 86  
I 5.104  30% 41% 40%  
 2.5.104  58% 30% 59%  
II 5.104  44% 22% 65%  
 2.5.104  44% 16% 45%  
III 10.104  21% 14% 29%  
 5.104  36% 20% 29%  
A Relative suppression of co-cultures with anergic T-cells was compared to the proliferative 
response of co-cultures with control cells as shown in Fig.5A. 
B Experiment numbers refer to Fig.5A.Anergic T-cells were generated in the primary  
MLC according to the different mAb tolerizing regimen described above. 
 
Phenotypical analysis of tolerized T cells 
T-cells derived from either control or mAb-blocked MLC were phenotypically ana-
lyzed by flowcytometry. Cells were harvested after 7 days of culture, allowed to re-
cuperate for 2 days and analyzed. From a primary control MLC two distinct 
CD4+/CD3+ T-cell populations emerged with distinct forward scatter characteristics 
(Fig 6A,B). A similar distribution pattern was found after mAb-blocking (no differ-
ence was observed between the different mAb-blocking combinations), but the blast 
like large sized CD4+ T-cell population was markedly reduced in cell number (Fig 
6A). Notably, the large sized T-cells from the mAb-blocked MLC showed an increase 
in TcR expression and a decrease in CD4 expression (Fig 6b) as compared to large 
sized T-cells from a control MLC. Irrespective of the presence or absence of mAb in 
the primary MLC, the majority of the blast like CD4+ T-cell population were 
CD45RO+, but in case of the mAb-blocked MLC a clear relative increase in the 
CD45RA+ large sized CD4+ cells was observed (Fig 6B). Large sized CD4+ T-cells 
from both control and mAb-blocked MLC were HLA class II positive and generally 
expressed CD25 to similar levels (not shownCD8+ population from both control and 
mAb-blocked MLC consisted of one uniformly sized population, with similar CD8+ 
cell numbers and CD8 expression levels (Fig 6A). CD8+ cells derived from a MLC 
blocked with anti-CD86+CD40 or anti-CD86 +CD40+CD80, showed a reduced num-
ber (and expression) of CD45RO+/CD8+ T-cells, which was not observed in the 
CD8+ T-cells from the CD80+CD86 blocked MLC (Fig 1C). This indicates the impor-
tance of the CD154-CD40 interaction in the activation of CD8+ T-cells and might 
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explain the relatively higher cytotoxic response of T-cells derived from a 
CD80+CD86 MLC as compared to T-cells from a mAb-blocked MLC where in addition 
CD40 was blocked (Fig 1C). These data support an important role for the CD154-
CD40 pathway in the generation of cytotoxic effector function in the human poly-
clonal MLC as was recently demonstrated in murine models 49-51.  
In addition, phenotypical analysis excluded the presence of putatively tolerizing APC 
(i.e. the presence of B cells or monocytes with cell surface bound anti CD80, CD86 
of CD40 mAb) that might interfere during restimulation and would inadvertently 
lead to the observed hyporesponsiveness (data not shown). 
F I G U R E  6  
Phenotypical analysis of tolerized T-cell populations.  
After a 7 day primary MLC in the absence or 
presence of mAb, the responder lymphocytes 
were harvested, allowed to rest and analyzed 
by flowcytometry. A. Contour plots showing 
forward scatter (linear scale) and either CD4 
(upper two panels) or CD8 (lower two pan-
els) expression (fluorescence log scale) in 
the live lymphocyte gate. The left panel 
shows T-cells from a control MLC and the 
right panel shows T-cells from a mAb-
blocked MLC (no differences were observed 
between mAb combinations). The percent-
ages in the upper two panels indicate rela-
tive number of CD4+ T-cells with a large 
blast like appearance, while in the lower two 
panels total percentage CD8 + T-cells are 
indicated. B. The upper panel shows the size 
difference in a forward scatter histogram. 
The three lower panels show the expression 
of CD4, TcR (WT31) and CD45RA on the 
large sized back-gated CD4+ T-cell popula-
tion which were derived from either a control 
(shaded histogram) or mAb-blocked MLC 
(open histogram). The histograms show the 
number of events on the vertical axis (lin 
scale) and fluorescence intensity (log scale) 
on the horizontal axis. C. CD8+ cells from an 
MLC where at the same time CD86 and CD40 
(additional CD80 blocking had no effect) 
were blocked showed a decrease in the num-
ber of CD45RO expressing cells and CD45RO 
intensity. Cells were derived from either a 
control MLC or a mAb-blocked MLC where the 
indicated mAb were present. The contour 
plots show the fluorescence intensity of 
CD45RO on CD8 expressing T-cells. Note 
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that the Y-axis shows a log scale from 102-
104, indicating that all cells shown are CD8 
positive.
 
DISCUSSION 
Allo antigen-specific immunosuppression is one of the main goals in preventing 
graft rejection. Here we demonstrate the ex vivo generation of anergic allo-specific 
T-cells from a primary polyclonal MLC by mAb-blocking of CD86, CD40 and/or 
CD80. These anergic T-cells have an antigen specific immunoregulatory function, 
since they are able to suppress the response of naive alloreactive T-cells via linked 
recognition. Importantly, although hyporesponsiveness of these T-cells was recov-
ered by antigenic restimulation with exogenous IL-2, this did not extend to anergy 
reversal, in that nonresponsiveness was still observed in a tertiary MLC, implying 
that anergy was maintained. Anergic immunoregulatory T-cells generated by this 
anti-CD86+CD40 based tolerizing protocol might be a putative tool for antigen-
specific adoptive immunotherapy in transplant medicine 15. 
During the anergy induction phase, especially anti-CD86 led to a strong inhibition of 
the primary MLC. This dominant effect, sorted on proliferation and cytokine produc-
tion, might be explained by the constitutive expression of CD86 on the majority of 
APC. Activation through costimulatory ligands also appeared to be essential for the 
induction of allo-specific cytotoxic effector T-cell function, since combined mAb-
blocking of both CD86 and CD40 in the primary MLC, resulted in a strongly affected 
cytotoxic response. This inability was not the result of differences in CD8+ T-cell 
number, but rather reflects an intrinsic defect either caused directly or indirectly by 
the lack of help. Moreover, although minimal cytolytic activity was found after anti-
CD86 blocking of the primary MLC, the cytotoxic response was even more attenu-
ated after additional blocking with anti-CD40 mAb. This fits the notion that the 
CD40-CD154 pathway actively contributes to the induction of cytotoxic effector 
function 49-51. Of interest here is the change observed in CD45RO expression in the 
CD8+ population; CD8+ cells from a CD40+CD86 blocked MLC clearly showed a de-
creased number of CD45RO+ cells, suggesting that CD40-CD154 ligation delivers an 
important signal for differentiation into cytotoxic effector cells. 
The large sized, blast like, CD4+ T-cells derived from the mAb-blocked MLC, all ex-
pressed the CD45RO marker, indicating that activation occurred. In contrast to the 
CD4+ blastoid cells from the control MLC, blast like CD4+ T-cells from the tolerized 
MLC were higher in CD45RA number, which might be a characteristic of anergized 
cells in our model. These large sized tolerized CD4+ T-cells are indulged to spot an-
tigen as judged by their increased TcR expression, however at the same time the 
decrease in CD4 co-receptor density might result in the loss of proliferation which is 
reminiscent of the data described by Madrenas et al. 52 showing that partial activa-
tion is the result of inefficient CD4 recruitment to the TcR. 
Recovery of the proliferative response of anergic T-cells by exogenously added IL-2 
was previously demonstrated in distinct experimental settings, albeit using two dis-
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tinct approaches. Either anergic T-cells were restimulated in the presence of IL-2 
24,44, as in our experiments, or alternatively anergic T-cells were first left in culture 
medium with exogenously added IL-2 only and subsequently restimulated 45,46. We 
show that hyporesponsive T-cells were recovered by antigenic restimulation in the 
presence of IL-2, this however did not lead to reversal of the anergic state as such, 
since a subsequent antigenic restimulation of these recovered cells in a tertiary MLC 
still left these cells nonresponsive. This means that anergy persisted, this particular 
characteristic was also found in a T-T presentation model 53, revealing the impor-
tance of the absence of costimulation in this type of anergy. 
The implications of this ‘recovery sensitive persistent anergy’ for the in vivo situa-
tion are as yet speculative, but it might serve the purpose of specific tolerance in-
duction after transplantation. After the initial period of trauma, the transplanted 
organ itself could serve as a source to maintain tolerance, and there would be little 
risk of reversing the anergic state of circulating anergic allo-specific T-cells upon 
encounter with IL-2 far from the site of transplantation (in the absence of antigen). 
Only if e.g. local inflammation occurs and IL-2 is produced at the transplant site, 
the proliferative capacity of the anergic cells could be re-established. However, 
since these cells remain dependent on IL-2, suppression of this particular cytokine 
would restore the tolerant state.  
In a polyclonal MLC with stimulator cells carrying many potential target antigens, 
antigen specificity of anergic T-cells is difficult to demonstrate. To circumvent this 
problem we used the characteristics of anergic cells to recover their response upon 
antigenic restimulation in the presence of exogenously added IL-2. We reasoned 
that if the anergy is antigen specific, this state can be recovered only by third party 
stimulator PBMC that share a specific HLA antigen with the stimulator cells that 
were used for anergy induction. In our set-up it appeared that the proliferative re-
sponse was directed against class II and not class I antigens and consequently that 
anergy was induced against the former. This is not entirely surprising, since we and 
others, have obtained evidence that proliferation and cytokine production in a pri-
mary MLC are mainly class II driven 48. An isolated class I mismatch appears to be 
an insufficient trigger during a standard 7 day MLC for a substantial response to 
take place. 
Recently, it was shown that in vivo anergized T-cells displayed a phenotype of regu-
latory cells, which were not able to proliferate but nevertheless produced high lev-
els of IL-10 after in vitro stimulation 54. Others also showed that IL-10 and TGFβ 
were generated in anergic or regulatory T-cell subsets 10,14,39,55. In our model, we 
did not observe elevated IL-10 or TGFβ production after restimulation of the anergic 
T-cells which is probably the consequence of the limited number of anergic cells per 
well due to the heterogeneous cellular composition in our polyclonal system. In fact 
only a small percentage of the T-cells present will have specificity for the stimulator 
cells used and therefore the bulk will be left untouched. However, IL-10 did play a 
role in suppression, since neutralizing IL-10 antibody counteracted the suppression 
C H A P T E R  2  
 
 
64
caused by the anergic T-cells. Apparently very small amounts of IL-10 are produced 
which confer a suppressive function in the microenvironment comprising of the an-
ergic T-cell, naive alloreactive T-cell and stimulator PBMC. 
Non-specific suppression in a system like this can occur in several ways. Previously, 
we have reported on the kinetics of this in vitro co-culture model; it appeared that 
the addition of more than 1.104 control cells (live or irradiated) cells prohibited the 
response of the responding cells 42. Irradiation proved necessary since primed T-
cells respond with secondary kinetics upon subsequent encounter with antigen and 
thus prohibit a newly set-up primary MLC simply by consumption of culture nutri-
ents and overcrowding. Consequently, to detect an immunoregulatory phenomenon 
in a primary MLC, small numbers of irradiated anergic or control cells were co-
cultured with freshly isolated responder and irradiated stimulator cells. Others 
showed suppression of primary MLC with large numbers of non-irradiated anergic T-
cells (ratio anergic T-cells : responders PBMC : stimulator PBMC = 
3.105:1.105:1.105 as compared to our setting  5.103:5.104:2.5-5.104),  which raises 
questions about the mechanism and specificity of the suppression described by this 
group 40. In addition, even when using small numbers, we and others 56, observed 
that control T-cells added to a culture can affect the response of naive T-cells in a 
non-specific manner, therefore the antigen-specific immunoregulatory effect can 
only be deduced after comparison with an appropriate control set-up. Consequently, 
we compared co-cultures of anergic cells with antigen primed control T-cells, and 
showed that HLA specific suppression occurs. Only when third party stimulators 
shared an HLA antigen with the stimulator PBMC used for anergy induction the an-
ergic T-cells led to suppression of naive responder T-cells directed towards third 
party HLA antigens. This antigen-specific manner of suppression has previously 
been shown to occur locally via linked recognition 11,12,17,18 and implies that for 
suppression direct contact is necessary between T-cells of different specificity 9,13. 
Lombardi et al 9 showed that local competition for the antigen binding site might be 
one of the suppressive mechanisms; indeed reduction of stimulator APC numbers in 
our set-up led in most co-cultures to an increase in suppression. Furthermore, 
specificity of the response in this kind of system is not always easy to confirm, as 
linked recognition might also lead to third party tolerance via minor antigens 17. 
Finally, from our model we hypothesize that blocking of the CD86-CD28 pathway 
induces anergy in the CD4+ T-cell subset, which as a consequence provides insuffi-
cient cytokine mediated help for complete activation of CD8+ cytotoxic effector T-
cells. The CD40-CD154 interaction predominantly controls the activation of CD8+ 
cytotoxic T-cells in a direct way, since mAb blocking of CD40 attenuated the cyto-
lytic response. 
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ABSTRACT   
Clinical trials designed to achieve tolerance in humans by selectively antagonizing 
one of the T-cell costimulatory pathways, CD40-CD40L or CD80/CD86-CD28, are 
pending. However, simultaneous blockade of both pathways synergistically pre-
vented graft rejection and successfully induced donor-specific tolerance in animal 
models. Synergism is also supported in human T-cells in vitro following anti-CD86 
mAb and anti-CD40 mAb blockade. Therefore, in our view the most promising clini-
cal strategy would be to antagonize both CD40 and CD86. Fast clinical entrance of 
this anti-CD86 and anti-CD40 bi-directional concept is highly facilitated by a single 
molecule approach. In the present study, a single bi-specific fusion protein was 
constructed that specifically binds human CD40 and CD86, and which combines the 
antagonistic activities of both anti-CD40 and anti-CD86 humanized mAb. The anti-
CD40/86 fusion protein showed tolerance inducing potential as it prevented both 
allogeneic T-cell expansion and generation of cytotoxic effector T-cells, and induced 
anergic regulatory T-cells. Of interest, as compared to the use of single or com-
bined mAb, the anti-CD40/86 fusion protein appeared superior in preventing cyto-
toxic T-cell induction and resulted in more potent immunosuppressive regulatory T-
cells. These data provide proof of concept in successfully combining the antagonis-
tic activity of two humanized mAb with great clinical potential in transplantation 
and autoimmunity, in one single molecule.  
[TRANSPLANTATION 2004, IN PRESS] 
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INTRODUCTION 
Interference in either the CD40L-CD40 or CD28-CD80/86 pathway by antagonist 
mAb directed against CD40, CD40L, CD80 and/or CD86 or CTLA4-Ig (CTLA4 fusion 
protein that antagonizes both CD80 and CD86) successfully prolonged allograft sur-
vival and modulated autoimmune diseases in experimental animal models 1-10. 
Hence, blockade of the CD40L-CD40 or CD28-CD86/CD80 pathways is an important 
target in transplantation and autoimmune therapy 11,12. 
Importantly, simultaneous blockade of both the CD80/CD86-CD28 and CD40-CD40L 
pathways proved synergistic in preventing acute and chronic transplant rejection in 
rodent and non-human primate transplant models 8,9,13-15. Blockade of both 
costimulatory pathways by CTLA4-Ig and anti-CD40L mAb during transplantation 
reduced the alloreactive T-cell pool, and in some studies donor specific tolerance 
was obtained 7,8,16,17. In vitro data on co-stimulation blockade of human T-cells re-
vealed that blockade of CD86 was crucial in the inhibition of T-cell expansion and 
the induction of anergic immunoregulatory T-cells 18.  Single mAb blockade of CD40 
did not result in T-cell anergy nor affected the induction of cytotoxic T-cells 19. 
CD40 blockade appeared important in further reducing the inhibition of cytotoxic T-
cells as induced by anti-CD86 mAb treatment 18. These findings underline the im-
portance of combining CD86-CD28 and CD40-CD40L blockade in the reduction of T-
cell effector functions and generation of regulatory T-cells in humans.  
Clinical trials, using either CTLA4-Ig or anti-CD40L mAb were recently performed. 
CTLA4-Ig was successful in a human clinical trial in psoriasis vulgaris 20 
(www.clincialtrails.gov). Anti-CD40L mAb studies were halted by the unexpected 
occurrence of thrombosis, likely. caused by anti-CD40L mAb binding of CD40L pre-
sent on activated platelets 21. In contrast, the antagonist anti-human CD40 mAb 
(5D12) targets the CD40-CD40L interaction at the APC-side. 5D12 was shown to be 
effective in the prevention and treatment of experimental autoimmune encephalo-
myelitis (EAE) and proved to be safe in a non-human primate model 22-24. This anti-
human CD40 mAb was under investigation in a Phase I dose escalation study in pa-
tients suffering from Crohn’s disease (www.organtx.org).  
T-cells, upon activation express CD152 (CTLA4) that binds to CD80 and CD86 25,26. 
CTLA4 was shown to provide inhibitory signals to T-cells 27-30. In vivo blockade of 
the CTLA4 pathway abrogated long-term allograft survival and tolerance induction 
31-33. Recently, a dominant role for CD80 as the relevant ligand for CTLA4 was 
shown both in vitro 34,35 and in vivo in a cardiac transplant model 31. Consequently, 
simultaneous blockade of the CD86 and CD40 costimulatory ligands, permitting 
CD80-CTLA4 mediated negative signaling, would be the preferable therapeutic in-
tervention to achieve T-cell tolerance. 
As clinical development of two antagonist mAb for a single treatment is unattrac-
tive, we investigated whether an antagonistic single bi-specific anti-CD40/CD86 fu-
sion protein could be constructed. 
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Here, we describe the successful construction of an anti-CD40/CD86 fusion protein, 
that specifically binds to human CD86 and CD40, and antagonizes CD40 and CD86 
mediated functional responses. Moreover, in a human in vitro alloantigen model this 
fusion protein inhibited clonal expansion and generation of cytotoxic T-cells, and 
resulted in anergic immunoregulatory T-cells; all of which are crucial in the induc-
tion of T-cell tolerance in transplantation.  
 
MATERIALS  & METHODS 
Construction of anti-CD40/CD86 fusion protein  
A bi-specific antibody molecule with specificity for human CD40 and CD86 was con-
structed as described by Coloma and Morrison 36. Briefly, two mammalian expres-
sion plasmids were constructed, one encoding for the light chain of the anti-CD40 
mAb (short construct) and the other encoding for the heavy chain of the anti-CD40 
mAb linked to the anti-CD86 single chain antibody variable region fragments (scFv) 
(long construct). The chimeric anti-CD40 V regions were cloned as Fab constructs. 
The anti-CD86 V-regions were in a single chain (scFv) format, in which the VH re-
gion is linked by a (Gly4Ser)3 linker with the VL region.  
 
Generation of short construct 
Starting with the plasmid containing a chimeric anti-CD40 light chain construct 
(mouse kappa leader followed by V light chain region linked to human kappa CL) 
BamHI restriction sites were introduced by PCR using primers 5’-gcgc ggatcc acc 
atg gac atg agg gtc ccc gct–3’ and 5’–gcgc ggatcc cta aca ctc tcc cct gtt gaa-3’. Af-
ter cloning this modified construct in pGEM-T-Easy (Promega, Madison, WI, USA) it 
was verified by sequence analysis. The appropriate construct was subcloned in 
pcDNA3.1(+) zeo (Invitrogen, Breda, The Netherlands) using the BamHI sites.  
 
Generation of long construct 
Starting from the plasmid containing the anti-CD40 heavy chain, part of the VH re-
gion together with a mouse IgG VH leader was subcloned in pGEM-3Zf(+) 
(Promega, Madison, WI, USA) by using HindIII from the polylinker together with a 
naturally occurring BamHI site in the Complementary Determining Region 2 (CDR2) 
of the anti-CD40 mAb. In the remaining part of the VH region the BamHI restriction 
site in CDR2 was modified to a BglII site ( Using PCR with primers 5’-gcgc agatct 
aca gac tat aat tca gct ctc–3’ and 5’-gcc ctt ggt gga ggc tga gga gac ggt gac–3’). 
Human IgG4 (CH1-hinge-CH2-CH3) was amplified, using primers 5’-gtc acc gtc tcc 
tca gcc tcc acc aag ggc–3’ and 5’-gcgc gga tcc gcc tcc acc ttt acc cag aga cag gga 
gag-3’, introducing a short Gly4Ser linker at the C-terminus. By overlap PCR using 
both PCR products as templates, the remaining part of the VH CD40 antibody was 
linked to human IgG4 and cloned in pGEM-T-Easy. The IgG4 construct with cloning 
sites 5’ BglII and 3’ BamHI was verified by sequence analysis. The plasmid contain-
ing the CD86 scFv construct was amplified with the specific primers 5’-gcgc agatct 
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cag gtc cag ctg cag cag tca-3’ and 5’-gcgc ggatcc tca ccg ttt gat ctc gag ctt-3’ to 
introduce 5’ BglII and a 3’ BamHI restriction sites and subsequently cloned in 
pGEM-T-Easy. The modified construct was verified by sequence analysis. Next, the 
final cDNA construct encoding for a VH anti-CD40-human IgG4-scFv-anti-CD86 
molecule was generated. In brief, using the 5’ BglII sites the IgG4 fragment was 
cloned into the BamHI site of CDR2. Subsequently, the scFv part was cloned into 
the BamHI site of the IgG4 construct. Finally, the complete construct was sub-
cloned in pcDNA3.1(+) neo (Invitrogen) using the HindIII and BamHI sites. 
 
Generation of the fusion protein producing cell line 
A stable cell line was obtained after electroporation (200V, 900µF, BioRad Gene 
Pulser, BioRad, Hercules, USA) of both pcDNA3.1 plasmids in NS0 cells and selec-
tion on G418 (200 µg/ml) and Zeocin (200 µg/ml). NS0 cells were cultured in stan-
dard IMDM medium containing 5% FCS and 50 µg gentamycin/ml in a humidified 
CO2 incubator.  The anti-CD40/CD86 fusion protein was purified from the super-
natant of this anti-CD40/CD86 fusion protein-expressing cell line. 
 
Cells and culture media 
Human peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) from buffy coats 
of normal healthy donors. PBMC were stored in liquid nitrogen. Upon thawing, vi-
ability of the cells was determined by trypan blue exclusion. B cells and T-cells were 
isolated from the PBMC by density gradient centrifugation using lymfokwik-B or 
lymfokwik-T (One Lambda Inc, Canoga Park, CA), respectively.  
Cell cultures were either carried out in IMDM culture medium (BioWhittaker Europe, 
Verviers, Belgium) supplemented with 10% fetal calf serum and 80 µg/ml gentamy-
cin (Gibco, Paisley, UK) or RPMI culture medium (RPMI-1640 with glutamax sup-
plemented with pyruvate (0.02 mM)), 100 U/ml penicillin, 100 µg/ml streptomycin, 
(all from Gibco) and 10% heat inactivated pooled human serum) at 370C, 95% hu-
midity and 5% CO2. All cell cultures were performed at 37º C, 5% CO2 in a humidi-
fied atmosphere (95% relative humidity). 
 
Anti CD40 and CD86 antibodies and Fab fragments 
Humanized chimeric anti-CD40 (ch5D12) and anti-CD86 (chFun-1) were generated 
by Bioceros (Utrecht, The Netherlands) as described previously 24 and used at the 
indicated concentrations. Single Fab fragments were made using the ImmunoPure 
Fab preparation kit (Pierce, Rockford, USA). 
 
CD40 and CD86 binding characteristics by ELISA 
CD40 and CD86 binding was studied in ELISA.   96-well flat bottom plates (Costar, 
Corning B.V. Life Sciences, The Netherlands) were coated with 20 ng/ml recombi-
nant generated soluble human fusion protein CD40-Fc or CD86-Fc. CD80-Fc served 
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as control. A goat-anti-human IgGκ polyclonal antibody labeled with HRP (Jackson 
ImmunoResearch Laboratories, West Grove, U.S.A.) was used for detection. TMB 
was used as substrate (Promega, Madison, WI, USA).  
 
CD40-dependent B-cell proliferation 
Isolated B cells (5x104 per well) were preincubated for 5 minutes in the absence or 
presence of fusion protein or mAb at room temperature in 96 well round bottom cul-
ture plates in IMDM culture medium. Thereafter, membrane fragments obtained by 
repetitive freezing and thawing of 1x104 CD40L expressing Sf9 insect cells were 
added. After a 72 hours culture period proliferation was measure by 3H-thymidine 
incorporation.  
 
Bioassay for CD40-dependent IL-8 production by THP-1 cells 
The monocytic human cell-line THP-1 (ATCC, Rockville, MD) and the CD40L express-
ing Jurkat 39.8/50 human T-cell line were cultured in IMDM medium. THP-1 cells 
were stimulated for 48 hours with 500 U/ml recombinant human IFN-γ  to up-
regulate CD40 expression. These cells were collected, washed, and resuspended in 
IMDM supplemented with 2% human AB serum. 1x104 THP-1 cells and 2x104 
39.8/50 Jurkat-cells were cocultured in 96 well round bottom plates in a final vol-
ume of 100 µl, in the absence or presence of the indicated mAb or fusion protein. 
The production of IL-8 by the THP-1 cells was completely dependent on CD40-
CD40L. After 48 hours supernatants were collected and analyzed for the presence of 
IL-8 by ELISA (Biosource, Camarillo, CA). 
 
Bioassay for CD86 costimulation-dependent activation of T-cells  
Freshly isolated T-cells  (1x105/well) were co-cultured with mitomycin-c (Sigma-
Aldrich Chemie, Zwijndrecht, The Netherlands) treated murine FcγRI expressing 
P815 cells transfected with human CD86 (1x105 cells/well) in IMDM culture medium. 
To these cultures 1 µg/ml anti-CD3 mAb (UCHT-1, Dr.Kasran, Leuven, Belgium) and 
either chFun-1, ch5D12 or fusion protein were added.  After 48 hours supernatants 
were analyzed for the presence of IFN-γ by ELISA (Biosource). Proliferation was 
studied by 3H-Thymidin incorporation.  
 
Selective binding capacity of-CD40/CD86 fusion protein   
Epstein-Barr virus-transformed normal human B-lymphoblasts (JY-cells) were used 
to determine the binding capacity of the anti-CD40/CD86 fusion protein. JY-cells 
typically co-express high levels of CD40 and CD86 as indicated by ch5D12-FITC and 
chFun-1-FITC staining. This mAb binding was prevented when JY-cells were first in-
cubated with the fusion protein . The anti-CD40/CD86 fusion protein (500 ng/ml) 
was preincubated for 10 minutes at room temperature with a fixed concentration of 
soluble CD40-Fc (1000 ng/ml) and various concentrations of CD86-Fc (and vice 
versa). Subsequently, JY-cells (1x106/ml) were exposed to these CD40-Fc and 
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CD86-Fc pre-adsorbed anti-CD40/CD86 fusion proteins for 30 minutes at 4 °C. After 
extensive washing in PBS containing 1% BSA, cell samples were incubated with 
FITC-conjugated goat anti-human IgG (500 ng/ml; Jackson ImmunoResearch Labo-
ratories) for 30 minutes at 4 °C. The presence of anti-CD40/CD86 fusion proteins, 
indicated by fluorescence, was analyzed by flowcytometry using a FACScalibur flow-
cytometer and CellQuest software (BD Biosciences, Erembodegem, Belgium). Data 
were expressed as mean fluorescence intensity after subtraction of non-specific 
background staining. 
 
Mixed Lymphocyte Cultures  
Primary one-way Mixed Lymphocyte Cultures (MLC) were performed by culturing 
1x105 30 Gy γ-irradiated stimulator PBMC with 1x105 HLA mismatched responder 
PBMC in 96 wells round bottom plates (Greiner, Frickenhausen, Germany) in 200 µl 
RPMI culture medium. Proliferation was analyzed by 3H-thymidine incorporation at 
the indicated time-points. To this end, 1 µCi  3H-thymidine (ICN-Pharmaceuticals, 
Irvine, CA, USA; specific activity 2.0 Ci/mmol) was present during the last 18 hours 
of culture. 3H-thymidine incorporation (3H-incorporation) was analyzed by scintilla-
tion counting.  
 
Cytotoxicity by 51Cr-release assay 
The cytotoxic capacity of allogeneically primed T-cells was examined by 51Cr-release 
of  51Cr labeled PHA-blasts. Briefly, allogeneic PHA-blasts were generated by cultur-
ing PBMC for 48 hrs with PHA-M (Boehringer, Mannheim, Germany) and subse-
quently for 48 hrs with IL-2 (50U IL-2/ml, Proleukine, Eurocetus, Netherlands). 
2.106 PHA-blasts were labeled with 100 µCi 51Cr (Amersham, UK) and used as tar-
get cells at 1000 cells/well. Different effector/target (E/T) ratios were tested in 
triplicate. Culture supernatants were examined for released 51Cr on a γ-irradiation 
counter (Wallac, Turku, Finland).  Cytotoxic capacity is shown as percentage target-
cell lysis, calculated according to the following equation: 
(CPM sample release - CPM spontanous release)
(CPM total release - CPM spontanous release)
Percentage lysis = X 100%
 
 
Detection of T-cell anergy and immunoregulaiton 
To analyze the potential of the fusion protein to induce T-cell anergy, primary MLC 
were performed for 7 days in 24 wells plates at concentrations of 1x106 responders 
versus 1x106  30 Gy γ-irradiated stimulator PBMC in the presence ch5D12 (1 µg/ml)  
and chFun-1 (1 µg/ml) or anti-CD40/CD86 fusion protein. Cells were harvested, 
washed and allowed to rest for 2-3 days. Viable T-cells (2x104) collected by density 
gradient centrifugation were restimulated with 1x105 allo-specific 30 Gy irradiated 
stimulator PBMC in the absence and presence of IL-2 (12.5U/ml) in 96 well round 
bottom plates. T-cell anergy was defined as hyporesponsiveness upon antigenic res-
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timulation that is reversed by addition of exogenous IL-2 18. Immunoregulation was 
studied in co-cultures, to this end the cells of interest were co-incubated at the in-
dicated dose with 5x104 responder PBMC and 5x104 30 Gy γ-irradiated stimulator 
PBMC. 
 
RESULTS 
Generation and ligand specific binding of the anti-CD40/CD86 fusion 
protein  
Pilot studies using CD40 and CD86 specific ELISA’s and functional assays revealed 
that bivalent antibody binding (mAb) was essential for the antagonistic activity of 
chimeric anti-CD40 (ch5D12), while monovalent (fragment antigen binding, Fab) 
binding to CD86 was sufficient for functional antagonistic activity by anti-CD86 
(chFun-1) (Fig.1A). Therefore we constructed a single recombinant bi-specific mAb 
fusion protein consisting of a bivalent anti-CD40 (ch5D12) antibody part and a 
monovalent anti-CD86 (chFun-1) single chain (scFv)  (Fig.1B). CD40 and CD86 
binding of the fusion protein was studied using a CD40 or CD86 specific sandwich 
ELISA, respectively (Fig.2). Binding of the fusion protein was compared to binding 
of ch5D12 and chFun-1mAb. ch5D12 mAb and the anti-CD40/86 fusion protein 
bound to CD40 at equivalent concentrations, while chFun-1 did not bind to CD40 
coated plates. Similarly, chFun-1 and the anti-CD40/86 fusion protein showed com-
parable binding of CD86 (Fig.2). No binding of CD86 by ch5D12 was observed. Nei-
ther mAb, nor the anti-CD40/86 fusion protein bound to an irrelevant CD80 coating 
(Fig.2).  
 
The anti-CD40/CD86 fusion protein antagonizes both CD40 and CD86 
mediated functional activity  
Functional activity of the anti-CD40/CD86 fusion protein was examined in bioassays 
that depend on either CD40-CD40L or CD86-CD28 interactions. The anti-CD40/CD86 
fusion protein inhibited CD40-induced B-cell proliferation (Fig.3A) as well as CD40-
CD40L mediated IL-8 production by the THP-1 cells (Fig.3B) in a dose-dependent 
manner.Comparable inhibition was observed for ch5D12. As expected, chFun-1 
alone did not affect these responses (Fig.3A+B).  
In a CD86 costimulation dependent T-cell stimulation assay the anti-CD40/CD86 
fusion protein, like chFun-1, inhibited T-cell proliferation (Fig.3C) and IFNγ produc-
tion (Fig.3D) in a dose dependent way. Thus, the anti-CD40/CD86 fusion protein, 
like ch5D12 and chFUN-1, antagonizes both CD40 and CD86 dependent immune re-
sponses. 
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F I G U R E  1   
Construction of the bi-specific CD40/CD86 fusion protein. 
A. Functional activity by ch5D12 requires 
bivalent binding, while monovalent chFun-1 
(ch Fun-1 Fab) binding results in antagonis-
tic activity. Binding of chFun-1 (upper left) 
and ch5D12 (lower left ) mAb and single Fab 
chains (indicated in the legends) was ana-
lyzed in a sandwich ELISA assay.  Mab and 
Fab concentrations are indicated on the X-
axis (Log scale). CD86-dependent IFN-γ pro-
duction (upper right) and CD40 dependent 
IL-8 production (lower left) were determined 
by ELISA. Representative experiments are 
shown (n=3).B. A bi-specific antibody mole-
cule was constructed against human CD40 
and human CD86, using 5D12 (CD40)mAb 
and Fun-1 (CD86)mAb, respectively. The 
construct consists of a human IgG4 molecule 
attached to the bivalent heavy and light 
chain of the 5D12 mAb, linked to a monova-
lent Fun-1 single chain antibody variable 
region fragments (scFv). Two mammalian 
expression plasmids were constructed, one 
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encoding the light chain of the anti-CD40 
antibody and the other encoding the anti-
CD40 heavy chain linked to the anti-CD86 
single chain (scFv). The plasmids were 
transfected into NS0 cells, resulting in a 
anti-CD40/CD86 producing cell line. Details 
are given under materials and methods. 
F I G U R E  2   
Specific binding of CD40 and CD86 by the anti-CD40/CD86 fusion protein in ELISA. 
Binding of the anti-CD40/CD86 fusion pro-
tein to both CD40 (left), CD86 (middle) and 
CD80 (right; irrelevant control coating) was 
compared to binding of the parent mAb 
ch5D12 (anti-CD40) and chFun-1 (anti-
CD86) by a sandwich ELISA assay. Fusion 
protein and mAb concentrations are indi-
cated on the X-axis (Log scale). ch5D12 and 
chFun-1 are recombinant generated chimeric 
mAb containing identical IgG4 human back-
bone construct, and were used as mutual 
isotype controls. The conditions are given in 
the legends. Absorbance is shown on the Y-
axis, mAb or Fusion protein concentration is 
shown on the X-axis. One representative 
experiment out of 6 is shown.
 
The anti-CD40/CD86 fusion protein is unable to bind CD86 on cells 
when CD40 occupies the fusion protein, reducing the potential risk of 
activation by cross-linking  
Since the anti-CD40/CD86 fusion protein is able to bind both CD40 and CD86 anti-
gens, cross-linking induced activation of cells may occur in PBMC. Therefore, we 
analyzed whether simultaneous binding of CD40 and CD86 took place by the fusion 
protein (Fig.4).  The anti-CD40/CD86 fusion protein was unable to bind CD86 on JY-
cells when the fusion protein was pre-adsorbed with soluble CD40 antigen. Con-
versely, in the presence of soluble CD86 some degree of CD40 binding was present 
which disappeared at low concentrations of soluble CD40 (31-64 ng/ml). Thus, 
CD40 occupancy of the anti-CD40/CD86 fusion protein prevented the anti-CD86 side 
from binding to the CD86 antigen. This implies that cross-linking is not likely to oc-
cur. On the other hand, CD86 adsorption of the fusion protein allowed residual 
binding of CD40, a result that does not completely preclude activation induced via 
cross-linking. 
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F I G U R E  3  
Functional antagonistic activity at the CD40 and CD86 binding side by the anti-
CD40/CD86 fusion protein.  
A. CD40-dependent B-cell proliferation. Puri-
fied B cells were stimulated with membrane 
fragments of CD40L-transfected sf9 cells in 
the absence or presence of the bivalent anti-
CD40/CD86 fusion protein, ch5D12 or chFun-
1 (Legend). Proliferation (Y-axis) is shown in 
the presence of the indicated concentrations 
of anti-CD40/CD86 fusion protein and mAb 
(X-axis). B. CD40L-CD40 interaction de-
pendent IL-8 production by CD40+ THP-1 
cells. CD40+ THP-1 cells were co-cultured 
with CD40L+ Jurkat T-cells and decreasing 
concentrations (X-axis) of CD40/86 fusion 
protein, ch5D12 and chFun-1 (isotype) IL-8 
production was detected by ELISA. Repre-
sentative experiments out at least 3 inde-
pendent experiments are shown.  
C. CD86-dependent T-cell proliferation and 
D. IFN-γ production. Freshly isolated T-cells 
were co cultured with 1 µg/ml soluble anti-
CD3 and CD86 expressing P815 cells and 
decreasing concentrations of the anti-
CD40/CD86 fusion protein, chFun-1 and an 
isotype matched chimeric mAb (chBAT123) 
(X-axis, Log scale). Proliferation (Y-axis) and 
IFNγ production are shown. In both assays, 
CD86 stimulation is required to induce high 
levels of IFN-γ production and proliferation 
by T-cells. Representative experiments out 
of 3 independent experiments are shown. 
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Anti-CD40/CD86 fusion protein inhibits proliferation of allogeneic T-
cells and generation of cytotoxic effector cells 
Allograft tolerance is the consequence of multiple immunological events such as re-
duction of the alloreactive T-cell pool, prevention of the generation of alloreactive 
cytotoxic T-cells and the induction of anergic immunoregulatory T-cells. The effect 
of the anti-CD40/CD86 fusion protein on these immunological phenomena was ex-
amined in an in vitro human alloantigen T-cell stimulation model . First, the inhibi-
tion of alloantigen mediated T-cell expansion was studied in primary MLC that were 
performed in the absence or presence of anti-CD40/CD86 fusion protein, chFun-1, 
or chFun-1 together with ch5D12. The anti-CD40/CD86 fusion protein resulted in 
similar inhibition (~80% inhibition) of the proliferative response of naive allogeneic 
T-cells as compared to chFun-1 (~72%) or the combination of ch5D12 + chFun-1 
(~82%) (Fig.5). Inhibition of the proliferative response by the fusion protein and 
the mAb was the result of reduced proliferation, and not due to increased cell 
death, as the vast majority of cell remained viable after culture (data not shown). 
Moreover, the fact that the anti CD40/CD86 fusion protein resulted in inhibition ex-
cludes the possibility of activation due to feasible cross-linking of CD40 and CD86 
surface molecules in PBMC.  
Secondly, the anti-CD40/CD86 fusion protein was examined for its potential to in-
hibit the generation of cytotoxic effector T-cells. The anti-CD40/CD86 fusion protein 
effectively inhibited the induction of cytototoxic T-cells (28-17% lysis as compared 
to 55-45% lysis by control cells, at E/T-ratio 75-19) (Fig.5B). In fact, the fusion 
protein showed superior inhibition of cytototoxic T-cell generation when compared 
to combined blockade by ch5D12+chFun-1 (39-27% lysis, p<0.05), or the single 
use of either chFun-1 (44-34% lysis, p<0.05) or ch5D12 (55-38% lysis, p<0.05). 
These results once more emphasize the importance of additional blockade of CD40, 
next to CD86 blockade, in reducing the induction of human cytotoxic effector T-
cells.  
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F I G U R E  4   
Binding capacity of the anti-CD40/CD86 fusion protein after adsorption with CD40-
Fc and CD86-Fc. 
The anti-CD40/CD86 fusion protein was pre-
incubated by a constant concentration (1000 
ng/ml) of either CD40 (CD40-Fc) or CD86 
(CD86-Fc) in the presence of various in-
creasing concentration (X-axis, Log scale) of 
soluble CD86 or CD40, respectively (See 
legend). Next, CD40 and CD86 expressing JY 
human B cell lymphoblasts, were exposed to 
the fusion protein (derived from clone 19 or 
26) which was pre-adsorbed with soluble 
CD40-Fc and CD86-Fc. After washing, the 
cells were incubated with a FITC conjugated 
anti-IgG which labels the anti-CD40/CD86 
fusion protein. CD40-Fc and CD86-Fc soluble 
antigens did not bind JY lymphoblasts (data 
not shown). The presence of anti-CD40/CD86 
fusion protein (either adsorbed with CD40-Fc 
or CD86-Fc) on JY cells was detected by 
flowcytometric analysis. Mean fluorescence 
intensity is shown on  the Y-axis. A repre-
sentative experiment is shown (n=3).
 
Costimulation blockade by the anti CD40/CD86 fusion protein in-
duces immunosuppressive anergic T-cells  
The induction of T-cell anergy by the anti-CD40/CD86 fusion protein was studied in 
secondary MLC . To this end, T-cells derived from primary MLC that were inhibited 
by the anti-CD40/CD86 fusion protein, ch5D12+chFun-1 or chFun-1 were alloanti-
gen specifically restimulated in a secondary MLC. Single anti-CD40 mAb were not 
examined as they do not result in T-cell anergy 19. Primed control T-cells typically 
showed a secondary response characterized by an early peak in proliferation at day 
2-3. Fusion protein treatment, like the use of mAb, led to T-cell hyporesponsiveness 
(Fig.6A). This hyporesponsive state was reversed by allogeneic stimulation in the 
presence of exogenously added IL-2 (Fig.6A), which is a classical characteristic of 
T-cell anergy.  
Immunoregulation by T-cells derived from fusion protein, chFun-1 and 
ch5D12+chFun-1 blocked MLC was examined in co-cultures. Cell-dose dependent 
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suppression of the proliferative response was observed (Fig.6B). As compared to 
anergic T-cells generated by Fun-1 or ch5D12+chFun-1 the fusion protein appeared 
superior suppressor T-cells. In accordance with our previously reported ob-
servations 18,37 T-cell anergy as well as induction of suppression appeared antigen 
specific (data not shown). 
F I G U R E  5  
The anti-CD40/CD86 fusion protein inhibits allogeneic naïve T-cell proliferation and 
the generation of alloreactive cytotoxic effector T-cells.  
A. The anti-CD40/CD86 fusion protein inhib-
its T-cell proliferation. One way primary MLC 
using PBMC of two HLA mismatched donors, 
(responder PBMC versus γ-irradiated (30Gy) 
stimulator PBMC)  were cultured in the ab-
sence or presence of 1µg/ml anti-CD40/CD86 
fusion protein, ch5D12 (anti-CD40), chFun-1 
(anti-CD86) or ch5D12+chFun-1 (Y-axis). 
Proliferation (X-axis) is shown at day 6 of 
the cultures.  
B. The anti-CD40/CD86 fusion protein inhib-
its induction of cytotoxic T-cells. Naïve T-
cells were primed in a primary MLC for 7 
days in the presence or absence (Control) of 
the indicated costimulation blocking agents 
(legend). The responder cell were allowed to 
recuperate, the viable cells were used as 
effector cells in a 51Cr-release assay using 
51Cr labeled allogeneic T-cells blasts as tar-
get cells. Percentage cell lysis is shown at 
the Y-axis. Autologous target T-cells were 
not affected by the effector cells (data not 
shown). Representative experiments out of 4 
independent experiments performed with 
different donor PBMC combinations are 
shown. P values between the indicated 
groups were determined by nonparametric 
ANOVA.
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F I G U R E  6  
The anti-CD40/CD86 fusion protein induces anergic immunoregulatory T-cells 
Primary MLC were performed in the absence 
or presence of the anti-CD40/CD86 fusion 
protein, chFun-1 mAb or ch5D12 + chFun-1. 
From these cultures the responder T-cells 
were harvested and allowed to rest. After 
density gradient centrifugation the viable T-
cells were examined for anergy (A) and im-
munoregulation (B).   The culture conditions 
during the primary cultures are indicated in 
the legends 
A. T-cell anergy was examined upon alloan-
tigen specific restimulation by γ-irradiated 
(30Gy) stimulator PBMC in the absence (left) 
or presence of 12.5 U/ml exogenous IL-2 
(right). Proliferation (Y-axis) is shown during 
the time-course (X-axis) of restimulation. 
Antibodies or fusion protein were absent 
during restimulation.  
B. Immunoregulation was studied in co-
culture experiments performed with 5x104 
responder, 5x104 γ-irradiated stimulator 
PBMC and titrated numbers (X-axis) of the 
indicated cells (Legends). Proliferation (Y-
axis) is shown at day 5 the culture. The 
stimulator PBMC used in restimulation assays 
and stimulator PBMC and responder PBMC 
used in co-culture assays were derived from 
the original frozen PBMC pool that were used 
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in the primary MLC. P values between the 
indicated groups were determined by non-
parametric ANOVA. 
C. Immunoregulatory T cells generated by 
the anti-CD40/CD86 fusion protein suppress 
in an antigen specific way. Immunosuppres-
sion was examined in co-cultures as men-
tioned under 6B. The co-cultures consisted 
of the original responder and stimulator 
PBMC (original MLC) or the original re-
sponder PBMC and completely HLA mis-
matched stimulator PBMC (as compared to 
the original stimulator PBMC) (third party 
MLC). A representative experiment out of at 
least 3 independent experiments conducted 
with different donor PBMC is shown. 
 
DISCUSSION 
Inhibition of the costimulatory pathways CD40-CD40L and CD80/86-CD28 is a 
promising strategy to prevent allograft loss and autoimmunity 11,12. This is empha-
sized by the clinical trails that are focusing on blockade of either of these costimu-
latory pathways. However, simultaneous blockade of both the CD80/CD86-CD28 and 
CD40-CD40L pathway has been reported to be synergistic in preventing transplant 
rejection in rodents and non-human primates 8,9,13-15.  In human T-cells combined 
anti-CD86 and anti-CD40 mAb blockade resulted in the generation of anergic regu-
latory T-cells and prevented the induction of cytotoxic T-cells 18. In addition, given 
that signaling through CTLA4, most likely via CD80 on the APC 34,35, is essential for 
attenuating T-cell responses 9,27-29 and induction of T-cell tolerance 31-33 we focused 
on a bi-directional CD40 and CD86 blocking therapeutic approach.  Therefore, we 
generated a bi-specific anti-CD40/CD86 fusion protein that specifically binds and 
functionally antagonizes human CD40 and CD86 costimulatory molecules. 
The anti-CD40/CD86 fusion protein consists of a bivalent anti-CD40 (ch5D12) anti-
body side   and a monovalent anti-CD86 (chFun-1) single chain (scFv).  5D12 biva-
lency was required for functional anti-CD40 antagonism while monovalent chFun-1  
Fab fragments antagonized CD86 function . This chFun-1 monovalency of the fusion 
protein did not affect the avidity as it resulted in similar binding as the bivalent 
chFun-1 mAb (Fig.2).  
Besides the induction of anergic regulatory T-cells by costimulation blockade, 
CTLA4-Ig and anti-CD40L mAb might mediate their tolerizing effect via additional 
mechanisms. CTLA4Ig, next to blocking CD86 and CD80 costimulatory functions, 
regulates tryptophan catabolism in B7-expressing dendritic cells (DC) 38 which 
might contribute to the induction and maintenance of peripheral tolerance. Simi-
larly, regulatory T-cells initiated trypthophan catabolism in DC 39. It is unknown 
whether the anti-CD40/CD86 fusion protein directly mediates DC modulation. But as 
the fusion protein induced regulatory T-cells it is tempting to speculate that the 
tryptophan catabolism might be affected.  The mechanism underlying anti-CD40L 
mAb mediated graft survival, next to inducing infectious tolerant regulatory T-cells 
40,41 were recently shown to depend on the selective depletion of activated T-cells 
via complement- and Fc receptor–mediated mechanisms  42. In our strategy, we fo-
cused on blockade of CD40 and CD86 on the APC, instead of targeting CD40L on 
effector T-cells, which results in ‘mAb untouched’ anergic regulatory T-cells. These 
C H A P T E R  3  
 
 
84
regulatory suppress aggressive alloreactive T-cells 18 and, eventually the regulatory 
T-cells might spread their tolerant state to otherwise aggressive alloreactive T-cells 
by a mechanism known as infectious tolerance 43,44. 
Simultaneous binding of CD40 and CD86 by the anti-CD40/CD86 fusion protein 
might inadvertently induce activation via cross-linking of these surface ligands pre-
sent on the APC, B-cells or memory T-cells 45,46. Interestingly, the anti-CD40/CD86 
fusion protein lost its binding activity for CD86 when saturated with CD40 (Fig. 4), 
which reduces the likelihood of activation via cross-linking. On the other hand, 
CD86 adsorption of the anti-CD40/CD86 fusion protein allowed some degree of 
CD40 binding, which still might pose a risk for cross-linking induced activation. 
However, fusion protein induced activation was excluded in MLC performed with 
PBMC, which in fact resulted in inhibition of the response. Microscopically no differ-
ences in cell clustering were observed between MLC performed with the fusion pro-
tein or the chimeric mAb (data not shown).  
Clinical development of a combination of two novel molecules for a single indication 
is more complicated than development of a single molecule. Such dual development 
is expensive and time consuming since it requires development of two production 
cell-lines, two purification methods, two GMP products and safety assessments of 
both products individually as well as that of the combined clinical grade mAb. 
Therefore, the  generation of a single molecule that antagonizes  CD40 and CD86 is 
a more straightforward approach and facilitates accelerated clinical applicability.  
Summarizing, the described bi-specific anti-CD40/CD86 fusion protein functionally 
inhibits both CD40-CD40L and CD86-CD28 costimulation. From a clinical perspec-
tive, this fusion protein is of great interest for tolerance induction in transplantation 
scenarios as it reduces both allogeneic T-cell proliferation and generation of cyto-
toxic effector T-cell, and, moreover it results in potent anergic immunoregulatory T-
cells. 
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ABSTRACT 
An important prerequisite in using regulatory T-cells for immunotherapy is their ex 
vivo expansion without loss of suppressor function. Human anergic regulatory T-
cells are expandable by antigen-specific stimulation in the presence of IL-2. IL-15, 
like IL-2, is a T-cell growth factor that in contrast to IL-2 stimulates survival of T-
cells. Here, we studied whether IL-15 could be exploited as a superior growth factor 
of human CD4+ anergic regulatory T-cells that were generated by costimulation 
blockade. Next, IL-15 as compared to IL-2, was investigated with respect to expan-
sion and function of these regulatory T-cells. Optimal expansion required cognate 
allogeneic stimulation in the presence of exogenous IL-15. IL-15 resulted in en-
hanced survival that was paralleled by an increased number of Bcl-2 expressing 
cells. Moreover, IL-15 induced a distinct type of anergy characterized by hyper-
reactivity to IL-15, resulting in improved expansion. This is likely attributed to in-
creased propensity of these cells to upregulate both α and γ chain of the IL-2 and 
IL-15 receptor. Notably, IL-15 expanded regulatory CD4+ T-cells suppressed both 
naive and memory T-cells in a superior way. Immunosuppression required alloanti-
gen specific stimulation, appeared γ-irradiation resistant and independent of IL-10, 
TGFβ or CTLA-4 interactions. These regulatory T-cells were stable suppressors, me-
diating bystander suppression upon TCR stimulation but leaving recall responses 
unaffected in the absence of cognate antigen. Finally, human naturally occurring 
regulatory CD4+CD25+ T-cells appeared important in generating regulatory T-cells 
by costimulation blockade. Concluding, IL-15 expanded de novo induced human an-
ergic regulatory CD4+ T-cells are of interest in antigen specific immunotherapy. 
[THE JOURNAL OF IMMUNOLOGY 2003; 171 (12): 6431] 
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INTRODUCTION 
Immunoregulatory suppressive T cells play a crucial role in homeostasis of the im-
mune system and in prevention of immune pathology 1,2. Immunoregulatory T cells 
were identified in rodents and humans and may broadly be divided into two groups; 
naturally occurring regulatory cells (i.e. CD4+CD25+) 3-7 and various types of de 
novo induced suppressive T cells 8-12. Both kinds of immunosuppressive regulatory T 
cells share an anergic phenotype (low proliferative capacity in vitro) and need T cell 
receptor triggering to become suppressive, yet contrasting and incomplete under-
stood suppressor mechanisms have been postulated. Briefly, immunoregulatory T 
cells might inhibit target T cells directly and/or indirectly by impairment of the anti-
gen presenting cell (APC) function, often in a cell-cell contact dependent manner 
2,13. Some studies indicated an important role for immunosuppressive cytokines 
such as IL-10 and TGFβ 9,14-16 or interactions via CTLA-4 15,17,18. 
Immunosuppressive regulatory T cells play an evident role in allograft tolerance and 
prevention of autoimmune disease; hence there are substantive therapeutic pros-
pects for these cells in transplantation and autoimmunity 2,13,19-21. Moreover, the 
therapeutic use of antigen-specific suppressor T cells would be an advantage to the 
currently used non antigen-specific immunosuppressive drugs. For future human 
immunotherapy sufficient immunosuppressive cell numbers will be needed and 
therefore it is crucial to reverse the anergic state and enhance the growth of these 
cells, while preserving their (antigen-specific) suppressor function.  
In previous work, we have shown the novo induction of human anergic allo-MHC 
specific suppressive regulatory T cells via anti-CD86/CD40 mAb blockade 10. More-
over, we showed that exogenous IL-2 recovered the anergic state and enhanced 
growth whereby the cells retained their anergic state after withdrawal of IL-2 10. 
Similar observations were made for human naturally occurring CD4+CD25+ T cells 
following TcR stimulation in the presence of exogenous IL-2 or mixtures of IL-2 and 
either IL-4 or IL-15 4-6. In addition, naturally occurring CD4+CD25+ regulatory T 
cells preserved their suppressive potential following TcR stimulation in the presence 
of exogenously added cytokines 4,7,22,23. These cytokine mediated growth features 
are of interest in the expansion of alloantigen-specific suppressor T cells for future 
immunotherapy. Therefore, in this study we examined the potential of IL-2 and IL-
15 in alloantigen specific expansion of anergic suppressor T cells.  
IL-15 and IL-2 share two receptor subunits; the β chain (CD122) 24,25 and the com-
mon γ chain (CD132) 26 including a number of biological functions 27,28. Both cyto-
kines stimulate the proliferation of activated T cells 25, but they distinctly contribute 
to T cell survival 29,30. IL-15 is generally considered to be an inhibitor of apoptosis 
30,31, while IL-2 is important in activation induced cell death (AICD) of CD4+ T cells 
32,33. In addition, IL-15, in contrast to IL-2, selectively stimulated proliferation of 
the CD8+ memory T cell subset 34-36 and re-directed apoptosis towards anergy in 
partially stimulated T cells 37. Recently, IL-15 was proposed to be critical in the 
proliferation of human regulatory T cells 38,39.  
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Considering the opposite effects of IL-2 and IL-15 on T cell survival and selective 
growth of certain T cell subsets, we hypothesized that IL-15 would be ideally suited 
for expansion of the novo-induced anergic regulatory CD4+ T cells.  In this report, 
we describe superior expansion of de novo induced anergic regulatory CD4+ T cells 
by stimulation with cognate antigen and exogenously added IL-15. After expansion 
these cells remained anergic and immunosuppressive. Immunosuppression required 
alloantigen-specific TcR triggering, was independent of TGFβ, IL-10 or CTLA-4, and 
sustained in the presence of a concurrent autologous productive T cell response. 
 In conclusion, these IL-15 expanded de novo induced regulatory CD4+ T cells meet 
important criteria needed for donor specific immunosuppression and hence are of 
potential interest for clinical application in prevention of graft rejection. 
 
MATERIALS  & METHODS 
Cells 
For all experiments, peripheral blood mononuclear cells (PBMC) were isolated by 
density gradient centrifugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) 
from buffy coats  of normal healthy donors. Cells were frozen and stored in liquid 
nitrogen until use. After thawing, viability of the cells was determined by trypan 
blue exclusion.  
CD4+ T cells were purified from PBMC by a magnetic bead based negative selection 
system purchased from Stem Cell Technologies (Vancouver, BC, Canada) in combi-
nation with the Stem Sep CD4+ T cell enrichment cocktail (Stem Cell Technologies, 
Vancouver, BC, Canada). Naturally occurring CD4+CD25+ T cells were depleted us-
ing CD25+ microbeads (Miltenyi GmbH, Germany). The isolation procedures were 
carried out according to manufacturers instructions and resulted in an enrichment 
of 90-95 % CD4+ T cells and in depletion (<0.2%) of CD25+ T cells, respectively.  
 
Flowcytometry, intracellular cytokine staining and antibodies 
Cells were phenotypically analyzed by three or four color immunofluorescence. 
Briefly, cells were washed twice with buffer (PBS containing approx. 0.2 % BSA) 
and labeled with the antibodies of interest conjugated with FITC, PE, ECD or PC5. 
Cells were incubated for 20 minutes in the dark at room temperature, washed twice 
and analyzed on a Coulter Epics XL flowcytometer (Beckman Coulter, Fullerton, CA). 
5000-10.000 living cells were collected and analyzed by Coulter Epics Expo 32 
(Beckman Coulter, Fullerton, CA, USA). Isotype matched antibodies, usually below 
background staining, were used to define marker settings.  The following conju-
gated mAb were used: CD3(UCHT1), CD4(MT310), CD8(DK25), CD25(ACT1), 
CD27(M-T271), CD45RA(4KB5), CD45RO(UCHL1) FITC or PE labeled (DAKO, Glos-
trup, Denmark), CD122(CF1) PE labeled (Immunotech, Marseille, France), CD4(T4), 
CD8 (T8)ECD-labeled (Coulter Corporation, Miami, Fl, USA) and CD152 (BNI13) PE, 
CD4(T4), CD8(T8) and CD25(B1.49.9) PC5-labeled (Immunotech, Marseille, 
France), CD25(M-A251) PE, CD132(AG184) PE anti-Bcl2(Bcl2/100) PE (BD, San 
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Jose, CA) and anti human IL-15Rα-biotin (R&D systems, United Kingdom) which was 
used in combination with streptavidin-PC5 (Beckman Coulter, USA). Anti Human  IL-
2 PE, IL-4 PE, IL-10 PE, IFNγ FITC and TNFα FITC were purchased from BD Biosci-
ences (BD, Belgium). Intracellular cytokine staining was analyzed after polyclonal 
stimulation with PMA and Ionomycin, such as described previously 40. Data were 
analyzed by Coulter Epics Expo 32 software (Beckman Coulter, Fullerton, CA, USA).  
To detect intracytoplasmic CTLA-4 (CD152), Bcl-2 or cytokines, the cells of interest 
were fixed and permeabilised  (Fix and Perm reagent A and B, Caltag Laboratories, 
An Der Grub, Vienna, Austria) according to the instructions of the manufacturer, 
and thereafter labeled with the mAb of interest. After 45 minutes incubation at 
room temperature the cells were washed 3 times and analyzed by flowcytometry. 
Appropriate isotype control mAbs were used for marker settings. 
 
Cell division kinetics according to CFSE dilution. 
Cell division was studied by labeling responder T cells with 2µM Carboxyfluorescein 
Diacetate Succinimidyl Ester (CFDA-SE, Molecular Probes, Eugene, OR) just before 
stimulation. In the cell esterases cleave the acetyl group leading to the fluorescent 
diacytylated carboxyfluorescein succinimyl ester (CFSE). At each cell division the 
mean CFSE fluorescence halves. Simultaneous antibody labeling of selective T cell 
subsets enables division kinetics of a particular subset. Samples were measured by 
flowcytometry. Data were analyzed using ModFit LT (Verity Software House, Top-
sham, ME) or Coulter Epics Expo 32 software (Beckman Coulter, Fullerton, CA, 
USA). 
 
Cell cycle analysis by flowcytometry  
Cell cycle analysis was performed by analyzing the DNA content with the vital cell 
dye TOPRO-3 (Molecular Probes Eugene, OR). Cells were washed in PBS and perme-
abilised in cold 70 % ethanol for at least 1 hr. Next the cells were washed and 
stained with TOPRO-3 (0,3 µM) containing 0.1 mg/ml RNAase. TOPRO-3 staining 
was measured on a Coulter Epics Elite flowcytometer (Beckman Coulter, Fullerton, 
CA). Surface staining by FITC and/or PE labeled mAb was performed prior to per-
meabilization of the cells as mentioned above. Data were analyzed by ModFit LT 
(Verity Software House, Topsham, ME) and/or Coulter Epics Expo 32 software 
(Beckman Coulter, Fullerton, CA, USA). 
 
HLA-typing  
Serological HLA-A, HLA-B, HLA-DR and HLA-DQ phenotyping (broad specificities and 
splits) was performed using the standard microcytoxicity assay. Additional class I 
and II (sub)typing was performed by molecular methods.  Preparation of genomic 
DNA was performed using the QIA-Amp Blood Kit (QIAGEN, Germany). HLA A, B, DR 
and DQ low to intermediate resolution typing was by a PCR-SSP technique (Pel-
Freeze Clinical Systems, Deerbrook Trail, USA). HLA-DRB and DQB sub-typing was 
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performed using a PCR-SSP technique (Dynal DRB1*, B3*, B4*, B5* and DQB sub-
typing kits, Oslo, Norway).  
 
Primary MLC 
Primary one-way Mixed Lymphocyte Cultures (MLC) were performed by culturing 
5.104 isolated CD4+ T cells with 1.105 HLA mismatched γ-irradiated (30 Gy) stimu-
lator PBMC in 96 wells round bottom plates (Greiner, Frickenhausen, Germany) in 
200 µl culture medium (RPMI-1640 with glutamax supplemented with pyruvate 
(0.02mM), 100 U/ml penicillin, 100 µg/ml streptomycin, (all from Gibco, Paisley, 
UK) and 5-10% heat inactivated pooled human serum) at 370C, 95% humidity and 
5% CO2. Proliferation was analyzed by 
3H-thymidine incorporation at the indicated 
point of measurement. To this end 0.037MBq (1 µCi) 3H-thymidine (ICN Pharmaceu-
ticals, Irvine, CA, USA; specific activity 7.4X1010 Bq/mmol (2.0 Ci/mmol)) was pre-
sent during the last 18 hours. 3H-thymidine incorporation was analyzed by a Gas 
Scintillation Counter (Canberra Packard, Matrix 96 Beta counter, Meriden, U.S.A.). 
The 3H-incorporation is expressed as mean ±SD counts per 5 minutes of at least 
quadruplicate measurements. 
 
Induction of T cell anergy and secondary MLC 
To induce anergic CD4+ T cells, primary MLC were performed for 7 days in the 
presence of two antagonistic mAb directed against either CD40 or CD86 (ch5D12 
and chFUN-1 respectively; 0.5-1 µg/ml, kindly provided by Tanox Pharma, Amster-
dam, Netherlands). Anergy was examined in the secondary MLC as follows: the cells 
from the primary MLC were harvested, washed and allowed to recuperate for 2-3 
days. Thereafter the cells were washed again and the non-viable cells were re-
moved by density gradient centrifugation (Lymphoprep, Oslo, Norway). Next, 2.104 
recovered viable CD4+ T cells were restimulated with 1.105 γ-irradiated (30 Gy) 
stimulator PBMC in 96 well round bottom plates, referred to as secondary MLC. The 
stimulator PBMC used in the second and first step were derived from the same do-
nor PBMC pool to assure allo-specific responsiveness. Completely MHC mismatched 
stimulator PBMC did not result in recall responses. The proliferative response of the 
secondary MLC was examined at the indicated time-points. T cell anergy was de-
fined as hyporesponsiveness upon antigenic restimulation that is reversed by addi-
tion of exogenous IL-2 (12.5 U/ml, Proleukine, Eurocetus, The Netherlands) 10. 
 
Tertiary MLC  
To analyze whether anergic T cells that were reversed by IL-2 or IL-15 preserved 
their anergic state, tertiary MLC were performed according to a 3-step culture sys-
tem. In step 1 primary MLC were performed in the presence or absence of costimu-
lation blockade and in step 2 these cells were allogeneically restimulated in the ab-
sence or presence of exogenous IL-2 (12.5 U/ml, Proleukine, Eurocetus, The 
Netherlands) or IL-15 (10 ng/ml, BioSource International, Nivelles, Belgium) as 
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mentioned earlier. IL-15 titration curvess revealed that concentrations of 10 ng/ml 
resulted in optimal proliferative responses. In step 3, the tertiary MLC, 2.104 viable 
T cells (obtained after density gradient centrifugation) that were derived after ex-
pansion in the secondary MLC in the presence of IL-2 or IL-15 were restimulated by 
1.105 irradiated (30 Gy) allogeneic PBMC. At each (re)stimulation step allogeneic 
stimulator PBMC derived from the same donor were used. 
 
Co-cultures to study immunosuppression  
The regulatory capacity of IL-2 or IL-15 reversed anergic CD4+ T cells was studied 
in co-culture MLC. To this end, anergic CD4+ T cells or control primed CD4+ T cells 
that were expanded with alloantigen and exogenously added IL-2 or IL-15 were 
added to a newly set-up primary MLC or secondary MLC. Co-cultures were per-
formed in 96 wells round-bottom plates; 5x104   previously expanded anergic CD4+ 
T cells or control primed CD4+ T cells were added to a newly-setup MLC consisting 
of the 5.104 original responder PBMC (from which the anergic cells originate) 5.104 
original γ-irradiated (30 Gy) stimulator PBMC (used to generate the anergic cells). 
In some experiments the responder cell fraction was labeled with CFSE. In case of 
3H incorporation studies the tests were performed in quadruplicate. Relative sup-
pression was calculated according to the following equation; %-suppression= ( 1- 
(3H-incorporation co-culture/ 3H-incorporation control MLC) x 100%). 
Antigen-specificity of the regulatory phenomenon was examined in co-cultures per-
formed with third party stimulator PBMC that were either completely HLA mis-
matched or partially HLA matched (with an isolated class II mismatch) in relation to 
the original stimulator cells used.  Neutralizing antibodies (20 µg/ml) against IL-10 
(MAB217) and TGFβ (MAB1835) (both R&D Systems Europe, Ltd., United Kingdom) 
or blocking anti-CTLA-4 mAb (20 µg/ml; Innogenetics, Ghent, Belgium) were added 
during the co-culture to study the role of these cytokines or surface marker in im-
munosuppression. Irrelevant isotype matched antibodies were used to control for 
specificity. These antibodies never abrogated suppression. 
To study whether expanded regulatory CD4+ T cells interact with autologous T cell 
responses, fresh autologous donor PBMC from which the regulatory cells originate 
were used in a recall antigen stimulation assay. To this end, 1.10 5 autologous γ-
irradiated (30 Gy) stimulator PBMC and 1.105 autologous responder PBMC and 5.104 
expanded regulators or primed control CD4+ T cells were co-cultured in 96 round 
bottom well plates in the presence of 10 µg/ml Candida albicans extract (ARTHU 
Biologicals N.V., The Netherlands) or Tetanus toxoid (RIVM, Bilthoven, The Nether-
lands). Proliferation was measured at the indicated time-points. In some experi-
ments γ-irradiated (30 Gy) original stimulator cells (i.e. used to generate the aner-
gic regulatory T cells) or MHC-II mismatched allogeneic stimulator cells were added 
(at the indicated ratio) to the autologous stimulator fraction. The proliferative re-
sponse of quadruplicate samples was analyzed by 3H-incorporation. 
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RESULTS 
Increased reversal of the hyporesponsive state of anergic CD4+ T 
cells by exogenously added IL-15 
In isolated allogeneic CD4+ T cells, anergy was induced in primary MLC by the addi-
tion of two antagonistic monoclonal antibodies (mAb) directed against the costimu-
latory ligands CD40 or CD86. The presence of these antagonistic mAb resulted in 
inhibition of the primary MLC (Fig. 1A). Anergy in the recovered CD4+ T cell popu-
lation was examined by allogeneic restimulation in the absence or presence of exo-
genously added IL-2 or IL-15 (Fig. 1B). Allogeneic restimulation of CD4+ T cells 
that were previously primed in the presence of anti-CD40 and anti-CD86 mAb re-
sulted in T cell hyporesponsiveness as compared to the response of control primed 
T cells, which evidently showed a memory-like response (Fig. 1B). Hyporesponsive-
ness was reversed upon allogeneic restimulation in the presence of exogenous 
added IL-2 or IL-15 (Fig. 1B). This reversion occurred only when allo-specific stimu-
lator PBMC were used (data not shown and previously reported data 10). Notably, 
IL-15 resulted in a more vigorous reversal of the hyporesponsive state as compared 
to the use of IL-2. IL-15, as compared to IL-2, also enhanced the restimulatory pro-
liferative response of primed control CD4+ T cells to higher extent. Reversal of the 
hyporesponsive state by IL-2 or IL-15 required the presence of antigen, as the ad-
dition of IL-2 or IL-15 alone resulted in background proliferation levels only (Fig. 
1C).  
 
IL-15 results in increased expansion and elevated Bcl-2 expression 
in anergic CD4+ T cells  
To better understand the increased responsiveness following allogeneic restimula-
tion with exogenous IL-15 in terms of cell death and cell survival, cell cycle levels 
were studied by DNA content analysis (Fig. 2A). Compared to IL-2, addition of ex-
ogenous IL-15 during allogeneic restimulation of anergic CD4+ T cells resulted in 
enhanced survival as the numbers of dividing cells in S-G2-M phase were increased 
(19% vs. 28%) while the numbers of cells in the hypoploid (apoptotic) phase of the 
cell cycle were reduced (17% vs. 4%, Fig. 2A). Anti-apoptotic molecules such as 
Bcl-2 are known to promote cell survival 41,42. To determine whether Bcl-2 might 
play a role in the increased survival of anergic CD4+ T cells during allogeneic res-
timulation in the presence of exogenous IL-15 or IL-2, the presence of intracellullar 
Bcl-2 was analyzed by flowcytometry. Exogenous IL-15, as compared to IL-2, re-
sulted in a higher number of anergic CD4+ T cells expressing Bcl-2 (48.1% vs. 
12.4%, Fig. 2B). Similar observations were made for allogeneically primed control 
CD4+ T cells, therefore IL-15 does not selectively or specifically act on anergic 
cells. During a 5 days culture period with alloantigen-antigen in the presence of 
exogenously added IL-15, anergic CD4+ T cell numbers increased about 10 fold, as 
compared to a six fold increase in the presence of exogenous IL-2 (Fig. 2C)  Thus, 
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IL-15 results in increased survival of anergic CD4+ T cells, which is paralleled by an 
increased number of cells expressing Bcl-2. 
F I G U R E  1  
Increased reversal of the hyporesponsive state of anergic CD4+ T cells by exoge-
nously added IL-15 
A. Primary MLC were performed with isolated 
CD4+ responder T cells (5.104) and irradi-
ated allogeneic PBMC (1.105) as stimulator 
cells in the presence of two antagonistic 
monoclonal antibodies (mAb) directed 
against CD40 and CD86, respectively. Cell 
division according to 3H-incorporation (Y-
axis) is shown at day 5 and 6 of the culture. 
As a control the response to autologous γ-
irradiated PBMC and the response of alloge-
neic stimulator PBMC only are shown.  
B. At day 7 of the primary MLC the cells 
were collected, washed and rested for 2-3 
days. Next, the dead cells were removed by 
density gradient centrifugation. The recov-
ered viable CD4+ T cells (2.104) that were 
derived from primary mAb treated MLC or 
control primary MLC were antigenically res-
timulated by γ-irradiated fresh original al-
logeneic PBMC (1.105) in the absence or 
presence of exogenously added IL-2 (12.5 
U/ml) or IL-15 (10 ng/ml). Note scale differ-
ences.C. The recovered viable CD4+ T cells 
(2.104) that were derived from primary mAb 
treated MLC or control primary MLC were 
stimulated by exogenously added IL-2 (12.5 
U/ml) or IL-15 (10 ng/ml) only, in the ab-
sence of stimulator PBMC. Note scale differ-
ences. Proliferation (3H-Incorporation; Y-
axis) is shown during the course of restimu-
lation (Days; X-axis). Figures show repre-
sentative results of at least 4 individual ex-
periments. Results are shown as mean±sd of 
quadruplicate measurements 
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F I G U R E  2  
IL-15 results in enhanced survival of anergic CD4+ T cells that is paralleled by an 
increase in Bcl-2 
A. IL-15 results in an increased survival of 
anergic CD4+ T cells. Cell cycle progression 
of anergic (and control) CD4+ T cells was 
studied by flowcytometric analysis of the 
DNA content according to TOPRO-3 labeling.  
Anergic and control CD4+ T cells were de-
rived from primary MLC that were performed 
in the presence (or absence) of anti-CD40 + 
anti-CD86 antagonistic mAb. These cells 
were allogeneically restimulated (secondary 
MLC) in the presence of IL-2 or IL-15. At day 
5 of the cultures the cells were harvested, 
surface stained and analyzed for DNA con-
tent. The histograms show the DNA content 
of anergic and control CD4+ T cells in the 
presence of either IL-2 or IL-15 (conditions 
are indicated at the top). Numbers indicate 
the percentage of CD4+ cells in <G1 (left), 
G1 (middle) and S/G2/M (right) cell cycle 
phase, representing the dead cells, resting 
cells and dividing cells, respectively. 
B.  IL-15 results in an increased expression 
of Bcl-2 in anergic CD4+ T cells. The effect 
of exogenously added IL-2 or IL-15 during 
allogeneic restimulation on the presence of 
Bcl-2 in CD4+ anergic (and control) T cells 
was analyzed by flowcytometry. Dot plots 
(Bcl-2 expression on the X-axis, forward 
scatter on the Y-axis) show the relative 
number (%) of CD4+ T cells expressing in-
tracytoplasmic Bcl-2 at day 5 of cultures. 
The conditions during the cultures are indi-
cated. One representative experiment is 
shown (n=5). 
C. Compared to IL-2, IL-15 results in an in-
creased expansion. CD4+ T cells were 
counted at start of secondary cultures and 
after 5 days of culture in the presence of 
stimulator cells and the indicated cytokines. 
The cellular expansion of 6 individual ex-
periments was calculated. Mean±sd of the six 
experiments are included. 
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Both IL-15 and IL-2 expanded anergic CD4+ T cells retain their an-
ergic state, but IL-15 results in advanced growth and a distinct type 
of anergy 
Previously, we reported that hyporesponsive anergic T cells that were recovered by 
allogeneic restimulation in the presence of exogenously added IL-2 retained their 
anergic state 10. This finding was again observed for isolated CD4+ T cells in our 
current study (Fig. 3A). Now, we addressed the question of whether this effect was 
also observed when IL-15 was used during allogeneic restimulation of anergic CD4+ 
T cells. To this end, in the first expansion cycle, anergic CD4+ T cells or control 
primed CD4+ T cells were allogeneically restimulated in the presence of exoge-
nously added IL-2 or IL-15. The viable recovered CD4+ T cells were allogeneically 
restimulated in a tertiary MLC in the absence or presence of exogenous IL-2 or IL-
15. Figure 3A shows that both IL-2 and IL-15 expanded allogeneic anergic T cells 
retained their anergic state, i.e. compared to expanded allogeneically primed con-
trol CD4+ T cells the cells were hyporesponsive, while addition of exogenous IL-2 or 
IL-15 reversed their hyporesponsive state. Notably, anergic CD4+ T cells that were 
first expanded in the presence of IL-15, showed an increased proliferative response 
(hyper-reactivity) and expansion upon allogeneic restimulation and exogenously 
added IL-15 as compared to the use of IL-2 (Fig. 3B+C). In contrast, allogeneic 
restimulation in the presence of IL-2 in the first expansion phase prevented the IL-
15 mediated hyper-reactivity during the second expansion phase (Fig. 3B+C). Thus, 
during the first expansion cycle the presence of IL-15 is essential to ensure hyper-
reactivity upon re-encounter with alloantigen and IL-15. 
Following allogeneic activation in a tertiary MLC, IL-15 expanded anerigic cells, as 
compared to IL-2 expanded cells, showed an increased number of cells expressing 
both the α-chain (92% vs. 75%) and γ-chain (53% vs. 41%) of the IL-2 and IL-15 
receptor (Fig. 3D). Similar β-chain expression was observed (Fig. 3D). Prior to acti-
vation IL-15 and IL-2 expanded anergic T cells showed similar receptor expression 
patterns of the IL-15Rβ/γ-chains and the IL-2Rα/β/γ-chains, while IL-2 expanded 
cells showed an upregulated IL-15Rα chain expression.  
The improved expansion of IL-15 expanded cells when stimulated by alloantigen 
and IL-15 is likely the result of the above-mentioned increase in IL-15 and IL-2 re-
ceptor expression, especially the IL-15Rα chain.  
Together these data indicate that repeated allogeneic restimulation in the presence 
of exogenous IL-15 results in advanced growth of anergic CD4+ T cells and a func-
tionally distinct anergic state.  
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F I G U R E  3   
Both IL-2 and IL-15 expanded anergic CD4+ T cells retain their anergic state, but IL-
15 results in advanced growth and a distinct type of anergy  
Anergic or primed control CD4+ T cells were 
expanded by allogeneic restimulation, in a 
secondary MLC, in the presence of exoge-
nously added IL-2 or IL-15 (Ag+IL-2 or 
Ag+IL-15 exp cells, respectively). At day 5 
of the culture the cells were collected, al-
lowed to rest for 2 days.  
A. The recovered viable CD4+ T cells (2.104) 
were restimulated with γ-irradiated alloge-
neic stimulator PBMC (1.105), in a so-called 
tertiary MLC, in the absence or presence of 
exogenously added IL-2 or IL-15. Conditions 
during restimulation are given on top of the 
figures.  
B. Repeated allogeneic stimulation in the 
presence of IL-15 results in increased ex-
pansion. Anergic T cells were derived from a 
secondary MLC, which was performed in the 
presence of either IL-2 or IL-15 (at the right 
in the first column). These cells were alloge-
neically restimulated in a tertiary MLC, again 
in the presence of either IL-2 or IL-15 (at 
Ag only Ag + IL-15Ag + IL-2
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the right in the second column). The tertiary 
proliferative response (3H-Incorporation) is 
shown at day 3 of the cultures. Mean±sd of 
one representative experiment are shown 
(n=3).C.Viable cell number were microscopi-
cally determined at day 5 and 6 of the cul-
tures (X-axis). Anergic cells were first ex-
panded by stimulation with  alloantigen and 
either IL-15 or IL-2 and restimulated by an-
tigen only or antigen and IL-2 or IL-15 (leg-
ends). Cell numbers were counted in tripli-
cate, SD were <10%  
D. IL-15 and IL-2 receptor α/β/γ-chain ex-
pression on antigen and IL-15 or IL-2 ex-
panded anergic T cells. Anergic T cells ex-
panded with antigen and either IL-15 or IL-2 
were derived from secondary MLC. These 
cells were rested and allogeneically restimu-
lated (tertiary MLC). Surface expression of 
the IL-15 and IL-2 receptor α/β/γ-chain (X-
axis) at the start (dashed histogram) and 48 
hours after stimulation (gray shaded histo-
gram) was analysed by flowcytometry. Num-
ber of events, scaled to 100% of the peak 
value, are shown on the Y-axis.  Percentage 
positive cells and mean fluorescence inten-
sity of the activated cells are shown in the 
upper and lower right corner of each histo-
gram, respectively. CD25 (IL-2Rα- chain), 
CD122 (IL-15/IL-2Rβ-chain) and CD132 (IL-
15/IL-2Rγ-chain). One of two similar experi-
ments is shown. 
 
Superior suppression of naive and memory T cell division by IL-15 
expanded anergic CD4+ T cells 
Next, we addressed the question of whether IL-15 or IL-2 expanded anergic CD4+ T 
cells were indeed able to suppress naive and memory T cell responses. This was 
studied in co-culture experiments, whereby IL-2 or IL-15 expanded anergic or 
primed control CD4+ T cells were added to cultures consisting of fresh allogeneic 
stimulator γ-irradiated (30 Gy) PBMC and either fresh naive or memory responder T 
cells, respectively. Both stimulator and responder PBMC were derived from the do-
nor cell pool that was originally used to generate the anergic or control primed 
CD4+ T cells. The responder PBMC were labeled with CFSE and cell division of CD4+ 
and CD8+ T cells was analyzed by flowcytometry. Both IL-15 and IL-2 expanded 
anergic CD4+ T cells suppressed the division of naive CD4+ T cells (naive CD8 + T 
cells hardly divide in primary MLC) (Fig. 4A). Especially IL-15 expanded anergic T 
cells were powerful suppressors of naive T cell proliferation (Fig. 4A; 20% vs. 31% 
dividing cells in the presence of IL-15 or IL-2 expanded anergic cells, respectively). 
This phenomenon was also observed at effector cell:regulatory cell ratios of 1:0.5 
and 1:0.25 (data not shown). Despite the suppression of T cell division, activation 
of the responder population was evident as blast formation (increase in forward 
scatter) and concomitant CD25 expression took place (Fig. 4A). This indicates that 
expanded anergic regulatory CD4+ T cells did not mediate suppression by killing 
the responder population. Importantly, immunosuppression by IL-2 or IL-15 ex-
panded anergic CD4+ T cells appeared dose dependent (Fig. 4C) and γ−irradiation 
resistant (Fig. 4D). The latter suggests that suppression is not the result of copious 
IL-2 consumption by the regulatory T cells. IL-15 expanded anergic CD4+ T cells, 
as compared to their IL-2 expanded counterpart, were also better suppressors of 
CD4+ and CD8+ memory T cell division (Fig. 4B; 44% vs. 64% dividing CD4+ 
memory T cells, 71% vs. 85% dividing CD8+ memory T cells in the presence of IL- 
15 or IL-2 expanded anergic cells, respectively). Generally, memory T cells were 
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suppressed to a lesser degree than naive T cell. Thus, although both IL-2 and IL-15 
expanded anergic CD4+ T cells are immunosuppressive, IL-15 expanded regulatory 
CD4+ T cells clearly are more potent suppressors. 
 
Phenotype and intracellular cytokine staining pattern of IL-15 ex-
panded regulatory CD4+ cells 
Anergic regulatory CD4+ T cells and control primed CD4+ T cells were expanded by 
allospecific restimulation in the presence of exogenous IL-15. At day 6 these ex-
panded cells were harvested, washed and allowed to rest for 48 hrs. The recovered 
viable T cells (>95% CD4+) were analyzed by flowcytometry for surface expression 
of CD25 (IL-2 α receptor chain), CD122 (IL-2/IL-15 α receptor chain), the differen-
tiation markers CD45RO, CD45RA and CD27, and intracellular expression of CTLA-4. 
The majority of expanded anergic regulatory CD4+ T cells expressed CD45RO 
(~90%), part of these cells expressed CD27 (~50%), CTLA-4 (~30%) CD25 
(~30%), CD122 (~19%) and a minority expressed CD45RA (~10%) (Fig. 5A). Upon 
comparison of expanded anergic CD4+ T cells versus primed control CD4+ cells, the 
latter showed an increased percentage of CD25+, CD45RO+ and CTLA-4+ cells, 
similar numbers of CD122+ cells and a reduced number of CD27+ and CD45RA+ 
cells (Fig. 5). The use of IL-2 or IL-15 resulted in a similar phenotype (data not 
shown). 
Intracellular cytokine production was examined by flowcytometry after activation 
with PMA and Ionomycin (Fig. 5B). Regulatory T cells as compared to the control 
cells led to a reduced number of IFNγ (30% vs. 41%), IL-2 (18% vs. 32) and TNFα 
(44% vs. 57%) producing cells. Minute amounts of IL-4 (<2%) and IL-10 (<0.3%) 
were produced by both regulatory and control T cells (Fig 5B). 
 
Immunosuppression by IL-15 expanded anergic CD4+ T cells re-
quires antigen specific TcR triggering and is independent of IL-10, 
TGFβ or CTLA-4  
Immunosuppressive therapy should ideally be antigen specific. We hypothesized (in 
line with Waldmann and Cobbold 19) that recognition of the cognate MHC-antigen on 
the APC by the suppressive immunoregulatory CD4+ T cells as generated in our 
model system is a prerequisite to activate the suppressor function of the regulatory 
T cells. In this scenario, omission of the cognate allo-MHC-II (i.e. fully MHC-
mismatched APC) precludes activation of regulatory anergic CD4+T cells. Figure 6A 
shows that addition of IL-15 expanded anergic regulatory CD4+ T cells suppressed 
the proliferative response of naive alloreactive cells only in the presence of fully 
(83% suppression) or partially HLA-DR matched (59% suppression) stimulator APC 
(i.e. cognate antigen), but not in the case of MHC-II mismatched stimulators (8%  
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F I G U R E  4  
Superior suppression of naive and memory T cell division by IL-15 expanded anergic 
regulatory CD4+ T cells 
IL-2 or IL-15 expanded anergic or primed 
control CD4+ T cells were added to a pri-
mary MLC (A) or a secondary MLC (B) to 
study their immunosuppressive capacity to 
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wards naive and memory T cells respec-
tively. The responder cells used in both the 
primary and secondary MLC were labeled 
with the fluorescent dye CFSE. Cell division 
of anti-CD4, anti-CD8 and anti-CD25 labeled 
responder cells was measured by flowcy-
tometry. 
A. 5.104 naive CFSE labeled responder PBMC 
were stimulated with 5.104 γ-irradiated 
(30Gy) stimulator PBMC (primary MLC) in 
D
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the presence of 5.104 IL-2 or IL-15 expanded 
anergic CD4+ T cells or primed control CD4+ 
T cells. The dotplots show forward scatter on 
Y-axis and CFSE intensity on the X-axis at 
day 5 of the culture. The activated CD4+ 
dividing cells were gated and analyzed for 
CFSE intensity and CD25 expression as 
shown in the histograms below. Percentages 
shown in the histograms indicate the relative 
number of dividing cells and CD25 express-
ing cells respectively. The gray cells at the 
left of the dotplots are the non-CFSE labeled 
cells. B. 2.104 previously allogeneically 
primed T cells were CFSE labeled and stimu-
lated with 5.104 allo-specific γ-irradiated 
(30Gy) stimulator PBMC (secondary MLC) in 
the presence of 2.104 IL-2 or IL-15 expanded 
anergic CD4+ T cells or primed control CD4+ 
T cells. The dotplots show forward scatter on 
Y-axis and CFSE intensity on the X-axis at 
day 2 of the cultures. The dividing cells were 
gated and analyzed for CFSE intensity in 
anti-CD4 and anti-CD8 stained T cell subset 
(shown in the histograms below). Percent-
ages indicate the relative number of dividing 
CD4+ and CD8+ T cells. The gray colored 
cells at the left of the dotplots are the non-
CFSE labeled cells. C. Suppression by alloan-
tigen and IL-2 or IL-15 expanded regulatory 
CD4+ T cells is dose dependent. Proliferation 
(Y-axis; 3H-Incorporation) of naïve T cells 
(5x104 PBMC) was studied in primary MLC in 
the absence or presence of increasing num-
bers of regulatory T cells (X-axis).D. Immu-
nosuppression of naive T cells by the ex-
panded anergic regulatory CD4+ T cells is γ-
radiation resistant. Co-cultures of primary 
MLC and either live or γ-irradiated (30Gy) 
expanded (IL-2 or IL-15) anergic regulatory 
cells or primed control cells were performed. 
The percentage of dividing cells in the pres-
ence of anergic or primed control cells was 
analyzed according to CFSE dilution. From 
these percentages the relative suppression 
(X-axis) per condition (Y-axis) was calcu-
lated. Data for live cells are derived from the 
dotplots mentioned under A (data for irradi-
ated cells are not show). One representative 
experiment is shown (n=3).
 
suppression).To further characterize the mechanism of suppression by IL-15 ex-
panded anergic regulatory CD4+ T cells, the role of formerly postulated I mmuno-
suppressive mechanisms (i.e. CTLA-4 or the cytokines TGFβ and IL-10) was exam-
ined. Previously, we have demonstrated that regulatory cells that were generated 
by costimulation blockade did not produce detectable levels of IL-10 or TGFβ as 
measured by ELISA 10. Here, we show that IL-15 expanded anergic regulatory CD4+ 
T cells did not mediated suppression via either CTLA-4, TGFβ or IL-10, as neither 
blockade of CTLA-4 nor neutralization of TGFβ or IL-10 by monoclonal antibodies 
reversed suppression (Fig. 6B).  
Thus, de novo induced IL-15 expanded anergic regulatory CD4+ T cells need anti-
gen specific stimulation to become immunosuppressive. Suppression appeared in-
dependent of TGFβ, IL-10 or CTLA-4. 
 
IL-15 expanded regulatory CD4+ T cells are stable suppressors that 
mediate bystander suppression upon TCR stimulation but do not af-
fect recall responses in the absence of cognate antigen 
Next, we studied whether IL-15 expanded alloantigen-specific regulatory CD4+ T 
cells suppress T cells specific for other antigens. Allo-specific IL-15 expanded 
autologous regulatory CD4+ T cells were added to autologous PBMC in the presence 
of soluble recall antigens (C. Albicans or Tetanus Toxoid). Recall responses against 
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C.albicans or Tetanus Toxoid were not suppressed by these  regulatory CD4+ T cells 
(Fig. 7A). Notably, addition of 20% or more allo-specific stimulator APC (carrying 
cognate alloantigen-antigen) to the above  co-cultures restored the immunosup-
pressive function of the regulatory cells (~55% suppression). In contrast, addition 
of HLA class II mismatched APC, instead of the original stimulator cells, did not re-
store the suppressor function of the regulatory T cells (Fig. 7B). This again confirms 
the need for cognate antigen to activate suppression by these IL-15 expanded regu-
latory cells, as was also shown in figure 6A. In addition, these results indicate that 
TCR stimulation of IL-15 expanded regulatory T cells likely results in bystander 
suppression, leading to down regulation of proliferation by Candida specific T cells. 
Importantly, autologous T cell responses against soluble recall antigens, resulting in 
cytokine production (e.g. IL-2, IFNγ and TNFα; data not shown) and proliferation, do 
not abolish the suppressor function of IL-15 expanded regulatory CD4+ T cells. This 
underlines the stable suppressive potential of these IL-15 expanded regulatory T 
cells. Moreover, it indicates that suppression by these cells is not likely to be the 
result of cytokine deprivation from the culture medium.  
F I G U R E  5   
Phenotype and intracellular cytokine staining pattern of IL-15 expanded regulatory 
CD4+ cells 
Anergic regulatory CD4+ T cells and primed 
control CD4+ T cells were allogeneically res-
timulated in a secondary MLC in the pres-
ence of IL-15. After 5 days the cells were 
collected and rested for 2 days. The viable 
CD4+ T cells (>95% CD4+ T cells) were 
analyzed for surface expression (A) and in-
tracellular cytokine staining (B) by flowcy-
tometry. A. Histograms show the expression 
of the indicated markersintra cytoplasmatic 
staining of CTLA-4. Mean Fluorescence in-
tensity and relative number of events are 
shown (X and Y-axis respectively. Percent-
age positive cells are indicated at the right 
upper corner of each histogram. B. Iintracel-
lular cytokine fluorescence intensity (X-axis) 
and forward scatter (Y-axis) after activation. 
Percentage positive cells and MFI intensity 
are shown. A representative experiment o is 
shown( n=4) 
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F I G U R E  6   
Suppression by IL-15 expanded de novo induced anergic regulatory CD4+ T cells re-
quires antigen specific stimulation and is independent of IL-10, TGFβ or interactions 
via CTLA-4. 
A. IL-15 expanded de novo induced regula-
tory CD4+ T cells require specific antigen to 
become suppressive. 5.104 γ-irradiated IL-15 
expanded anergic regulatory CD4+ T cells or 
IL-15 expanded primed control CD4+ cells 
were co-cultured with 5.104 autologous re-
sponder PBMC and 5.104 γ-irradiated (30 Gy) 
stimulator PBMC. The stimulator PBMC were 
either allospecific (from the source originally 
used to generate the regulatory cells), par-
tially matched (isolated HLA class-II match) 
or completely HLA class-II mismatched with 
respect to the allo-specific stimulator PBMC 
used. Proliferation at day 5 of the culture 
was examined by 3H-Incorporation (X-axis) 
B. IL-15 expanded regulatory CD4+ T cells 
or primed control CD4+ cells were γ-
irradiated and co-cultured in a primary MLC 
(consisting of fresh autologous responder 
PBMC and stimulator PBMC, from the source 
originally used to generate the regulatory 
CD4+ T cells) in the presence of neutralizing 
mAb against TGFβ (20 µg/ml) and IL-10 (20 
µg/ml), and anti-CTLA-4 mAb (20 µg/ml). 
Antibodies were titrated up to 75 µg/ml 
showing identical results (data not shown). 
3H-Incorporation is shown at day 6. One rep-
resentative experiment out of 3 is shown. 
 
Naturally occurring CD4+CD25+ T cells are necessary for the genera-
tion of anergic regulatory CD4+ T cells by costimulation blockade 
 Recently, Blazar and coworkers 43 showed the importance of naturally occurring 
CD4+CD25+ T cells in the generation of regulatory T cells via costimulation block-
ade in mice. Similarly, we analyzed the role of human naturally occurring 
CD4+CD25+ T cells.  Isolated CD4+ T cell were depleted from naturally occurring 
CD4+CD25+ T cells (Fig. 8A) and allogeneically stimulated in the absence or pres-
ence of mAbs directed against CD40 and CD86 (Fig. 8B). Depletion of CD4+CD25+ 
T cells did not affect the inhibitory potential of the mAbs (Fig. 8B). Conversely, the 
anergic state (Fig. 8C) and suppressive potential (Fig. 8D) were abrogated when 
CD4+CD25+ were depleted during costimulation blockade. 
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F I G U R E  7  
IL-15 expanded regulatory CD4+ T cells  are stable suppressors mediating bystander 
suppression upon TCR stimulation but do not affect recall responses in the absence 
of cognate  antigen. 
A. Self MHC restricted recall responses 
against C.albicans and Tetanus toxoid were 
carried out by culturing 1.10 5 γ-irradiated 
(30 Gy) autologous stimulator and 1.105 live 
autologous responder PBMC in the presence 
of C.albicans extract or Tetanus toxoid 
(10µg/ml). To these cultures either no cells 
(Autologous cells only) or 5.104, γ-irradiated 
(30 Gy) autologous IL-15 expanded anergic 
regulatory cells or primed control cells were 
added (see legend). B.  Autologous PBMC 
were cultured without (No antigen) or with 
C.albicans, in the presence of IL-15 ex-
panded regulatory T cells and increasing 
numbers of γ-Irradiated (30 Gy) cognate al-
logeneic stimulator PBMC (i.e. from the 
source originally used to generate the aner-
gic regulatory T cells, left figure) or MHC-II 
mismatched allogeneic stimulator PBMC 
(right figure) were added. The relative num-
ber of added allogeneic APC is shown on the 
X-axis. Proliferation (mean±sd) is shown on 
the Y-axis at day 5 of the cultures. The leg-
end indicates the culture conditions. Similar 
results were obtained when Tetanus toxoid 
was used as a source of soluble antigen 
(data not shown). 
 
DISCUSSION 
Antigen specific immunosuppression and tolerance induction are important goals in 
transplantation and autoimmunity. In recent years, various animal studies have in-
dicated that immunotherapy by ex vivo induced regulatory T cells or ex vivo ma-
nipulated naturally occurring immunoregulatory suppressive T cells might serve this 
goal 44-49. One of the practical hurdles for future therapy by human immunoregula-
tory T cells is the expansion of these immunosuppressive regulatory T cells while 
preserving their (preferentially antigen specific) suppressive potential 2. In the cur-
rent study, we showed that allogeneic restimulation in the presence of exogenous 
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recombinant IL-15, as compared to IL-2, resulted in superior expansion of de novo 
induced anergic regulatory CD4+ T cells. Both IL-15 and IL-2 expanded cells re-
mained anergic and immunosuppressive, but strikingly, IL-15 expanded regulatory 
CD4+ T cells were more powerful suppressors. In this model, IL-15 expanded regu-
latory CD4+ cells required antigen specific triggering to become suppressive. Im-
munosuppression by these cells was independent of IL-10, TGFβ or CTLA-4 and per 
sisted in the presence of concurrent autologous productive T cell responses. 
 F I G U R E  8  
Naturally occurring CD4+CD25+ T cells are necessary for the generation of anergic 
regulatory CD4+  T cells by costimulation blockade of CD40 and CD86. 
A. Isolated CD4+ T cells (CD4 Total; upper 
dotplot) were depleted from CD4+ CD25+ 
naturally occurring T cells (CD4 CD25-; 
lower dotplot) by magnetic microbeads. 
CD25 (m-A251)and CD4 fluorescence are 
shown on X-axis and Y-axis, respectively. 
B. Primary MLC using either CD4 total or 
CD4 CD25- as responder cells were per-
formed  in the absence or presence of anti-
CD40 and anti-CD86 mAb. Proliferation (3H-
Incorporation; X-axis) is shown at day 6 of 
the primary MLC. 
C. T cells derived from primary MLC as per-
formed in figure 8B, were allogeneically res-
timulated in the absence (upper 2 graphs) or 
presence  of exogenously added IL-2 (lower 
2 graphs). Proliferation of CD4 total (left) 
and CD4 CD25- (right) are shown in time (X-
axis), (n=3). 
D. Anti-CD40 and anti-CD86 mAb mAb 
blocked CD4 Total or CD4 CD25- cells 
(5x104) derived from primary MLC were ex-
amined for their suppressive potential in MLC 
co-cultures consisting of 5x104 naïve re-
sponder PBMC and 5x104 stimulator PBMC. 
Relative suppression (Y-axis) was calculated 
as mentioned in methods. 2 independent 
suppression assays are shown (X-axis).
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Both IL-2 and IL-15 stimulate proliferation of activated CD4+ and CD8+ T cells 
50,51, but differ with respect to T cell survival. IL-2 plays an important role in T cell 
death 33,52, while IL-15 is generally considered as an inhibitor of apoptosis 30,31. 
This inhibition is at least partially mediated via up-regulation of the anti apoptotic 
protein Bcl-2 (53 and this report). In addition, in murine models IL-15, but not IL-2, 
supported survival of activated CD4+ T cells 29, selectively propagated growth of 
CD8+ memory T cells 34-36 and redirected T cell apoptosis towards anergy in par-
tially stimulated T cells 37. Similarly, human CD4+ memory effector T cells and 
regulatory Tr1 cell clones especially proliferated in response to IL-15 39,54. Espe-
cially the latter study 39 and our current study, underline the importance of IL-15 in 
the maintenance of regulatory CD4+ T cells 38. It should however be noted that it is 
not likely that IL-15 plays a prominent role in the induction of regulatory cells 39 
such as has been recently described for IL-10 + IFNα 55 and TGFβ 56.  
Notably, allogeneic restimulation of anergic regulatory CD4+ T cells in the presence 
of either exogenously added IL-2 or IL-15 resulted in a distinct type of T cell an-
ergy. The first expansion cycle with alloantigen and IL-15 resulted in anergic cells 
that are hyper-responsive to subsequent allogeneic restimulation and exogenously 
added IL-15. In contrast, the use of alloantigen and IL-2 in the first expansion 
phase prevented this IL-15 induced hyper-reactivity. Thus, optimal expansion of 
anergic regulatory CD4+ T cells by exogenous IL-15 required the presence of this 
cytokine from the start of the expansion phase. 
Expansion of human de novo induced regulatory CD4+ T cells by either IL-15 or IL-
2 required alloantigen specific TcR stimulation, as hardly any proliferation occurred 
to IL-15 or IL-2 alone. This latter finding is in contrast with a recent observation 
showing that expansion of human regulatory T cell (Type 1 cell) clones is independ-
ent of TcR signaling and requires exogenous cytokines only 39. However, the need 
for antigen in cytokine mediated expansion of naturally occurring CD4+CD25+ 
regulatory T cells was also shown in two murine  studies 47,48. The necessity of do-
nor antigen was stressed by the finding that only antigen specific stimulation of the 
regulatory T cells resulted in antigen specific immunosuppressive T cells whereas 
polyclonal stimulation did not 48.  
In the current study, allo-specific anergic T cells were generated by stimulating 
human peripheral CD4+ T cells with MHC mismatched stimulator cells (primary 
MLC) in the presence of mAb directed against CD40 and CD86. Within the human 
peripheral T cell pool only a fraction of cells (5-10%) will respond to a particular 
allogeneic mismatch. In our experiments it are these particular alloreactive T cells 
that are made anergic by costimulation blockade, while T cells with other specifici-
ties will be unaffected and remain present or die and disappear. This results in a 
polyclonal population of anergic allo-specific and non-anergic T cells with other 
specificity. The presence of the latter was shown by stimulating this polyclonal 
population with a third party allo-antigen, which resulted in a primary proliferative 
response (data not shown). This strongly indicates that next to allo-specific anergic 
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T cells, non-anergized T cells with distinct antigen specificity are present. In the 
experiments that we describe here, the anergic T cell population is antigen specifi-
cally restimulated in the presence of IL-15 (or IL-2), which specifically results in 
growth of the anergic allo-specific T cells. This will enrich the allo-specific anergic T 
cells, at the expense of T cells with other specificity, which still might be present.  
An important feature of suppressor regulatory T cells is their ability to inhibit the 
proliferation of conventional responder T cell populations in vitro. In our experi-
ments IL-15 (or IL-2) expanded de novo induced immunoregulatory suppressor T 
cells inhibited proliferation of responder T cells, but in this responder population 
blast formation and concomitant expression of CD25 still occurred.  In a similar 
way, naturally occurring regulatory CD4+CD25+ T cells were shown to induce cell 
cycle arrest in conventional responder T cells, but initial T cell activation was not 
affected, as early activation antigens were up-regulated 22. Taken together, this in-
dicates that suppression is not mediated by elimination of conventional responder T 
cells, but by controlling the proliferative response of this population in an active 
way.  
Immunosuppression by expanded suppressor CD4+ T cells such as generated in our 
model, required alloantigen specific TcR triggering. This ensures that suppression 
only takes place when cognate antigen is present and, moreover, it prevents ran-
dom suppression by the regulatory cells. It is likely, that for this reason regulatory 
T cells did not affect autologous recall T cell responses in the absence of specific 
alloantigen. However, the presence of allo-specific APC in autologous recall co-
cultures recovered the suppressor activity by the regulatory T cells. This means 
that either the allogeneic response or the autologous recall response was sup-
pressed, in the latter case we cannot exclude that bystander suppression took 
place. Be that as it may, using less than 20% allogeneic APC we did not observe 
suppression. Given that regulatory T cells preferentially reside in the tolerated graft 
57 and the unlikelihood that each lymphoid organ contains more than 20% alloge-
neic cells, we speculate that generalized nonspecific immunosuppression by regula-
tory cells such as generated in our model system is improbable upon in vivo use. 
Some studies indicated an important role for soluble molecules such as IL-10 and 
TGFβ 9,14-16 or interactions via CTLA-4 15,17,18 as the mechanism of immunosuppres-
sion. Previously, we demonstrated in our protocol that de novo generated anergic 
regulatory T cells did not produce detectable amounts of IL-10 or TGFβ as measured 
by ELISA 10. In this study, immunosuppression by IL-15 expanded de novo induced 
regulatory T cells appeared not mediated via TGFβ, IL-10 or CTLA-4, as neutralizing 
mAb did not reverse suppression. Also, immunosuppression by IL-15 (as well as IL-
2) expanded de novo induced regulatory CD4+ T cells appeared γ-irradiation resis-
tant. This indicates that proliferation and concordant IL-2 consumption by these 
regulatory T cells is not likely to be the mechanism of suppression. We are aware 
that irradiated T cells might bind IL-2 and other cytokines and thereby deplete 
them from the cell cultures at the expense of alloreactive T cells responsiveness. 
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However, we here showed that antigen specific activated IL-15 expanded regulatory 
CD4+ T cells remained suppressive when simultaneously productive autologous re-
call T cell responses (i.e. cytokine production of IL-2, IFNγ and TNFα with concomi-
tant proliferation) were taking place. Together this indicates that suppression by 
these regulatory cells does not merely depend on cytokine deprivation from the cul-
ture media. Recently, it has been claimed that suppression by human naturally oc-
curring CD4+CD25+ regulatory T cells was (partially) reversed by exogenous addi-
tion of T cell growth factors 5,7,11. However, addition of growth factors might 
unintendently result in proliferation of the naturally occurring CD4+CD25+ T cells, 
and thus not reflect abrogation of suppression perse.  
The IL-15 expanded costimulation blockade induced human regulatory CD4+ T cells 
such as described in this study are anergic and suppressive upon cognate TCR trig-
gering, and they do not appear to mediate their suppressor function via the typical 
Th3 or Tr1 associated cytokines TGFβ or IL-10. Among human de novo induced 
CD4+ regulatory T cell the Tr1 and Th3 cells are the best known. Tr1 cells were 
generated in vitro by culturing CD4+ T cells in the presence of antigen and IL-10, 
these Tr1 cells predominantly secrete IL-10, have low proliferative potential and 
suppress antigen specific T cell responses 14. Th3 cells are CD4+ T cells that are 
characteristically generated following oral administration of antigens 58, and espe-
cially produce TGFβ with various amounts of IL-4 and IL-10 and suppress antigen 
specific T cell proliferation 9,58. Whether Th3 cells are unresponsive to TCR- trigger-
ing is unknown 16. The CD4+ regulatory cells such as described in our current study 
are not related to Th3 or Tr1 cells, and appear to be an other subset of regulatory 
cells.  
Mouse CD25+CD4+ naturally occurring immunoregulatory T cells facilitate the in-
duction of T cell anergy 59 and are necessary to induce a tolerant state via costimu-
latory blockade in mice 43. Also, human naturally occurring CD4+CD25+ regulatory 
T cells contribute to de novo generation of suppressor T cells 60, according to the 
process of infectious tolerance 61,62. In our human experimental model, depletion of 
naturally occurring CD4+CD25+ T cells prior to the induction of regulatory anergic 
T cells by costimulation blockade, prevented the generation of de novo induced sup-
pressor CD4+ T cells. Thus, the presence of naturally CD4+CD25+ T cells (usually 
4-10% of the CD4+ T cells) appears a prerequisite in de novo induction of human 
suppressive CD4+ regulatory T cells by costimulation blockade in the primary MLC. 
Apparently, these naturally occurring CD4+CD25+ cells facilitate a proper environ-
ment during costimulation blockade, resulting in de novo anergic regulatory CD4+ T 
cells. 
The property to revert to an anergic or suppressive condition once the hyporespon-
sive state is abrogated (e.g. by IL-15 or IL-2), is a shared feature of both de novo 
induced regulatory T cells (10 and this report) and naturally occurring CD4+CD25+ 
T cells 23. Especially IL-15 appeared of particular interest for large scale ex vivo 
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generation of donor-specific regulatory T cells to be used as a clinical immunosup-
pressive tool in humans.  
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ABSTRACT   
Immunosuppressive therapy is best achieved with a combination of agents targeting 
multiple activation steps of T-cells. In transplantation, Cyclosporin-A (CsA) or Tac-
rolimus (FK506) are successfully combined with Rapamycin (Rap). Rap and CsA 
were first considered for combination therapy because FK506 and Rap target the 
same intracellular protein and thus may act in an antagonistic way. However, in 
clinical studies FK506+Rap proved to be effective. To date, there is no in vitro data 
supporting these in vivo findings and it is unclear whether the observed effects are 
T cell mediated. In a human polyclonal allogeneic in vitro model, we found that al-
though combined drug treatment markedly reduced expansion of naive T cells, T 
cell activation occurred irrespective of the drug combination used. The induction of 
cytotoxic effector T cells was reduced by CsA+Rap, but completely abolished by 
FK506+Rap. Importantly, combined immunosuppression allowed generation of 
memory CD4+ and CD8+ T cells and hence did not result in T cell anergy. However, 
FK506+Rap treatment resulted in a reduced number of allo-specific memory T cells 
showing a decreased cell cycle turnover and cytokine producing capacity. In con-
trast, CsA+Rap treatment led to increased memory T cell numbers responding with 
elevated kinetics. The ability of Rap to promote apoptosis, which contributes to T 
cell suppression, remained unaffected upon combination with FK506 or CsA. These 
data support the combined use of FK506+Rap over CsA+Rap for immunosuppressive 
therapy. 
[TRANSPLANTATION 2003; 75 (9):1581] 
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INTRODUCTION 
Immunosuppressive agents, like Cyclosporin A (CsA), Tacrolimus (FK506), and Ra-
pamycin (Rap), are widely used to prevent clonal T cell expansion in transplanta-
tion. CsA and FK506 are both pro-drugs that need to form complexes with the cyto-
plasmic targets cyclophilin-A and FK506-binding protein (FKBP), respectively. These 
complexes hinder T cell receptor mediated signaling by prohibiting the protein 
phosphatase calcineurin to dephosphorylate cytoplasmic nuclear factor of activated 
T cells (NFAT). Dephosphorylation is required for entry of NFAT into the nucleus. 
Accordingly, an array of genes essential for a productive T cell response is not tran-
scribed and consequently the cell is inhibited in the G0-G1 phase of the cell cycle 
1,2. 
Rap, like FK506, forms a complex with FKBP, but Rap-FKBP binds to a kinase called 
target of Rap (TOR). TOR plays a central role in growth factor receptor mediated 
control of the cell cycle. Rap affects downstream phosphorylation activities of TOR, 
preventing the translation of proteins (i.e. phosphatases and kinases) that regulate 
G1 to S phase cell cycle transition 
2-5. Rap also permits T cell apoptosis 6,7 which is 
prevented by CsA or FK506 8-11.  
Theoretically, immunosuppression is best achieved with a combination of immuno-
suppressive agents which target distinct T cell activation routes. Moreover, combi-
nation therapy aims to minimize side effects by dose reduction of any single drug 
while maintaining adequate immunosuppression 12. Since FK506 and Rap share a 
common intracellular target they were initially considered as an antagonistic drug 
combination 13,14. Recently however, combination treatment with FK506 and Rap, 
like the combined use of CsA and Rap, showed synergistic effects in experimental 
animal models 15-18. Moreover, encouraging outcomes were observed in clinical 
transplant studies using combination treatment with either CsA+Rap or FK506+Rap 
19-21.  
Kahan et al 16 showed synergism for CsA+Rap in the inhibition of proliferation, gen-
eration of cytotoxic effectors and maturation of cytotoxic precursors in vitro, which 
is in line with in vivo findings 15-18. Although profound immunosuppressive effects 
by combined FK506+Rap treatment are observed in vivo 17,18,20,21, a detailed under-
standing which T cell functions are affected by FK506+Rap is missing. Moreover, for 
both the combined use of CsA+Rap and FK506+Rap information is lacking with re-
spect to the induction of cell death, memory T cell generation (and reactivity kinet-
ics of memory cells). Therefore in this study, we compared the efficacy of combined 
CsA+Rap and FK506+Rap treatment, and focused on T cell characteristics which are 
critical in T cell mediated graft rejection versus graft survival such as: T cell activa-
tion, expansion, apoptosis, induction of cytotoxic effector T cells, generation and 
reactivity rate of CD4+ / CD8+ memory T cells and T cell anergy induction.  
In conclusion, co-treatment with FK506+Rap, as compared to the use CsA+Rap, re-
sulted in superior suppression of multiple T cell characteristics. This provides a ra-
tionale to choose a combination of FK506+Rap in clinical transplantation. 
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MATERIALS  & METHODS  
Cells and reagents 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient cen-
trifugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) from buffy coats of 
normal healthy donors. Cells were stored in liquid nitrogen until use. After thawing, 
viability of the cells was determined by trypan blue exclusion. FK506 (Tacrolimus; 
Dr. B.Buiten, Fujisawa, The Netherlands) and Rapamycin (Dr S.N.Sehgal, Wyeth-
Ayerst, NJ, USA) were kindly provided for research purposes. Sandimmune Cyc-
losporine A (CsA) was obtained from Novartis Pharma B.V. (Arnhem, The Nether-
lands).  
 
Primary MLC and analysis of memory responses 
Primary one-way Mixed Lymphocyte Cultures (MLC) were performed by culturing 
1.105 30 Gy γ-irradiated stimulator PBMC with 1.105 HLA mismatched responder 
PBMC in 96 wells round bottom plates (Greiner, Frickenhausen, Germany) in 200 µl 
culture medium (RPMI-1640 with glutamax supplemented with pyruvate (0.02mM), 
100 U/ml penicillin, 100 µg/ml streptomycin, (all from Gibco, Paisley, UK) and 10% 
heat inactivated pooled human serum) at 370C, 95% humidity and 5% CO2 . Prolif-
eration was analyzed by 3H-thymidine incorporation (3H-Incorporation) at the indi-
cated time-points. 3H-thymidine (0.037MBq (1 µCi), ICN Pharmaceuticals, Irvine, 
CA, USA; specific activity 7.4X1010 Bq/mmol (2.0 Ci/mmol)) was present during the 
last 18 hours of culture. 3H-Incorporation was analyzed by a Gas Scintillation 
Counter (Canberra Packard, Matrix 96 Beta counter, Meriden, U.S.A.). 3H-
incorporation is expressed as mean counts per 5 minutes of quadruplicate meas-
urements, standard deviations (SD) were usually <15%. 
Analysis of memory responses of allo-MHC primed T-cells was performed in secon-
dary MLC. To study the secondary response, first primary MLC were performed for 7 
days in 24 wells plates at concentrations of 1.106 responders versus 1.106  30 Gy γ-
irradiated stimulator PBMC. Cells were harvested, washed 3 times, allowed to recu-
perate for 2-3 days, washed again and the viable cells were recovered by density 
gradient centrifugation (Lymphoprep, Oslo, Norway). After vigorous washing, 2.104 
viable cells were restimulated with 1.105 γ-irradiated (30 Gy) stimulator PBMC in 96 
well round bottom plates.  Proliferation during the secondary MLC was examined by 
3H-Incorporation or CFSE based cell division analysis  
 
Cytotoxicity by 51Cr-release assay 
The cytotoxic capacity of allogeneically primed T-cells was examined by  51Cr-
release of  51Cr labeled PHA-blasts. Briefly, allogeneic PHA-blasts were generated by 
culturing PBMC 48 hrs with PHA-M (Boehringer Mannheim, Mannheim, Germany) 
and subsequently for 48 hrs with IL-2 (50 U IL-2/ml, Proleukine, Eurocetus, The 
Netherlands). 2.106 PHA-blasts were labeled with 100 µCi 51Cr (Amersham, UK) and 
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used as target cells at 1000 cells/well. Different effector/target (E/T) ratios were 
tested in triplicate. Culture supernatants were examined for released  51Cr on a γ-
irradiation counter (Wallac 1470 γ-counter, Turku, Finland). Control experiments 
were performed using autologous PHA-blasts and K562 cells as target cells. Cold 
target experiments were performed by using a target cell mixture of  51Cr labeled 
allogeneic PHA blasts and non-labeled K562 cells (ratio 1000/1000 cell per well).  
Cytotoxic capacity is shown as percentage lysis of the indicated target, calculated 
according to the following equation: 
(CPM sample release - CPM spontanous release)
(CPM total release - CPM spontanous release)
Percentage lysis = X 100%
 
 
Flowcytometry; Cell surface and Annexin-V staining 
Cells were phenotypically analyzed by three or four color immunofluorescence. 
Briefly, cells were washed twice with buffer (PBS containing 0.2 % BSA) and labeled 
with the antibodies of interest conjugated with either FITC, PE, ECD or PC5. Cells 
were incubated for 20 minutes in the dark at room temperature, washed twice and 
analyzed on a Coulter Epics XL flowcytometer (Beckman Coulter, Fullerton, CA). 
5000 or 10.000 events were collected based on live lymphocyte cell gating as indi-
cated by Propidium Iodide (PI, 5 µg/ml) staining and analyzed by Coulter Epics 
Expo 32 (Beckman Coulter, Fullerton, CA, USA) and/or WINMDI (Scripps Research 
Institute, La Jolla, CA, USA ) software. Isotype matched antibodies were used to 
define marker settings.  The following fluorochrome conjugated mAb were used: 
CD3, CD4, CD8, CD25  FITC or PE labeled (DAKO, Glostrup, Denmark), HLA-DR-PE 
and CD3-FITC (Becton and Dickinson, San Jose, CA, USA), CD4, CD8 ECD- labeled 
(Coulter Corporation, Miami, Fl, USA) and CD4, CD8 and CD25 PC5-labeled (Immu-
notech, Marseille, France). FITC conjugated annexin-V (Bender Medsystems, Vi-
enna, Austria ) was used according to the manufacturers instructions to detect early 
apoptosis in anti-CD4 and anti-CD8 antibody labeled T cells. Cell death was con-
firmed by cell cycle analysis according to DNA-staining by PI.  
 
Cell division kinetics according to CFSE dilution. 
The cell division rate of allo-MHC primed T cells was studied by labeling viable re-
cuperated (see above) responder T cells with Carboxyfluorescein Diacetate Suc-
cinimidyl Ester (CFDA-SE, Molecular Probe, Eugene, OR) just before restimulation. 
In the cell esterases cleave the acetyl group of CFDA-SE leading to the fluorescent 
diacetylated carboxyfluorescein succinimyl ester (CFSE). At each cell division the 
mean CFSE fluorescence halves. Simultaneous labeling of CD4+ and CD8+ T cells, 
by fluorochrome conjugated mAb against CD4 and CD8 enables the study of division 
kinetics by flowcytometry of these T cell subsets. Data, preferentially 50.000-
100.000 live gate events, were analyzed using Coulter Epics Expo 32 and/or ModFit 
LT (Verity Software House, Topsham, ME) software. 
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Intracellular cytokine staining 
The cytokine producing potential of viable recovered T cells that were allogeneically 
primed in the presence or absence of immunosuppressive drugs was examined after 
polyclonal restimulation (PMA+Ionomycin) by intracellular cytokine staining. Briefly, 
recovered cells were stimulated for 5 hrs with PMA (12.5 ng/ml) and Ionomycin 
(500 ng/ml). During the last 4 hrs of stimulation Brefeldin A (5 ng/ml) was present 
(chemicals from Sigma, Chemical CO, St.Louis, MO, USA). Next, the cells were 
washed and surface stained with monoclonal antibodies (mAb) directed against CD3 
and CD8. After washing the cells were fixed and permeabilised  (Fix and Perm re-
agent A and B, Caltag Laboratories, An Der Grub, Vienna, Austria) and washed 
again. Finally, the cells were stained with mAb directed against IFNγ, IL-2 and TNFα 
(PE or FITC labeled, Pharmingen, Europe) and washed 3 times. Appropriate isotype 
control mAbs were used for marker settings.  
 
RESULTS 
Superior suppression of clonal expansion by combined treatment 
with Rapamycin and Calcineurin inhibitors as compared to single 
drug use 
Single immunosuppressive drugs were titrated in primary MLC to analyze their in-
hibitory effect on naive alloreactive T cells in our experimental system (Fig.1A). 
Compared to CsA or FK506, Rap resulted in the highest inhibition of naive T cell ex-
pansion (Fig.1A).  
Combination drug treatment was studied using the following concentrations; CsA 
(100 and 400 ng/ml) or FK506 (10 and 40 ng/ml) and Rap (20 and 100 ng/ml). As 
expected, combination treatment of CsA or FK506 with Rap, as compared to single 
drug use, resulted in an increased inhibition of the proliferative response of naive 
allogeneic T cells (Fig. 1B).  
Next, the drug combinations were studied for T cell activation, apoptosis, induction 
of cytotoxic effector T cells and generation of memory T cells, all of which are inte-
gral components of alloantigen driven T cell responses.  
 
Rapamycin facilitates apoptosis even when combined with CsA or 
FK506  
To investigate whether apoptosis might play a role in the stronger inhibition of 
clonal expansion by Rap as compared to CsA or FK506 (Fig 1A), we investigated, 
Annexin-V binding during drug treatment in the primary MLC. Indeed, Rap mono-
treatment resulted in an increased percentage of Annexin-V binding CD4+ T cells 
(38.4-45.8%), as compared to the single use of either CsA (27.7-24.9%) or FK506 
(20.9-24.0%) (Fig 2A). The addition of Rap to either CsA or FK506, CsA+Rap (42.6-
46.4%) or FK506+Rap (43.5-45.7%) respectively, resulted in comparable percent-
ages of Annexin-V binding CD4+ T cells as found for Rap mono-treatment (38.4-
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45.8%). This implies that, at the investigated concentrations, neither CsA nor 
FK506 affected Rap facilitated apoptosis. Allogeneic stimulation preferentially re-
sulted in apoptosis of CD4+ T cells, whereas negligible apoptosis in CD8+ T cells 
was observed (data not shown). Apoptosis was confirmed by propidium iodide based 
DNA staining (data not shown).  
F I G U R E  1 .  
Combined immunosuppression of CsA or FK506 with Rap results in enhanced sup-
pression. 
A. Titration of immunosuppressive drugs. 
The indicated drugs (concentrations in ng/ml 
on the X-axis in log scale) were added at the 
start of the primary MLC. Percentages inhibi-
tion of the control MLC were calculated at 
day 6 of the culture. Data show mean per-
centage inhibition derived from 4 independ-
ent 3H-Incorporation based proliferation ex-
periments. B. The indicated drugs were 
combined at distinct concentrations (in pa-
renthesis in ng/ml) and administered at the 
start of the MLC. The proliferative response 
was measured at day 6. Mean 3H-
Incorporation of quadruplicate measure-
ments from one representative experiment 
out of 6 is shown, SD 10-15%. (FK=FK506).
 
CsA+Rap or FK506+Rap treatment still permits activation of CD4+ T 
cells  
Primary allogeneic stimulation in the absence of immunosuppressive agents resulted 
in CD4+ T cell blast formation (data not shown) and concomitant CD25 expression 
(69.2 % CD4+/CD25+ T cells) as was shown by flowcytometry (Fig. 2B). Combina-
tion treatment with CsA+Rap (5.7-9.5%) or FK506+Rap (10.4-16.4%) resulted in a 
decreased percentage of CD25 expressing CD4+ T cells as compared to single use 
of CsA (29.7-47.0%), FK506 (32.5-36.0%) or Rap (17.6-25.9%). The   
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F I G U R E  2 .  
Combined immunosuppression by CsA or FK506 with Rap permits apoptosis  
and does not completely prevent T cell activation 
Primary MLC were performed in the presence 
of the indicated drug(s) (C; CsA, R; Rap, F; 
FK506, concentrations in ng/ml in parenthe-
sis). A. Annexin-V binding of CD4+ T cells is 
shown at day 6 of the cultures. Histograms 
show number of events (Y-axis) and binding 
of Annexin-V (X-axis; log scale) on CD4+ 
gated T cells. The percentage Annexin-V 
positive cells are shown in the upper right 
corner of each histogram.  
B. CD25 expression on live-gated CD4+ T 
cells at day 6 of the primary MLC performed 
in the presence of immunosuppressive 
agents. Dot plots show CD4 and CD25 ex-
pression on the Y and X-axis, respectively. 
The percentages of CD4/CD25 double posi-
tive cells are indicated at the upper right 
corner. Isotype controls were used for 
marker settings. Similar results were ob-
tained in 4 other experiments. 
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culture and finally resulted in similar CD25 expression levels as found for CsA or 
FK506 treatment (data not shown). In some experiments CD25 expression on CD8+ 
T cells was observed in control primary MLC, but it was absent whenever single or 
combined drugs were used (data not shown). Thus, although the number of acti-
vated T cells was clearly reduced after combined drug treatment, still alloantigen 
driven activation of CD4+T cells occurred (Fig. 2B). 
 
FK506+Rap, in contrast to CsA+Rap, completely prevents induction 
of allogeneic cytotoxic effector T cells 
Next, we investigated whether combined drug treatment affected the induction of 
allogeneic cytotoxic T cells. Mono-treatment with FK506, as compared to single use 
of CsA or Rap, led to a reduced lysis of allogeneic target cells (Fig 3A). Combined 
drug treatment with CsA+Rap or FK506+Rap, as compared to mono drug treatment, 
resulted in a clear reduction of allogeneic target cell lysis (Fig 3A). Interestingly, 
the use of FK506+Rap (especially the addition of 100 ng/ml Rap to either 10 or 40 
ng/ml FK506) completely prevented the generation of cytotoxic effectors (Fig 3A). 
With respect to the combined use of CsA+Rap or FK506+Rap, the observed differ-
ences in cytolytic potential were not due to variations in activated (HLA-DR+) CD8+ 
T cell numbers (Fig 3A). 
Whenever allogeneic target cells were killed, K562 targets were lysed at a similar 
level, while autologous targets remained unaffected (Fig 3B). To ascertain antigen 
specificity of the cytotoxic T cells, K562 cold target inhibition assays were per-
formed. Addition of the K562 cold targets to labeled allo-specific target cells re-
sulted in a similar cytotoxicity as found for allo-specific target cells only. Indicating 
that allogeneic cells are the primary targets and that K562 cells, being extremely 
sensitive to lysis, suffered from bystander kill by activated CD8+ T cells. 
 
CsA+Rap or FK506+Rap treatment permits generation of memory T 
cells, but the use of FK506+Rap resulted in T cells responding at an 
attenuated level
 Immunosuppression still allowed T cell activation (Fig 2B) and therefore we exam-
ined whether drug treatment also permitted memory T cell generation. T cells de-
rived from either control or drug(s) treated primary MLC were rechallenged in sec-
ondary MLC. Antigen specific restimulation of allogeneically primed T cells was 
characterized by a fast proliferative response reaching an optimum at day 3 after 
rechallenge (Fig. 4).  In comparison, naive unprimed control T cells revealed an op-
timal response at day 6-7 (Fig. 4). Single or combined immunosuppression during 
the primary MLC still resulted in T cells responding with secondary kinetics(Fig. 4). 
This indicates that irrespective of the drug(s) previously used, generation of mem-
ory T cell took place. However, drug dependent changes in memory response kinet-
ics and magnitude of proliferation were observed. Previous combination treatment  
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F I G U R E  3 .  
Induction of cytotoxic T cells is prevented by combined FK506+Rap treatment 
A. T cells derived from primary MLC which 
were treated with drugs as indicated on the 
Y-axis (drug concentrations in parenthesis in 
ng/ml), were analyzed for their killing poten-
tial of allospecific PHA-blasts in a 51Cr-
release assay. Percentage specific lysis (X-
Axis) is shown at different E/T ratios (leg-
end). Drugs were absent  during analysis of 
cytotoxicity.  The percentage of CD8+ and 
CD8+/HLA-DR+ T cells (analyzed by flowcy-
tometry) in the responder population that 
were present in this cytotoxicity assay are 
indicated for each condition next to the Y-
axis. Previous treatment by either CsA+Rap 
or FK506+Rap resulted in similar numbers 
activated (HLA-DR+) CD8+ T cells.  B. Cyto-
toxic effector T cells are alloantigen specific. 
T cells derived from primary MLC were ana-
lyzed for their cytolytic capacity against 51Cr 
labeled allospecific, autologous or K562 tar-
get cells (see legend). Cold target inhibition 
assays were performed by using 51Cr labeled 
allogeneic targets together with non-labeled 
(cold) K562 cells (Ratio=1:1). Percentage 
lysis is shown at the Y-axis. The cold K562 
targets did not inhibit the cytotoxicity 
against the allogeneic targets, indicating the 
antigen specificity of the killer cells. Results 
are shown for control MLC derived T cells, 
similar observations were made for previ-
ously drug treated T cells. One representa-
tive experiment out of 4 is shown. 
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with CsA+Rap resulted in memory T cells that showed an increased mean peak pro-
liferative response (ppr; ~ 55.000) compared to control cells (ppr;~48.000) and 
similar kinetics as control MLC derived T cells. In comparison, previous FK506+Rap 
treatment resulted in T cells responding at a reduced level (ppr; 40.000) and show-
ing a one-day delay in response kinetics. Single drug treatment by Rap or CsA re-
sembled the response of CsA+Rap treated cells while single FK506 use resulted in T 
cells responding in a similar way as FK506+Rap treated cells (Fig. 4). Differences in 
drug dose that were used in the primary MLC hardly affected kinetics or the re-
sponse level of memory T cells. Furthermore, HLA mismatched third party stimula-
tor PBMC did not result in secondary responses, whereas in the absence of stimula-
tor PBMC only background proliferation was observed (data not shown and 
previously reported results 22).  
Thus, CsA+Rap treatment resulted in memory T cells responding at an elevated 
level, while in contrast, reduced and delayed memory responses were found after 
the use of FK506+Rap. Since memory T cell responses were evident irrespective of 
the drug(s) used, no T cell anergy induction took place. 
F I G U R E  4 .  
CsA+Rap or FK506+Rap treatment permits generation of memory T cells, but the use 
of FK506+Rap resulted in T cells responding at an attenuated level 
Elevated memory responses after priming in 
the presence of CsA+Rap. Recovered viable 
T cells derived from primary MLC that were 
treated according to the conditions men-
tioned in the legends (C; CsA, R; Rap, F; 
FK506, concentrations in ng/ml in parenthe-
sis) were allogeneically restimulated. Control 
cells were derived from non-drug treated 
primary MLC. Naive non-allogeneically stimu-
lated T cells were included. Drugs were ab-
sent in restimulation assays. Proliferation (Y-
axis) is shown in time (days, X-axis). One 
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representative experiment out of 6 is shown. 
SD in restimulation assays were typically 
<10%.
 
Strong memory responses after CsA+Rap treatment are due to high 
cell cycle turnover and elevated memory T cell numbers in both 
CD4+ and CD8+ T cell subsets 
The previous finding that CsA+Rap, as compared to FK506+Rap treatment, resulted 
in a more vigorous memory T cell response, prompted us to study the number and 
dynamics of dividing CD4+ and CD8+ allogeneic memory T cells in more detail by 
CFSE labeling studies. T cells derived from control (untreated) and drug treated 
primary MLC were labeled with CFSE and allogeneically restimulated in a secondary 
MLC. Irrespective of whether the cells were derived from control or drug(s) treated 
primary MLC, both CD4+ and CD8+ memory T cell division was evident (Fig 5A). 
Notably, in these restimulation assays it was found that T cells priming in the pres-
ence of CsA+Rap, as compared to FK506+Rap, consistently resulted in an increased 
number of allo-specific CD4+ and CD8+ memory T cells which in addition had an 
elevated cell cycle turn-over (Fig. 5A+B). Previous mono treatment with CsA, as 
compared to FK506 mono treatment, also resulted in increased memory T cell num-
bers that responded at an enhanced level (data not shown). Thus, the increased 
memory response observed for T cells primed in the presence of CsA+Rap (Fig 4) is 
the result of both increased frequency and cell cycle dynamics of allospecific CD4+ 
and CD8+ memory T cells (Fig. 5A+B). Finally, the cytokine producing potential of T 
cells that were allogeneically primed for 7 days in the presence of CsA+Rap or 
FK506+Rap was analyzed by flowcytometry. T cell priming  in the presence of 
CsA+Rap, as compared to FK506+Rap, resulted in an increased number of cytokine 
producing CD4+ T cells producing IFNγ and TNFα and IL-2 in higher amounts (in-
creased mean fluorescence) (Fig. 5C). Moreover, compared to primed control CD4+ 
T cells, FK506+Rap treatment resulted in a reduction of IFNγ and TNF producing 
CD4+ T cells. Together these findings are in accordance with the results found in 
the CFSE experiments in figure 5A+B showing that CsA+Rap treatment, as com-
pared to the use of FK506+Rap, resulted in memory T cells having an increased re-
activity potential. 
 
DISCUSSION 
Immunosuppressive combination therapy aims at minimizing side effects of any sin-
gle drug while maintaining adequate immunosuppression by targeting multiple steps 
in T cell activation 12.  Because it was initially reported that immunosuppressive 
drugs which target the same intracellular protein (e.g. FK506 and Rap) act in an 
antagonistic way 13,14, the most likely candidates for combination therapy were 
thought to be Rap and CsA. Indeed, in vivo and in vitro studies suggested that CsA 
and Rap act in a complementary way 15,16 and also in clinical organ transplantation 
this combination proved to be effective 19. However, recently Vu et al. 18 disputed f
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F I G U R E  5 .  
In contrast to FK506+Rap, CsA+Rap use results in higher numbers alloreactive 
memory T cells with increased cell cycle turnover and cytokine producing potential  
Primary MLC were performed in the absence 
of drugs (control) or with CsA+Rap or 
FK506+Rap (Y-axis; concentrations in paren-
thesis in ng/ml). After 7 days of culture cells 
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were washed and allowed to recuperate. The 
viable T cells were recovered by density gra-
dient centrifugation. A. The recovered T cells 
were labeled with CFSE and restimulated 
with allospecific stimulator PBMC. Cell divi-
sion of anti-CD4 and anti-CD8 mAb labelled 
T cells was analyzed by flowcytometry. His-
tograms show CFSE fluorescence of 
CD4+(left) and CD8+ (right) T cells 72 hrs 
after restimulation. Percentages dividing 
cells are indicated in the upper left corner. 
Naive non-allogeneically stimulated T cells 
were included. Restimulation assays were 
devoid of drugs. One representative out of 4 
experiments is shown. B. The number of 
cells per division (shown in figure A) was 
analyzed by modfit software. The percentage 
CD4+ (left) and CD8+ (right) T cells per di-
vision cycle are shown 72 hrs after restimu-
lation.  Cells were derived from either 
CsA+Rap (upper figures) or FK506+Rap 
(lower figures) treated primary MLC. The 
legends show the conditions during the pri-
mary cultures (concentrations in ng/ml in 
parenthesis). C. Recovered T cells derived 
from primary MLC that were treated as indi-
cated (Y-axis, concentrations in parenthesis 
in ng/ml) were restimulated with 
PMA+Ionomycin. After 5 hrs the production 
of intracellular IFNγ, IL-2 and TNFα (top) by 
anti-CD3 and anti-CD8 mAb labeled cells 
were measured by flowcytometry. Dotplots 
show forward scatter (Y-axis) and cytokine 
production (X-axis) by CD3+/CD8- cells 
(representing CD4+ T cells). Naive unprimed 
allogeneic T cells were included as a control. 
Percentage positive cells and mean fluores-
cence intensity, respectively, are indicated 
at the lower right corner of each dotplot. 
Drugs were absent during the assay. One of 
two similar experiments is shown. 
 
the in vivo antagonistic effect previously described for Rap combined with FK506 17. 
In addition, this combination has now been successfully used in human clinical 
transplantation studies 20,21. Despite the wealth oexperimental data on immunosup-
pressive drugs it is still unclear which T cell functions are precisely affected by). 
combining particular drugs. Consequently, no clear immunological basis exists for 
selecting a certain drug combination. In this study, we combined Rap with either 
CsA or FK506 and examined T cell characteristics that play a crucial role in rejection 
versus survival of allografts such as: T cell activation, T cell clonal expansion, 
apoptosis, generation of cytotoxic effectors T cell and induction of T cell memory 
versus T cell anergy (Table 1Transplant survival critically depends on the reduction 
of the clonal alloreactive T cell pool 23 which, in the simplest terms, is the result of 
blocked cell cycle progression and/or induction of cell death. CsA, FK506 and Rap 
prevent cell cycle progression albeit it via distinct mechanisms 1,2,2-5. In addition, 
Rap permits signaling for activation induced cell death 24 leading to increased cell 
cycle-dependent apoptosis 6. In contrast, the calcineurin inhibitors CsA and FK506 
inhibit NFAT activity thereby preventing induction of cell death 8-10. With respect to 
single drug treatment our data are in agreement with these observations, since Rap 
facilitated apoptosis while CsA or FK506 did not. 
The Bcl-2 protein family plays a crucial role in the protection from apoptotic cell 
death 25,26. In contrast to FK506, Rap selectively inhibits the expression of anti-
apoptotic Bcl-2 and BAG-1 mRNA 27. Bcl-2 forms a tight complex with calcineurin, 
this complex is unable to promote the nuclear translocation of NFAT 28. This indi-
cates a mechanism by which Bcl-2 suppresses NFAT mediated activation induced 
cell death in T cells 10. Inhibition of Bcl-2 by Rap 27 might thus result in an increase 
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in cell death probably by the activation of NFAT. Interestingly, in the present study 
we show that the combined use of CsA+Rap or FK506+Rap consistently resulted in 
apoptosis of allogeneically stimulated T cells. These results indicate that neither 
CsA nor FK506 reversed apoptosis induced by Rap. In addition they suggest that 
NFAT activity is not crucial in Rap induced apoptosis.  
Selective competition between Rap and FK506 for FKBP binding might dictate the 
outcome of combined drug treatment on T cell death 11. Previously, in a murine T 
cell hybridoma model it was shown that 100 times more Rap than FK506 was 
needed to result in cell death 11. In our experiments, cell death was still observed 
at Rap:FK506 dose ratio's ranging from 0.5:1 to 10:1. This indicates that, at these 
ratios, competition between Rap and FK506 for FKBP binding is not essential for Rap 
induced T cell death. 
T A B L E  1   
In contrast to the other conditions tested, only FK506+Rap inhibits clonal expan-
sion, prevents the induction of cytotoxic effector, allows apoptosis and results in 
reduced memory T cell numbers which in addition respond at a reduced level. 
Culture conditions primary MLC CsA Rap FK506 Rap + 
CsA 
Rap + 
FK506 
Naïve allo-reactive T cells      
Clonal expansion - -- - --- --- 
Number of activated T cells  - - - --- --- 
Apoptosis = / - ++ =/ - ++ ++ 
Effector and memory function after drug withdrawal 
Cytotoxic effector cells = = - - --- 
CD4+ memory response ++ + - +++ - 
CD8+ memory response ++ + - ++ - 
Semi-quantitative scores are shown using an arbitrary scale ranging from‘---‘ (reduced), = 
(similar) to ‘+++’ (increased) as compared to the control situation. 
 
Kahan and co-workers 16 showed synergism for the combined use of CsA+Rap in 
vitro. Especially, alloantigen driven T cell proliferation, generation of cytotoxic ef-
fector T cells and maturation of cytotoxic T cell precursors were affected to a higher 
level by combining CsA and Rap 16. Moreover, in a rat model, CsA+Rap treatment 
resulted in prolonged survival of heterotopic MHC incompatible cardiac allografts 16. 
As referred to before, initial in vitro studies using murine T cells stimulated by PMA 
and Ionomycin revealed antagonistic effects for FK506+Rap whereas Rap potenti-
ated the effects of CsA  13. In retrospect, progress in the combined use of 
FK506+Rap may have been impeded by these findings. However, more recently, 
various transplant studies clearly showed additive effects of combination treatment 
with FK506+Rap 17,18,20,21. In addition, we here demonstrate that combined treat-
ment with FK506+Rap or CsA+Rap, resulted in a similar inhibition of clonal expan-
sion. But most importantly, FK506+Rap treatment, in contrast to the combined use 
of CsA+Rap, completely abolished the generation of cytotoxic allospecific effector T 
cells.  
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Some of the progeny of antigen-stimulated T lymphocytes develop into memory T 
cells contributing to recall immunity 29,30. Here we show that irrespective of the 
drug(s) used, memory T cells were generated in the absence of vigorous T cell divi-
sion. Memory T cell generation in the absence of previous T cell expansion has also 
been described by others 30-33. Compared to naive T cells, memory T cells respond 
with superior efficacy which is the result of an increased T cell frequency and ele-
vated cell cycle pace 34,35. Memory T cells remain in the late G1 phase of the cell cy-
cle and therefore start cell division more rapidly 36. The cell cycle phase duration is 
dictated by regulators like cyclin dependent kinase inhibitor p27kip1 and Bcl-2 10. 
These regulators are disturbed by CsA, FK506 and Rap treatment 27,37,38, resulting 
in G1 cell cycle phase accumulation 
2,4,5. CsA+Rap treatment resulted in memory T 
cells having an increased cell cycle turnover and producing increased amounts of 
cytokines, while, in contrast, FK506+Rap treatment led to retarded T cells (Fig. 5). 
Apparently, CsA+Rap and FK506+Rap distinctly modify the cell cycle program of 
allogeneically primed T cells.  
In contrast to our findings showing that Rap treatment resulted in memory T cells, 
Rap was recently reported to induce T cell anergy 39. T cell anergy is characterized 
by hyporesponsiveness upon antigenic restimulation 22,40,41. A well-known method 
to induce T cell anergy, is antigenic stimulation in the absence of costimulation 
(signal 2) as we and others have previously described 22,40,41. We compared this 
well established anergy inducing protocol 22 with Rap treatment and definitely ex-
cluded T cell anergy induction by Rap in our allogeneic polyclonal model (data not 
shown). Although speculative, the most obvious reason for the observed differences 
might be the human polyclonal naive T cell allogeneic background of our experi-
ments while the aforementioned study was performed with a CD4+ murine T cell 
clone stimulated by anti-TcR mAb 39. In line with our findings is the observation 
that in vivo Rap treatment did not prevent in vitro recall responses 42. 
In this study we have compared different concentrations of each drug which re-
sulted in similar effects. This implies that the reported findings are drug specific. 
Taken together, the presented data, as summarized in Table I, provide an immu-
nological rationale to choose a combination of FK506+Rap over CsA+Rap in clinical 
applications. 
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ABSTRACT 
Costimulation blockade based tolerance-inducing therapies might be disrupted by 
adjunct conventional immunosuppressive drug use. In the current study we evalu-
ated the compatibility of various immunosuppressive agents on costimulation block-
ade-based immunosuppression and T-cell anergy induction of human alloreactive T-
cells in vitro. T-cell anergy is crucial in transplantation tolerance. We found that 
monoclonal antibodies against CD40 and CD86 and the simultaneous use of conven-
tional immunosuppressive drugs (CsA, rapamycin or FK506) resulted in strong im-
munosuppression of proliferation and cytokine production. Rapamycin, in contrast 
to FK506 and CsA, facilitated T-cell apoptosis. However, drug co-treatment pre-
vented costimulation blockade induced T-cell anergy. Induction of human T-cell an-
ergy in vitro required approximately 5 days of culture. Co-administration of drugs 
at day 5 after the start of mAb treatment, when anergy was established, did not 
increase the immunosuppressive effect of mAb treatment. But interestingly, in con-
trast to rapamycin and FK506, CsA did not affect the anergic state when given after 
T-cell anergy induction. Moreover, the cell death facilitating potential of rapamycin 
vanished when used later after T-cell activation. Thus, timing and choice of conven-
tional drug are crucial in the success of costimulation blockade based tolerance in-
duction therapies.  
[SUBMITTED FOR PUBLICATION] 
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INTRODUCTION 
Currently different non-specific immunosuppressive drugs are clinically used to pre-
vent T cell mediated graft rejection. Transplanted patients need to comply with 
these drug regimens life-long. Importantly, besides the advantages of these drugs 
most of them display major harmful side effects. Therefore a major goal in trans-
plant medicine is the development of treatment protocols to induce T cell tolerance. 
Tolerance is defined as specific immunological unresponsiveness, maintained either 
by ‘passive’ mechanisms such as deletion or functional non-responsiveness (anergy) 
of antigen-specific T cells, or by active suppression mediated by active suppression 
by regulatory T cells 1. The precise mechanisms involved in establishment of pe-
ripheral immune tolerance are still incomplete and elusive. However, it is firmly es-
tablished that the induction of operational transplantation tolerance is an actively 
regulated multistep process employing several non-mutually exclusive and comple-
mentary mechanisms such as anergy, immunoregulation and/or activation induced 
cell death (AICD) of alloreactive T cells 1,2. In a myriad of especially small experi-
mental animal models immunological tolerance was demonstrated 3,4. Simultaneous 
blockade of the costimulatory pathways CD86/CD80-CD28 and / or CD40-CD40L, 
which are crucial for productive T cell response 5,6, appeared a powerful mediator in 
the prevention of acute and chronic transplant rejection in rodent and non-human 
primate transplant models 7-11 and in some studies donor specific tolerance was ob-
tained 10,12-14. Costimulation blockade reduced the alloreactive T-cell pool in animal 
models and human alloreactive T cells, in vivo and in vitro respectively 10,15,16. Im-
portantly, co-stimulation blockade of human T cells resulted in the induction of an-
ergic antigen specific immunoregulatory T-cells 16. Hence, T-cell costimulatory 
blockade might be considered a promising clinical strategy to prevent rejection of 
human allografts. 
However, clinical implementation of new immunosuppressive therapies in contempo-
rary successful transplant protocols will require its combined use with currently ap-
proved immunosuppressive agents (e.g. CsA, FK506 or rapamycin). The effects of 
conventional immunosuppressive drugs on tolerance induction in animal models are 
controversial and it has been reported that the beneficial effects of costimulation 
blockade can be negated when combined with certain immunosuppressant 7,10. 
In this study we evaluated the effect of clinically used immunosuppressive drugs in 
combination with costimulatory blockade with mAb against CD86 and CD40. We 
thereby focused on alloreactive T cell expansion, cytokine production, survival and 
anergy induction.  
First, we show that concomitant treatment with mAb and adjunct immunosuppres-
sive therapy prevents T cell anergy. Second, we describe the immunological activa-
tion requirements needed for anergy induction by anti-CD40+CD86 mAb. Finally, we 
show that simultaneous treatment with ISD and anti-CD40+CD86 mAb abrogates 
the anergy inducing potential of costimulation 
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blockade. Ideally, an immunological window to establish T cell anergy should be 
created before adjunct immunosuppressive therapy is started. Once anergy is es-
tablished, CsA in contrast to rapamycin and FK506, did not abolish the anergic state 
in vitro. These findings have important implications in clinical allograft tolerance 
induction strategies in humans, especially with respect to timing of the tolerance 
induction protocol and the choice of immunosuppressive drugs.  
 
MATERIALS  & METHODS 
Cells and Immunosuppresive drugs 
For all experiments, peripheral blood mononuclear cells (PBMC) were isolated by 
density gradient centrifugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) 
from buffy-coats of normal healthy donors. Cells were frozen and stored in liquid 
nitrogen until use. After thawing, viability of the cells was determined by trypan 
blue exclusion.  
FK506 (Tacrolimus; Dr. B.Buiten, Fujisawa, The Netherlands) and Rapamycin (Dr 
S.N.Sehgal, Wyeth-Ayerst, NJ, USA) were kindly provided for research purposes. 
Sandimmune Cyclosporine A (CsA) was obtained from Novartis Pharma B.V. (Arn-
hem, The Netherlands). 
 
Primary MLC and induction of T cell anergy 
Primary one-way Mixed Lymphocyte Cultures (MLC) were performed by culturing 
1.105 30 Gy γ-irradiated stimulator PBMC with 1.105 HLA mismatched responder 
PBMC in 96 wells round bottom plates (Greiner, Frickenhausen, Germany) in 200 µl 
culture medium (RPMI-1640 with glutamax supplemented with pyruvate (0.02mM), 
100 U/ml penicillin, 100 µg/ml streptomycin, (all from Gibco, Paisley, UK) and 5-
10% heat inactivated pooled human serum) at 370C, 95% humidity and 5% CO2. 
Proliferation was analyzed by 3H-thymidine incorporation at the indicated point of 
measurement. To this end 0.037MBq (1 µCi) 3H-thymidine (ICN Pharmaceuticals, 
Irvine, CA, USA; specific activity 7.4X1010 Bq/mmol (2.0 Ci/mmol)) was present 
during the last 18 hours. 3H-thymidine incorporation was analyzed by a Gas Scintil-
lation Counter (Canberra Packard, Matrix 96 Beta counter, Meriden, U.S.A.). The 
3H-incorporation is expressed as mean counts and standard deviations (SD) per 5 
minutes of at least quadruplicate measurements, SD were usually <10-15%. 
To induce T cell anergy, primary MLC were performed for 7 days in the presence of 
humanized mAb directed against CD40 and CD86 (5D12 and Fun-1, respectively, 1 
mg/ml; kindly provided by Dr. L.Boon, Bioceros, Utrecht, Netherlands). Analysis of 
T cells anergy was performed in secondary MLC. To this end, first primary MLC were 
performed for 7 days as mentioned above. Cells were harvested, washed 3 times 
and allowed to recuperate for 2-3 days and washed again. Non-viable cells were 
removed by density gradient centrifugation (Lymphoprep, Oslo, Norway). Next, 
2.104 recovered viable cells were restimulated with 1.105 γ-irradiated (30 Gy) 
stimulator PBMC in 96 well round bottom plates. The proliferative response of the 
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secondary MLC was examined at the indicated time-points. T cell anergy was de-
fined as hyporesponsiveness upon antigenic restimulation that is reversed by addi-
tion of exogenous IL-2 (12.5 U/ml, Proleukine, Eurocetus, The Netherlands) 16. 
 
Cytokine ELISA 
Cytokines were measured in culture supernatants that were harvested at the indi-
cated time points and stored at –80 °C until further processing. Commercially avail-
able ELISA’s were used for cytokine analysis; IFNγ and IL-10 (Pelikine-compact 
ELISA kit; CLB, Amsterdam, The Netherlands) and IL-2 (Duoset; R&D Systems, Inc, 
Minneapolis, MN, USA) was used. 
 
Flowcytometry; Cell surface and Annexin-V staining 
Cells were phenotypically analyzed by three or four color immunofluorescence. 
Briefly, cells were washed twice with buffer (PBS containing approx. 0.2 % BSA) 
and labeled with the antibodies of interest conjugated with FITC, PE, ECD or PC5. 
Cells were incubated for 20 minutes in the dark at room temperature, washed twice 
and analyzed on a Coulter Epics XL flowcytometer (Beckman Coulter, Fullerton, CA). 
5000 or 10.000 events were collected based on live lymphocyte cell gating as indi-
cated by Propidium Iodide (PI, 5 µg/ml) staining and analyzed by Coulter Epics 
Expo 32 (Beckman Coulter, Fullerton, CA, USA) and/or WINMDI (Scripps Research 
Institute, La Jolla, CA, USA) software. Isotype matched antibodies, usually below 
background staining, were used to define marker settings.   
The following fluorochrome conjugated mAb were used: CD3, CD4,  FITC or PE la-
beled (DAKO, Glostrup, Denmark), CD4, CD8 ECD- labeled (Coulter Corporation, 
Miami, Fl, USA) and CD4, CD8 and CD25 PC5-labeled (Immunotech, Marseille, 
France). FITC conjugated annexin-V (Bender Medsystems, Vienna, Austria) was 
used according to the manufacturers instructions to detect early apoptosis. Cell 
death was confirmed by cell cycle analysis according to DNA-staining by TOPRO3.  
 
CFSE based cell division analysis. 
The cell division was studied by labeling responder T cells with 1-2 µM Carboxyfluo-
rescein Diacetate Succinimidyl Ester (CFDA-SE, Molecular Probe, Eugene, OR) just 
before stimulation. In the cell esterases cleave the acetyl group leading to the fluo-
rescent diacytylated carboxyfluorescein succinimyl ester (CFSE). At each cell divi-
sion, the mean CFSE fluorescence intensity halves. Samples were analyzed by flow-
cytometry at the indicated culture time points after the start of the secondary MLC. 
Data were analyzed using Coulter Epics Expo 32 software.  
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RESULTS 
High-level immunosuppression by combined blockade of signal 2 and 
immunosuppressive drugs 
Primary MLC were performed in the absence (control) or presence of humanized an-
tibodies against human CD40 and CD86 (together from here on referred to as mAb) 
and / or CsA (100 and 400 ng/ml), rapamycin (20 and 100 ng/ml), Tacrolimus 
(FK506, 10 and 40 ng/ml). Compared to single mAb treatment, combined treatment 
with mAbs and immunosuppressive drugs resulted in an increased inhibition of the 
proliferative response (Fig.1A) Inhibition by the mAb solely was 65±11% (n=13), 
while the combined use of mAb and ISD concomitantly added at the start of the cul-
tures resulted in ≥90% inhibition. Similar observations were made with regard to 
the production of IFNγ, IL-2 and IL-10 (Fig. 1B). 
F I G U R E  1   
Superior alloreactive T cell inhibition after combined use of anti-CD40 + anti-CD86 
mAb and conventional immunosuppressive drugs. 
Primary MLC were performed in the absence 
(control) of presence of anti-CD40 and anti-
CD86 mAb (mAb). MAb were added at the 
start of the cultures without or with the indi-
cated immunosuppressive drugs (concentra-
tions, ng/ml).A. Proliferation (X-axis, 3H-
Incorporation) was examined at day 6 of the 
cultures. B. The presence of IFNγ, IL-2, and 
IL-10 (indicated at the top) was examined by 
Elisa at day 4 and 5 (legends) of the primary 
MLC. Representative experiments are shown 
(n=3-5).
 
In human primary MLC both CD4+ and CD8+ T cells become activated, the majority 
of proliferating T cells is CD4 positive. Moreover, especially these CD4+ T cells that 
become anergic after costimulation blockade  16. Therefore we focused on CD4+ al-
loreactive T cells. 
In contrast to CsA and FK506, rapamycin facilitates T cell death 10,17. The combined 
use of mAb and rapamycin resulted in a high number of annexin-V positive CD4+ T 
cells (~55%), which was found to be substantially reduced in case of mAb treat-
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ment alone (~19%) or in combination with CsA (~19%) or FK506 (~18%) (Fig. 
4C). Similar observations were made for CD8+ T cells (data not shown). 
Thus, combined anti-CD40+anti-CD86 mAb costimulation blockade and immunosup-
pressive drug treatment resulted in high-level immunosuppression of naive alloreac-
tive T cells.  
 
Induction of T cell anergy by costimulation blockade is prevented by 
concomitant use of immunosuppressive drugs 
Next, we addressed the question of whether CsA, rapamycin, or FK506 influence the 
induction of T cell anergy by anti-CD40+anti-CD86 mAb. T cell anergy was studied 
in restimulation assays; viable responder T cells obtained from primary MLC per-
formed either in the absence or presence of mAb and/or drugs were alloantigen 
specifically restimulated with stimulator PBMC derived from the original donor pool.  
Costimulation blocking during the primary MLC resulted in T cell hyporesponsive-
ness (Fig. 2A). Addition of exogenous IL-2 during antigenic restimulation recovered 
the proliferative response, which is a hallmark for anergic T cells (Fig. 2B). Anti-
genic restimulation of T cells that were derived from a primary MLC that were inhib-
ited by mAb and either CsA, rapamycin or FK506, independent of the concentrations 
that we examined (data not shown}, lost their anergic phenotype (Fig. 2). Often, 
simultaneous treatment with mAb and drugs resulted in T cells that responded in a 
similar way as cells that were treated with immunosuppressive agents only (Fig 2, 
and reference 17). Apparently the drugs and not the costimulation blockade pre-
vailed in determining the functional outcome of the T cell population 
Thus, concomitant treatment with anti-CD40+CD86 mAb and either CsA, Rap or 
FK506 both administered at the start of allogeneic stimulation of naive T cells pre-
vented the induction of anergy in human T cells.  
 
Five days of primary culture are needed to induce T cell anergy 
Immunosuppressive drug treatment might prevent early signaling events that are 
required for costimulation blockade induced T cell anergy. It is plausible that T cell 
anergy needs to be established prior to the start of drug therapy. To examine this 
possibility, we first determined the culture-time that is required to induce T cell an-
ergy. Primary MLC, which were performed in either the absence or the presence of 
anti-CD40 and anti-CD86 mAb, were stopped after 3-6 days by harvesting, washing, 
and resting of these cells. After 2-4 days of rest the cell were allogeneically res-
timulated in a secondary MLC and assessed for T cell anergy. Anergy induction, 
characterized by hyporesponsiveness upon antigenic restimulation that is reversed 
by the addition of exogenous IL-2, required at least 5 days (in some experiments 4 
days) of primary culture (Fig. 3A and B). 
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F I G U R E  2  
Conventional immunosuppressive drugs prevent the induction of costimulation 
blockade induced T cell anergy. 
Primary MLC were performed without (con-
trol) or with mAb against CD40 and CD86, in 
the absence or presence of the CsA (100 
ng/ml, upper right), Rapamycin (20 ng/ml, 
lower left), or FK506 (10 ng/ml, lower right). 
Drugs and mAb were added at the start of 
the cultures. After 7 days the responder cells 
were harvested, washed an rested for 2-3 
days. The viable cells were restimulated by 
allogeneic PBMC derived from the same do-
nor that was used in the primary MLC.  A. 
The secondary proliferative response (Y-
axis) is shown in time (X-axis). The culture 
conditions during the primary MLC are indi-
cated in the legends. Neither mAb nor im-
munosuppressive drugs were present during 
the secondary cultures. B. Allogeneic res-
timulation in the presence of exogenously 
added IL-2 (12.5 U/ml) at day 3 of the sec-
ondary culture. One representative experi-
ment out of a total of 4 is shown. 
 
Delayed drug administration following costimulatory blockaded in-
duced T cell anergy 
Because anergy induction requires at least 5 days of culture in the primary MLC, we 
studied the effect of drug administration at day 5 of the primary culture. We 
thereby focused on direct inhibition of cell division, cytokine production, T cell 
death, and T cell anergy. 
Anti-CD86+anti-CD40 mAb were administered at the start of the primary MLC, while 
drugs were given at day 5 of the cultures. Proliferation and the presence of the cy-
tokines IFNγ, IL-2 and IL-10 were examined at day 6. Delayed co-administration of 
the immunosuppressive drugs resulted in similar inhibition of proliferation and cy-
tokine production as observed in case of mAb treatment alone (Fig. 4A). High-level 
immunosuppression (≥90% inhibition of proliferative response) by anti-CD86+anti-
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CD40 blocking mAb and immunosuppressive drugs was only established when both 
agents were co-administered at the start of the cultures. This high level of immuno-
suppression was clearly demonstrated by CFSE labeling experiments (Fig. 4B). In 
control MLC a high number of CD25+ activated are dividing CD4+ T cells (~46%) 
was observed, which was largely reduced by costimulation blockade (~11%). This 
latter residual proliferating T cell population is absent when costimulation blockade 
was coincided by immunosuppressive drugs (i.e. drugs and mAb were added at the 
start of the MLC). The addition of CsA, rapamycin or FK506 at day 5 of costimula-
tion blocked MLC (costimulation blocking mAb were added at the start of the cul-
tures), resulted in a similar residual cell division pattern as observed in case of 
anti-CD86+anti-CD40 treatment only. Interestingly, the cell death facilitating po-
tential of rapamycin disappeared when this drug was administered 4-5 days after 
the start of the culture (Fig. 4C). This implies that cell death induction by rapamy-
cin especially takes place at an early stage of activation. 
F I G U R E  3  
Culture time required to induce T cell anergy via anti-CD40 and anti-CD86 mAb 
costimulation blockade. 
A. Primary MLC were performed in the ab-
sence (Control) or presence of anti-CD40 
and anti-CD86 mAb (mAb). At day 3 (upper 
left), 4 (upper right), 5 (lower left), and 6 
(lower right) of the primary MLC responder 
cells were harvested washed and allowed to 
recuperate for 3 days. Thereafter the viable 
cells were allogeneically restimulated by the 
original PBMC. Proliferation (Y-axis) during 
the secondary MLC (X-axis) is shown. The 
conditions in the primary MLC are indicated 
in the legends. B. Allogeneic restimulation in 
the absence of presence of exogenously 
added IL-2, of cells obtained from primary 
MLC that were harvested at day 5 or 6 (X-
axis). Proliferation is shown at day 3 of the 
secondary culture. One representative ex-
periment is shown (n=3).
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Established T cell anergy is not abolished by CsA 
Given that anergy induction (in our experimental setting) took at least 5 days of 
culture and assuming that high-level immunosuppression prevents anergy induc-
tion, we next examined whether drug administration at day 5 of the primary culture 
affected established T cell anergy. Antibodies against CD40 and CD86 were given at 
the start of the primary MLC, different concentrations of drugs (CsA, 100 or 400 
ng/ml; rapamycin 20 or 100 ng/ml; FK506 10 or 40 ng/ml) were given either at the 
start or at day 5 of the cultures. Cells were harvested at day 7, washed and allowed 
to rest. Three days later the viable cells were allogeneically restimulated in a sec-
ondary MLC to examine the anergic state of the cells. In contrast to the use of CsA, 
Administration of rapamycin or FK506, but not of CsA, at day 5 of the cultures (i.e. 
after anergy was established) abrogated the anergic state of the T cells in the ma-
jority of experiments (Table I). This phenomenon was found independently of drug 
doses tested. 
Thus, in contrast to rapamycin and FK506, CsA preserved the anergic state that was 
induced upon anti-CD40 and anti-CD86 mAb blocking of the CD28-CD86 and CD40-
CD154 costimulatory pathways. 
 
T A B L E 1  
Established T cell anergy remains unaffected by CsA 
Anergy induction in human T cells by mAb blockade of the costimulatory molecules CD40 and 
CD86, is prevented by calcineurin as well as by rapamycin (2nd column and figure 2). Follow-
ing immunological engagement in the presence of anti-CD40 and anti-CD86 mAb for 5 days 
to establish T cell anergy induction, CsA is compatible with the anergic state while Rap and 
FK506 are not (3rd and 4th column).  
  mAb at T= day 0 
Drugs at T= day 0, n=4 
mAb at T= day 0 
Drugs at T= day 5, n=5 
  Anergy Anergy No anergy 
mAb (=Anti CD40 + CD86 ) Yes n.a. n.a. 
mAb + CsA No 4 1 
mAb + rapamycin No 1 4 
mAb + FK506 No 1 4 
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F I G U R E  4  
The effect of delayed immunosuppressive drug administration.  
A. At the start of the primary MLC anti-CD40 
and anti-CD86 mAb were added while immu-
nosuppressive drugs were given at day 5 of 
the cultures (indicated at the left). For com-
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parison the effect of addition of drugs at the 
start is included. Proliferation and the pres-
ence of IFNγ, IL-2 and IL10 (as indicated at 
the top) are shown at day 7 and day 6 of the 
primary cultures, respectively.  
B. The responder T cells were labeled with 
CFSE and subsequently used as responder 
cells in the primary MLC under the conditions 
given above. Cell division as indicated by the 
CFSE fluorescence intensity (X-axis), and 
CD25 expression (Y-axis) of gated CD4+ T 
cells was analyzed by flowcytometry. The 
dotplots indicate the relative numbers of 
cells present in the gates. Culture conditions 
are given at the left and the top of the fig-
ure. 
C. The facilitation of T cell death by rapamy-
cin takes place early during activation. Pri-
mary MLC were performed in the absence 
(control) or presence of costimulation block-
ing mAb, which were added at the start of 
the culture while CsA (100 ng/ml), Rap (20 
ng/ml), or FK506 (10ng/ml) were adminis-
tered either at the start, day 4, or day 5 of 
the primary cultures. The numbers of an-
nexin-V binding CD4+ T cells, which is an 
indication for T cell apoptosis, was analyzed 
by flowcytometry. Histograms show the rela-
tive number of Annexin-V positive CD4+ T 
cells following the administration of Rapamy-
cin at the start, day 4, and day 5 of the pri-
mary culture. In all these conditions mAb 
were present from the start of the cultures. 
Representative experiments are shown (n=3-
4). 
T=4
T=5
Control mAb
mAb + CsA mAb + Rap mAb + FK506
T=0
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DISCUSSION 
Here, we show that the induction of human T cell anergy by mAb blockade of the 
costimulatory molecules CD40 and CD86 is prevented upon concomitant use of CsA, 
FK506, or rapamycin. Anergy induction in primary MLC via costimulation blockade 
took approximately 5 days of culture. Once T cell anergy was established, CsA, in 
contrast to rapamycin and FK506, did not abolish this existing anergic state. To-
gether this study is supportive for a window of opportunity for immunological en-
gagement (WOFIE) 18 as well as proper selection of immunosuppressive drugs in 
accomplishing transplantation tolerance.  
Also, here we show that in case of costimulation blockade residual T cell prolifera-
tion and some degree of T cell apoptosis occurred. Concomitant treatment with ra-
pamycin, in contrast to CsA or FK506, increased the numbers of apoptotic T cells. 
This is in line with in vivo costimulation blockade studies performed in mice 10. The 
latter study indicated that the combined use of costimulation blockade and rapamy-
cin, in contrast to the use of CsA, led to massive apoptosis (in dividing and non-
dividing T cells), which is crucial component in operational allograft tolerance 10. 
Interestingly, the authors showed that the combined treatment with costimulation 
blockade and rapamycin still allowed residual T cell proliferation to take place, 
which was virtually abrogated when CsA was used instead of rapamycin. This com-
plete blockade of T cell activation and apoptosis, referred to as global immunosup-
pression 10 precluded the induction of allograft tolerance. In our current study, 
combined costimulation blockade, and the use of CsA, FK506, or rapamycin, re-
sulted in global immunosuppression; proliferation, cytokine production and T cell 
activation were almost completely prevented, and costimulation blockade induced T 
cell anergy was abrogated. On the contrary, costimulation blockade at the start of 
the cultures and delayed administration of the conventional immunosuppressive 
drugs allowed T cell activation and cell division in a similar way as observed with 
costimulation blockade solely. Remarkably, only in the case of CsA, established T 
cell anergy remained unaffected, whereas FK506 and rapamycin abrogated the an-
ergic state. Furthermore the apoptosis inducing potential of rapamycin disappeared 
upon delayed (4-5 days) administration after the T cell activation. Thus, it appeared 
that T cell activation and some degree of T cell division is a prerequisite in the in-
duction T cell anergy. This fits the notion that a rise in intracellular calcium is re-
quired to induce an anergic state in murine T clones 19 which was prevented by CsA 
20,21, much likely as the result of CsA to interfere in the calcium influx by its action 
on calmodulin 22. Why CsA as opposed to FK506 or rapamycin acts differentially on 
human anergic T cells remains unclear. 
The major advantage of using rapamycin is its potential to induce operational toler-
ance by deletion of the alloreactive T cell pool, which might critically shift the bal-
ance between aggressive alloreactive T cells and alloreactive immunosuppressive 
regulatory T cells 23. CsA and FK506 do not result in overt deletion of activated T 
cells but only prevent the alloreactive T cells from expanding, but still allow activa-
SIGNAL-2 BLOCKADE AND IMMUNOSUPPRESSIVE DRUGS 
 
 
147 
tion of these alloreactive T cells 17. The major disadvantage of rapamycin and 
FK506, in contrast to CsA is their potential to affect established T cell anergy. In 
case of costimulation blockade by mAb against CD86 and CD40 proliferation of the 
aggressive alloreactive T cell is minimized, and hence a shift in the balance of ag-
gressive and regulatory T cells is established. In contrast to conventional immuno-
suppressive drugs, costimulation blockade results in anergic regulatory T cells. 
Thus, our current data indicate that CsA is best suited when coincident conventional 
immunosuppressive drug treatment is desired. 
Kindled by transplantation studies that demonstrated the spontaneous acceptance 
of liver grafts, Calne proposed the WOFIE hypothesis in 1996 18. Immunological en-
gagement of donor and recipient in the early post transplantation period appeared 
important transplantation tolerance, which was supported by the fact that tolerance 
in animals was preceded by histological and biochemical defined rejection episodes 
24. A WOFIE has been successfully applied clinically to achieve a so called state of 
prope (almost) tolerance; kidney allografts were accepted after lymphocyte reduc-
tion by Campath-1H followed by low dose of CsA that was started 72 hours after 
transplantation 25. Of note, in a comparable clinical study where rapamycin was 
used instead of CsA the results appeared somewhat less successful 26.  
Several in vivo animal studies indicated that prolonged graft survival by costimula-
tion blockade was compatible with the use of CsA 27-33. On the other hand, the in-
compatibility of CsA in otherwise successful costimulation blockade protocols has 
been documented as well 7,10,34-37.  In one of the studies, long-term mixed chimer-
ism, and tolerance induction was established by bone marrow transplantation and 
costimulation blockade with anti-CD40L and CTLA4-Ig 37. The concomitant use of 
FK506 or CsA impeded the induction of mixed chimerism and tolerance, and this 
trend was also evident when the administration of CsA was 1 week delayed. The 
calcineurin inhibitors exert at least part of their detrimental effect on chimerism 
and tolerance after BMT with costimulation blockade, by abrogating the deletion of 
mature donor-reactive T cells 37. At odds, in a similar bone marrow transplantation 
model CsA appeared compatible with anti-CD40L mAb costimulation induced mixed 
chimerism 32. It is questionable whether the maintenance of T cell anergy by de-
layed CsA administration, such as demonstrated in the current report, contributes 
to the these mixed-chimerism depending transplantation models. 
Of note, few studies were able to show the induction of transplantation tolerance in 
mice 38 and miniature swine 39 by the single use of CsA. CsA was reported to spare 
the suppressor cells 40, which is of critical importance in the maintenance of trans-
plantation tolerance 41. Indeed, Hall 42 demonstrated that immunosuppressive regu-
latory CD4+ T cells were responsible in this CsA induced specific unresponsiveness.  
Thus CsA might be especially attractive in the maintenance of T cell mediated 
transplantation tolerance induced by costimulation blockade. Furthermore, our data 
supports the view that timing and selection of immunosuppressive drugs is crucial 
in tolerance inducing protocols employing costimulation blockade. 
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ABSTRACT 
Naturally occurring CD4+CD25+ regulatory T-cells (Treg) are crucial in immu-
noregulation and have great therapeutic potential for immunotherapy in the preven-
tion of transplant rejection, allergy, and autoimmune diseases. The efficacy of Treg-
based immunotherapy critically depends on the antigen-specificity of the regulatory 
T-cells. Moreover, the use of antigen-specific Treg as opposed to polyclonal ex-
panded Treg will reduce the total number of Treg necessary to be used for therapy. 
Hence it is crucial to develop ex vivo selection procedures that allow selection and 
expansion of highly potent antigen-specific Treg. Here we describe an ex vivo CFSE 
cell sorter based isolation method for human alloantigen-specific Treg. To this end, 
freshly isolated CD4+CD25+ Treg were labeled with CFSE and stimulated with (tar-
get) alloantigen and IL-2+IL-15 in short term cultures. The alloantigen-reactive di-
viding Treg were characterized by low CFSE content and could be subdivided by vir-
tue of CD27 expression. CD27/CFSE cell sorter based selection of CD27+ and CD27- 
cells resulted in two highly suppressive antigen-specific Treg subsets. Each subset 
suppressed naïve and antigen-experienced memory T-cells, and importantly, 
CD27+Treg also suppressed ongoing T-cell responses. Summarizing, the described 
procedure enables induction, expansion, and especially selection of highly suppres-
sive antigen-specific Treg subsets, which are crucial in antigen-specific Treg-based 
immunotherapy. 
[SUBMITTED FOR PUBLICATION] 
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INTRODUCTION  
Naturally occurring CD4+CD25+ regulatory T cells (Treg) are important in the regu-
lation of T cell homeostasis and pathogenesis 1,2. Preceded by evidence in animal 
models, it was recently demonstrated that CD4+CD25+ Treg are critical regulators 
of the human immune response in autoimmunity 3-5, allergy 6 and infectious dis-
eases 7. Not surprisingly, the use of naturally occurring CD4+CD25+ in Treg-based 
immunotherapy in prevention of T cell mediated disorders is currently intensively 
studied. In fact, in a variety of animal models CD4+CD25+ Treg, either freshly iso-
lated or ex vivo expanded, were successfully used to prevent transplant rejection 
and autoimmunity 8-14. 
Human naturally occurring CD4+CD25+ Treg comprise 5-10% of all CD4+ periph-
eral T cells 15-17, and like their murine counterpart, they are anergic and suppres-
sive when stimulated via the T cell receptor (TCR) 15-19. The human CD4+CD25+ 
Treg population displays a polyclonal TCR-Vβ repertoire 20,21 suggesting that a 
broad variety of antigens might be recognized. No unique phenotypical selection 
marker is available for human naturally occurring CD4+CD25+ Treg; the cells are 
best characterized by dose-dependent suppressor function in in vitro suppression 
assays. The effector mechanism(s) by which Treg exert their suppressive function is 
still largely unknown. There are indications that cytokines like IL-10, TGFβ 22-25 
and/or cell surface molecules like CTLA-4 24,26,27 play a role, in most studies, cell 
contact between Treg and effector T cell appeared to be required 28. 
Of great interest is the recent observation that the success of Treg-based immuno-
therapy in vivo critically depends on the antigen-specificity of the Treg. In a trans-
genic mouse model of multiple sclerosis, myelin basic protein specific Treg were su-
perior in protecting against disease, as compared to Treg specific for other antigens 
29. Similarly, in mouse models of autoimmune diabetes already small numbers of ex 
vivo expanded antigen-specific transgenic Treg reversed diabetes after disease on-
set 13,14. This was due to the fact that antigen-specifically expanded CD4+CD25+ 
Treg appeared far more effective in blocking autoimmune diabetes than polyclonally 
expanded (using anti-CD3 and anti-CD28 mAb) Treg 13. Also, ex vivo expansion of 
freshly isolated mouse CD4+CD25+ Treg with host-type stimulator cells resulted in 
better inhibition of graft versus host disease as compared to Treg activated with 
third-party stimulator cells 9,11. Together, these findings indicate that ex vivo ex-
panded antigen-specific Treg, rather than polyclonally expanded populations, are 
superior in suppressing graft rejection and autoimmunity. Moreover, since antigen-
specific Treg appear more efficient effector-suppressor cells than polyclonal ex-
panded Treg in vivo 13, it can be envisaged that a reduced total number of Treg will 
be required for successful immunotherapy; quality reduces the need for quantity. 
This is a further advantage of the antigen-specific approach. Accordingly, clinical 
Treg-based immunotherapy should ideally be performed with highly suppressive an-
tigen-specific Treg. Therefore, the availability 
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of a protocol to induce and select potent immunosuppressive human Treg with de-
fined antigen specificity seems crucial for the success of clinical Treg-therapy.  
The next important issue for clinical implementation of Treg therapy is the availabil-
ity of sufficient numbers of human Treg. Since only small numbers of polyclonal 
CD4+CD25+ Treg are present in peripheral blood ex vivo expansion is warranted. 
Expansion of freshly isolated human Treg with retention of effector-suppressor 
function was demonstrated after stimulation in the presence of exogenously added 
T cell growth factors 15,16,21,30,31. Successful large scale expansion was shown upon 
polyclonal stimulation with anti-CD3 and anti-CD28 mAb and high dose IL-2 21,31.  
Thus, at present the ex vivo expansion of freshly purified CD4+CD25+ Treg is well 
established, however protocols for the selection of Treg with defined antigen-
specificity are lacking. In this study we developed a robust ex vivo CFSE dye based 
technique to induce and purify highly potent human alloantigen-specific Treg (sub-
sets) from freshly isolated polyclonal CD4+CD25+Treg.  Freshly purified 
CD4+CD25+ Treg were CFSE labeled and stimulated with (target)alloantigen and 
IL-2+IL-15. Dividing alloantigen-reactive Treg were characterized by low CFSE con-
tent and by the presence or absence of CD27. CD27/CFSE cell sorter based isolation 
resulted in a CD27+CD25+CD70-CD62L+CTLA4high (CD27+Treg) and a CD27-CD25-
CD70+CD62L-CTLA4intermediate (CD27-Treg) CD4+ Treg subset. Following purification, 
an enhancement in suppressive potential of both Treg populations as compared to 
the freshly isolated population was observed. Both alloantigen-specific Treg subsets 
showed highly potent effector-suppressor potential; 50% inhibitory ratio’s of Treg 
versus responder T cells (Tresp) ranged from 1:500 to 1:50 for CD27+Treg and CD27-
Treg, respectively. Suppressor function was cell contact dependent, and independ-
ent of IL-10, TGFβ, CTLA-4 or CD27 signaling. The effector suppressor function of 
CD27+Treg, in contrast to CD27-Treg, appeared partially γ-irradiation resistant. The 
Treg subsets were further distinguished by virtue of migration receptor pattern and 
cytokine production profile. The Treg subsets showed suppression at multiple levels, 
as they suppressed naïve and memory T cell responses (CD27+Treg and CD27-Treg), as 
well as ongoing T cell responses (CD27+Treg), all of which are implicated in trans-
plant rejection.  
This CFSE based method for ex vivo induction and selection of alloantigen-specific, 
highly immunosuppressive Treg subsets, offers a potent tool for donor-specific Treg 
based immunotherapy in organ transplantation.  
  
MATERIALS  & METHODS  
Isolation of cells 
Peripheral blood mononuclear cells (PBMC) were obtained from buffy coats of nor-
mal healthy donors by density gradient centrifugation (Lymphoprep, Nycomed 
Pharma AS, Oslo, Norway). CD4+ T cells were purified from PBMC by negative se-
lection using monoclonal antibodies (mAb) directed against CD8(RPA-T8), 
CD14(M5E2), CD16(3G8), CD19(4G7), CD33(P67.6) and CD56(B159) (BD-
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biosciences, Erembodegem, Belgium) combined with sheep anti-mouse Ig coated 
magnetic beads (Dynal, Denmark). This resulted in a CD4+ T cell enrichment of 
>95 % and the absence of CD8+ T cells. From purified CD4+ T cells, naturally oc-
curring CD4+CD25+ T cells were isolated using the CD25+ magnetic microbead 
method (Miltenyi GmbH, Germany), using half the amount of beads as recom-
mended by the manufacturer. This resulted in a robust enrichment (complete MFI 
peak shift). Whenever mentioned, CD4+CD25high were isolated from purified CD4+ 
T cells by high purity flowcytometric cell sorting (Beckman Coulter, Miami, USA). 
CD4+CD25+ regulatory T cells were immediately used after isolation. All other cell 
types were either used fresh or after liquid nitrogen storage. HLA typing was con-
ducted as described previously 32. 
High purity CFSE and/or CD27 based cell isolation was conducted by flowcytometric 
cell sorting  (Beckman Coulter). 
 
Primary Mixed Lymphocyte Cultures  
Primary Mixed Lymphocyte Cultures (MLC) were performed by culturing 5x104 iso-
lated CD4+CD25- T cells with 0.5-1x105 HLA mismatched γ-irradiated (30 Gy) 
stimulator PBMC (target alloantigen) in 200 ml culture medium (RPMI-1640 with 
glutamax supplemented with pyruvate (0.02mM), 100 U/ml penicillin, 100 mg/ml 
streptomycin, (all Gibco, Paisley, UK) and 10% pooled human serum) at 370C, 95% 
humidity and 5% CO2. All experiments were conducted in 96 wells round bottom 
plates (Greiner, Frickenhausen, Germany). Proliferation was analyzed by 3H-
thymidine incorporation using a Gas Scintillation Counter (Canberra Packard, Matrix 
96 Beta-counter, Meriden, U.S.A.). To this end 0.037MBq (1µCi) 3H-thymidine (ICN 
Pharmaceuticals, Irvine, CA, USA) was present during the last 8 hours of culture. 
The 3H-incorporation is expressed as mean ±SD counts per 5 minutes of at least 
triplicate measurements. 
 
Allogeneic restimulation assays to study T cell anergy 
T-cell anergy was examined in restimulation assays 32. CD4+CD25+ or CD4+CD25- 
were primed with (target) alloantigen in the presence of recombinant human IL-2 
(12.5 U/ml, Proleukine, The Netherlands) and IL-15 (10 ng/ml, BioSource, Nivelles, 
Belgium). Following expansion the cell were harvested, washed, and allowed to re-
cuperate for 2 days. Viable cells were isolated by density gradient centrifugation 
and restimulated (1-2.5x104 cells/well) with γ-irradiated (30 Gy) stimulator PBMC 
(1x105 cell/well) derived from either the target donor stimulator PBMC pool or from 
completely HLA mismatched (3rd party antigen) blood donors. Proliferation was ex-
amined at the indicated time-points. 
 
MLC co-culture assay to study T cell effector-suppressor function 
The effector-suppressor capacity of cells was studied in MLC co-culture suppression 
assay. The cells of interest were added to a newly set-up primary MLC (consisting 
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of fresh original responder PBMC and target γ-irradiated (30 Gy) stimulator PBMC) 
or to a restimulation assay (set up with allogeneically primed responder CD4+ T 
cells and target γ-irradiated (30 Gy) stimulator PBMC). Antigen-specificity was ex-
amined in co-cultures that were performed with third party completely HLA mis-
matched stimulator PBMC. In some experiments round bottom plates coated with 5 
µg/ml anti-CD3 mAb (BD-Biosciences) were used to activate T cells.  When indi-
cated, mAb (20 µg/ml) directed against CD27 (DAKO(M-T271) or Beckmann Coulter 
(1a4CD27), both clones led to similar results), IL-10 (MAB217), TGFβ (MAB1835) 
(R&D Systems Europe, Ltd., United Kingdom) or CTLA-4 mAb (Innogenetics, Ghent, 
Belgium) were added at the start of the co-cultures. Proliferation was analyzed at 
the indicated time points.  
Contact dependency between Treg and responder T cells was studied in transwell 
experiments using 24-well plates (Greiner). Briefly, 1x106 CD4+CD25- autologous 
responder T cells and 1x106 γ-irradiated target allogeneic PBMC were cultured in the 
lower compartment of the well. Titrated numbers of Treg were cultured in the pres-
ence 1x106 of γ-irradiated target allogeneic stimulator PBMC in the transwell insert 
(Millicell, 0.4µm pore size; Millipore, Bedford, MA). At day 5 of the cultures the pro-
liferative response of the T cells present in the lower compartment were analyzed 
for proliferation. 
 
Flowcytometry, intracellular cytokine staining and antibodies  
Cells were phenotypically analyzed by four or five color flowcytometry as described 
previously 32. The following conjugated mAb were used: CD3 (UCHT1), CD4 
(MT310), CD8 (DK25), CD27 (M-T271), CD45RA (4KB5), CD45RO (UCHL1) FITC or 
PE labeled (DAKO, Glostrup, Denmark), CD25 (M-A251) PE, CD70 (Ki-24) PE, 
CD134 (ACT35) PE, Integrin β7 (FIB504) PE, CCR7 (3D12) Pe-Cy7 (BD-Biosciences), 
CD122 (CF1) PE and CD152 (BNI13) PE (Beckman Coulter Corporation, Miami, Fl, 
USA) PE (Ebioscience, San Diego, CA), CD4 (T4) ECD, CD4 (T4) PC5 and CD25 
(B1.49.9) PC5, CD62L (DREG54) ECD (Beckman Coulter) and GITR (110416) PE 
(R&D). Isotype matched antibodies were used to define marker settings. Intracellu-
lar analysis of CTLA-4 was performed after fixation and permeabilization using Fix 
and Perm reagent (An Der Grub, Vienna, Austria). Intracellular cytokines were stud-
ied by flowcytometry after stimulation with PMA and Ionomycin such as described 
previously 32. The following mAb were used; anti-human IL-2, IL-4, IL-10 (PE la-
beled) and IFNγ and TNFα (FITC-labeled) (BD-Biosciences). 
 
CFSE labeling 
T cells were labeled with 0.2-1 µM Carboxyfluorescein Diacetate Succinimidyl Ester 
(CFDA-SE, MolecularProbes, Eugene, OR, USA) just before stimulation. In the cell 
esterases cleave the acetyl group leading to the fluorescent diacytylated carboxy-
fluorescein succinimyl ester (CFSE). Cell division accompanied by CFSE dilution was 
analyzed by flowcytometry.  
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RESULTS 
Ex-vivo induction of alloantigen-specific Treg from freshly isolated 
naturally occurring CD4+CD25+ Treg 
Previously, we showed that co-stimulation blockade induced alloantigen-specific 
regulatory T cells can be successfully expanded using antigen and T cell growth fac-
tors 32. We further exploited this protocol to see whether we could successfully in-
duce alloantigen-specific Treg starting with freshly isolated naturally occurring 
CD4+CD25+ Treg population. CD4+CD25+ and CD4+CD25- T cells were isolated 
from freshly isolated PBMC (Fig. 1A) and studied for their proliferative potential 
upon alloantigen stimulation in the absence or presence of exogenously added hu-
man recombinant IL-15 and/or IL-2 (Fig. 1B). As compared to CD4+CD25- T cells, 
CD4+CD25+ Treg cells appeared hyporesponsive upon alloantigen stimulation 
alone. Addition of IL-2, IL-15, or a combination thereof reversed this hyporespon-
sive state. Especially the combined use of IL-2 and IL-15 resulted in profound pro-
liferation of allogeneically stimulated CD4+CD25+ T cells. Cytokine stimulation 
alone, in the absence of antigen, was not sufficient to induce proliferation of 
CD4+CD25+ T cells (Fig. 1B).  
Next, the effector-suppressor function, and antigen-specificity of the (target) allo-
antigen expanded CD4+CD25+ Treg was addressed in MLC co-culture suppression-
assays. The expanded CD4+CD25+ Treg showed dose-dependent suppression   
(50% inhibition at Treg:Tresponder ratio’s  of 1:20) (Fig. 1C). The expanded Treg 
appeared antigen-specific, as suppressor function was only activated upon stimula-
tion with target alloantigen stimulator PBMC, and not upon stimulation with third 
party HLA mismatched PBMC  (Fig. 1C). Restimulation assays revealed that the ex-
panded CD4+CD25+ T cells remained anergic. Antigen-specificity of the alloantigen 
expanded CD4+CD25+ Treg was confirmed, since only stimulation with target allo-
antigen, but not third party antigen, and exogenous IL-2 could reverse the hypore-
sponsive state of the Treg (Fig. 1D). 
In short term cultures of 9 -11 days, freshly isolated CD4+CD25+ stimulated with 
alloantigen and IL-2+IL-15 showed a 6.6±4.6 (n=7, range 3.2–14.4) fold expan-
sion, whereas CD4+CD25- expanded 20.9±9.4 (n=7, range 10.5–36) times. Similar 
expansion levels were found in subsequent stimulation cycles without loss of Treg 
function (data not shown).   
Thus, starting with freshly isolated CD4+CD25+ Treg in short term ex vivo cultures, 
we demonstrated the induction and expansion of Treg populations with defined an-
tigen specificity.  
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F I G U R E  1  
Ex-vivo induction of alloantigen-specific Treg from freshly isolated naturally occur-
ring CD4+CD25+ Treg by stimulation with alloantigen and IL-2+IL-15. 
A. Surface marker expression on freshly iso-
lated naturally occurring CD4+CD25+ Treg. 
CD4+ T cells were isolated from peripheral 
blood and either purified (CD4+CD25+, up-
per row) or depleted (CD4+CD25-, lower 
row) for CD4+CD25+ cells by magnetic mi-
crobeads. Parameters of the dotplots are 
indicated on X and Y-axis. Relative cell num-
bers in the gates are indicated. A represen-
tative experiment is shown out of 8 different 
isolations performed with cells obtained from 
different donors.  
B. Purified CD4+CD25+ or CD4+CD25- T 
cells (2.5x104) were stimulated with a total 
of 1x105 γ-irradiated (30Gy) HLA mismatched 
PBMC (Antigen) or without PBMC (No Anti-
gen), in the absence or presence of IL-2 
and/or IL-15. Proliferation (X-axis, 3H-
Incorporation) is shown at day 6 of the cul-
tures. C and D. Purified CD4+CD25+ or 
CD4+CD25- T cells (2.5x104) were stimu-
lated with target alloantigen (PBMC, 1x105) 
in the presence of IL-2+IL-15, at day 7 the 
responder cells were harvested, washed, and 
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allowed to rest. The viable cells were exam-
ined for effector-suppressor function, T cell 
anergy and antigen specificity. 
C. Expanded CD4+CD25+ or CD4+CD25- T 
cells were titrated (X-axis, Log scale) and 
added at the start of a MLC co-culture sup-
pression assay, consisting of a total of 5x104 
responder CD4+CD25- and either 5x104 γ-
irradiated (30Gy) fresh target (left) or third 
party HLA mismatched (right) stimulator 
PBMC. Proliferation (Y-axis) is shown at day 
5 of the co-cultures. D. Target alloantigen 
expanded CD4+CD25+ and CD4+CD25- 
(1x104 cells) were allogeneically restimu-
lated (1x104) with target (Target Ag) or third 
party (3rd Party Ag) HLA mismatched γ-
irradiated (30Gy) PBMC (1x105) in the ab-
sence (Ag) or presence (Ag+IL-2) of exoge-
nously added IL-2 (legends). Proliferation 
(Y-axis) is shown at the indicated days (X-
axis). Insert shows proliferation at an ad-
justed scale. One representative experiment 
out of 4-5 independent experiments per-
formed with cells obtained from different 
donors is shown.
 
CD27/CFSE-based selection and purification of ex vivo induced anti-
gen-specific Treg subsets with high effector-suppressor potential. 
For the purpose of antigen-specific Treg therapy, we looked for a method that al-
lows selection of alloantigen-reactive Treg from the freshly isolated Treg pool. 
Therefore, we exploited the feature that antigen reactive Treg proliferate well upon 
antigenic stimulation in the presence of IL-2+IL-15 (Fig. 1). We labeled freshly iso-
lated CD4+CD25+ Treg with CFSE and analyzed cell division upon allogeneic stimu-
lation in the presence of exogenously added IL-2+IL-15. As anticipated, CFSE 
analysis of cell division at day of 4 of the cultures revealed that a minor fraction of 
the CD4+CD25+ Treg pool was dividing in response to allogeneic stimulation and 
IL-2+IL-15 (Fig. 2A). This is in contrast to polyclonal stimulation with anti-CD3 
mAb and IL-2+IL15, which drove virtually all CD4+CD25+ Treg into cell division 
(Fig. 2B).  
We also studied differentiation markers on the dividing cell population. Strikingly, 
at day 6 of the culture (but also earlier in time) two dividing Treg subsets marked 
by differential CD27 expression could be distinguished: a CD27+ (CD27+Treg) and a 
CD27- (CD27-Treg) population (Fig. 2A). Following activation and division the 
CD27+Treg showed an increase in the level of CD27 expression (Fig. 2A/2C). At day 
6 of the cultures most cells were CD45RO+/CD45RA- and CD25+ (data not shown). 
In contrast to the CD4+CD25+ cells, the majority of dividing CD4+CD25- cells lost 
CD27 expression, while only a residual fraction was CD27+ (these cells will be re-
ferred to as CD27+CD4 control and CD27-CD4 control respectively). Of note, it was re-
cently shown that especially human peripheral CD4+CD25high cells exhibit suppres-
sor function 33. The use of highly purified flowcytometric cell sorted CD4+CD25high 
cells instead of magnetic bead isolated CD4+CD25+ (our standard isolation proce-
dure), also resulted in a similar CD27+ and CD27- subset division, upon antigenic 
stimulation in the presence of IL-2+IL-15 (data not shown).   
Purified CD27+Treg and CD27-Treg subsets were analyzed in more detail for effector-
suppressor function and T cell anergy. To this end, divided CFSElow/CD27+ and 
CFSElow/CD27- cells were cell sorted by flowcytometry as indicated in figure 2C. As 
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only minute cell numbers were obtained after cell sorting, the cells were first ex-
panded by stimulation with (target) alloantigen in the presence of IL-2+IL-15 prior  
F I G U R E  2  
CD27/CFSE-based selection of ex vivo induced alloantigen-specific Treg subsets. 
A. Freshly isolated CD4+CD25+ (left) or 
CD4+CD25- (right) T cells were labeled with 
CFSE, and stimulated (2.5x104 cells/well) 
with HLA mismatched γ-irradiated (30Gy) 
PBMC (1x105 cells/well) in the presence of IL-
2+IL-15. Cell division in the cultures was 
analyzed in time by flowcytometry. Dotplots 
show CFSE fluorescence (X-axis) vs. CD27 
expression (Y-axis) in time. A representative 
experiment is shown (n=6). B. Polyclonal 
stimulation with immobilized anti-CD3 
(5µg/ml) and IL-2+IL-15 drives cell division 
in almost all CD4+CD25+ T cells, while al-
logeneic stimulation in the presence of IL-
2+IL-15 result in a fraction of dividing 
CD4+CD25+ cells. Histograms show number 
of events (Y-axis) and fluorescence intensity 
(X-axis) at day 4 after stimulation. Stimula-
tory conditions are indicated at left (Allo 1 
and 2 are stimulator PBMC from different 
HLA mismatched donors). One representative 
experiment of 3 independent experiments 
conducted with cells from different donors is 
shown. C. Dotplots show CFSE content (X-
axis) and CD27 expression (Y-axis) by 
CD4+CD25+ (left) and CD4+CD25- (right) 
cells at day 9 after stimulation with alloge-
neic PBMC and IL-2+IL-15. Based on the 
gate settings that are shown high purity cell 
sorts were performed resulting in a 
CD27+/CFSElow and CD27-/CFSElow cell popu-
lation. CD4+CD25+ derived cell population 
are referred to as CD27+Treg and CD27-Treg, 
whereas CD4+CD25- derived cell population 
are referred to as CD27+CD4 and CD27-CD4 con-
trol cells. The relative number of cells pre-
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sent in the live gate is shown. A representa- tive CD27/CFSE cell sort is shown (n=5). 
F I G U R E  3   
CD27/CFSE cell sorter purified CD27+Treg and CD27-Treg subsets are antigen-specific 
and show high suppressor potential.  
Cell sorter isolated CD27+Treg and CD27-Treg 
subsets were antigen-specifically expanded 
by restimulation in the presence of IL-2+IL-
15 for 9-11 days. Subsequently, after a re-
cuperation period of 2 days, effector-
suppressor function, T cell anergy, and anti-
gen-specificity were analyzed. Expanded 
CD27-/+CD4 control cells that were cultured 
and purified under identical conditions 
served as control.  
A. To study the suppressive potential, the 
CD27+Treg and CD27-Treg subsets (Legends) 
were titrated (X-axis, Log scale) into a MLC 
co-culture suppression assays, consisting of 
5x104 CD4+CD25- responder cells and either 
5x104 γ-irradiated (30Gy) fresh original tar-
get (Target Ag, left panel) or third party HLA 
mismatched (3rd Party Ag, right panel) 
stimulator PBMC. In addition, the Treg sub-
sets were examined after γ-irradiation 
(30Gy) (Target Ag/γ-irradiation, middle 
panel). Proliferation is shown at day 5 of the 
co-cultures. B. T cell anergy was examined 
in restimulation assays; a total of 1x104 vi-
able responders were stimulated by 1x105 γ-
irradiated (30Gy) target (Target Ag, upper 
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panels) or third party HLA mismatched (3rd 
Party Ag, lower panels) stimulator PBMC in 
the absence or presence of IL-2 (Legends). 
Proliferation (Y-axis) is shown in time (X-
axis). Insert shows proliferation of CD27+Treg 
cells at an adjusted scale. One representa-
tive experiment out of 5 is shown. 
 
to further study. In short term cultures of 9-11 days a 10.2±7.7 (range 1.2–20.0) 
and 27.5±3.4 (range 22.6–30.0) mean fold expansion was observed for the 
CD27+Treg and CD27-Treg subsets respectively (n=5). For comparison CD27+CD4 and 
CD27-CD4 control cells showed mean expansion levels of 35.1±13.0 (range 16.8–
50.7) and 41.5±18.6 (range 22.4–72.0), respectively. Both CD27+Treg and CD27-Treg 
subsets showed potent effector-suppressor potential (50% inhibition at Treg:Tresp 
ratio’s of  1:500 and  1:50, respectively) in MLC co-culture suppression assays con-
ducted with naïve autologous CD4+CD25- responder T cells and target alloantigen 
stimulator PBMC (Fig. 3A). CD27+Treg consistently appeared approximately 10 times 
more potent suppressors than the CD27-Treg (Fig. 3A). The suppressor function of 
CD27+Treg and CD27-Treg was antigen-specific, as target alloantigen induced clear 
suppression, while MLC co-culture assays performed with third party HLA-
mismatched stimulator cells were hardly affected (Fig. 3A). Only at relatively high 
cell doses of CD27+Treg, suppression of third party responses was observed (Fig. 
3A). Of interest, CD27+Treg were partially γ-irradiation resistant, whereas CD27-Treg 
completely lost suppression after γ-irradiation (Fig. 3A). Inhibition of third party 
responses by CD27+Treg was prevented by γ-irradiation of the cells (data not shown). 
Additional support for the antigen-specificity of the isolated CD27+Treg and CD27-Treg 
was obtained in restimulation experiments. (Fig.3B). Both CD27+Treg and CD27-Treg 
were hyporesponsive upon target antigen stimulation, but addition of IL-2 resulted 
in recovery of the proliferative response. Restimulation with third party HLA-
mismatched stimulator PBMC and IL-2 did not recover the proliferative response of 
CD27+Treg or CD27-Treg (Fig. 3B), which indicates that the Treg are target alloanti-
gen-specific.  Notably, there was a difference in response to target alloantigen and 
IL-2 between the two Treg subsets. Whereas the addition of exogenous IL-2 to 
CD27+Treg resulted in limited reversal of proliferation (i.e. deep anergy), addition of 
IL-2 to CD27-Treg resulted in complete recovery of the proliferative response (i.e. 
classical anergy).   
Thus, starting with a freshly isolated CD4+CD25+ polyclonal Treg population we 
demonstrated the induction, expansion, and selection, of two highly suppressive 
alloantigen-specific Treg subsets.
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F I G U R E  4  
CD27+Treg constitutively express CD25, while CD27-Treg transiently express CD25 upon 
activation. Marker expression pattern and cytokine producing potential further dis-
tinguish the CD27+Treg and CD27-Treg subsets. 
A. CD27+Treg constitutively express high lev-
els of CD27 and CD25. After cell sorting, 
CD27+Treg and CD27-Treg subsets were allowed 
to recuperate overnight in the presence of 
IL-15 (5 ng/ml) and subsequently alloanti-
gen-specifically restimulated in the presence 
of IL-2+IL-15. Expression of CD27 (2 left 
columns) and CD25 (2 right columns) was 
examined, both at day 7 of the culture and 
after 2 days of rest (indicated at the top). 
Relative numbers (upper right corner) and 
mean fluorescence intensity (MFI, upper 
right corner) are indicated. One representa-
tive experiment (n=5) conducted with cells 
from different donors is shown. 
B. Cytokine production (indicated at the top) 
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by CD27+Treg and CD27-Treg subsets and con-
trols (indicated at the y-axis), was examined 
after stimulation with PMA and Ionomycin. 
CD27+CD4 and CD27-CD4 cells were used as 
control cells. Dotplots show the relative 
number (lower right corner) of cytokine pro-
ducing cells. C. Following 2 days of rest 
CD27+Treg and CD27-Treg subsets (indicated at 
the y-axis) were analyzed for surface and 
intracellular expression for the indicated 
marker (top).  Expanded CD27+CD4 and CD27-
CD4 control cells were included. Histograms 
show relative number of positive cells (indi-
cated in upper right corner).One representa-
tive experiment out of 4 is shown. 
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CD27+Treg and CD27-Treg subsets are distinguished by surface marker 
expression and cytokine producing potential.  
During the culture steps we noted that CD27+Treg constitutively expressed CD25 and 
CD27, whereas CD27-Treg, like CD27+/-CD4 control cells, only transiently express CD25 
upon activation and turned CD25 negative upon rest (Fig. 4A). Moreover, the ex-
pression levels of CD27 on CD27+Treg were consistently higher than that of control 
CD27+CD4 cells. At rest, the majority of CD27+Treg was positive for CD62L (84%), 
CD152 (88%), and β1 (CD29) (71%) and β7 integrin (74%) family members, a frac-
tion of the cells expressed GITR (50%) and CD122 (32%), a minor population, ex-
pressed OX-40 (CD134, 14%) and PD-1 (8%), and the majority of the population 
was negative for CD70 (Fig. 4C). Virtual all CD27-Treg were positive for CD70 (87%) 
GITR (84%), β1 (97%) and β7 integrin (99%) (both integrin members were ex-
pressed at a high level, Fig. 4B), a fraction of the cells expressed CD152 (55%) and 
CD122 (34%), a small proportion of cells expressed CD134 (13%) and PD-1 (8%) 
and the majority was negative for CD62L (3%). The TNF receptor family members 
4-1BB and CD30 were absent on both CD27+Treg and CD27-Treg (data not shown). 
Cytokine production by either Treg subset was analyzed by intracellular cytokine 
staining following stimulation by PMA and Ionomycin. CD27+Treg were characterized 
by relatively high numbers of IL-10, and low numbers of IL-2, IFNγ and TNFα pro-
ducing cells (Fig. 4B). In contrast, CD27-Treg produced IL-2, IFNγ and TNFα. 
Thus, antigen-specific CD27+Treg and CD27-Treg subsets were distinguished by virtue 
of distinct expression levels of CD25, CD27, CD70, CTLA-4 and the migratory mark-
ers CD62L, β1 and β7 integrins, and by a distinct cytokine profile. 
 
Suppression by CD27+Treg and CD27-Treg is contact dependent and in-
dependent of IL-10, TGFβ, CTLA4 and CD27.  
Currently, little is known with regard to how Treg exert their suppressive effect.  
They might perform their immunosuppressive function either in a contact dependent 
or independent way 28 via cytokines such as IL-10 and TGFβ 22-25 or CTLA-4 interac-
tions 24,26,27. We thus investigated whether these mechanisms play a role in the 
suppressor function of CD27+Treg or CD27-Treg. Additionally, the role of CD27 in effec-
tor-suppressor function was analyzed.  
In transwell MLC co-culture suppression assays, we demonstrated that for both sub-
sets contact between Treg and responder T cells is required for effector-suppressor 
function (Fig. 5A). Next, the role of CD27, IL-10, TGFβ and CTLA-4 in the suppres-
sion by antigen-specific CD27+Treg or CD27-Treg was studied by addition of neutraliz-
ing mAb directed against CD27 (Fig. 5B), TGFβ, IL-10 or CTLA-4 (Fig. 5C) to the co-
culture suppression assays. Neither of these mAb reversed the suppressor function 
of the Treg subsets (Fig. 5C). 
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F I G U R E  5  
Suppressor function of CD27+Treg and CD27-Treg subsets is contact dependent and does 
not rely on IL-10 or TGFβ or cellular interaction of CTLA4 or CD27. 
A. In transwell experiments that physically 
separate Treg and responder T cells the ef-
fector-suppressor function of both CD27+Treg 
and CD27-Treg subsets was abrogated. The 
indicated Treg were titrated into MLC co-
culture suppression assays. The Treg were 
either directly added to the MLC (contact) 
(consisting of 1x106 responder T cells and 
1x106 γ-irradiated allogeneic stimulator 
PBMC) or separated by a membrane (tran-
swell). In case of the latter Treg were stimu-
lated by allogeneic stimulator PBMC. The 
proliferation was measured at day 5 of the 
cultures. The numbers of added cells are 
given at the X-axis. One of two similar inde-
pendent experiments performed with cells 
from different donors, is shown. 
B. Anti-CD27 mAb do not affect suppression 
by CD27+Treg. Sorted and alloantigen-
specifically expanded CD27+Treg were titrated 
in a MLC co-culture suppression assay (X-
axis), in the absence or presence of anti-
CD27 mAb (20µg/ml) (Legends). 
CD27+CD4+ control cells were used as con-
trol. Proliferation (Y-axis) was analyzed at 
day 5.  
C. Sorted and alloantigen-specifically ex-
panded CD27+Treg and CD27-Treg subsets (indi-
cated at the top) were titrated in a MLC co-
culture suppression assay, in the absence or 
presence of neutralizing anti-TGFβ or anti-
IL-10 mAb, or anti-CTLA4 mAb (all mAb, 20 
µg/ml). Increased mAb concentrations (ti-
trated up to 75 µg /ml) did not abrogate 
suppression by the Treg subsets (data not 
shown). Proliferation (Y-axis) was examined 
at day 5 of the cultures. One representative 
experiment out of 3 is shown.
 
Both CD27+Treg and CD27-Treg subsets suppress memory CD4+ T cells, 
whereas only CD27+Treg suppress ongoing T cell responses. 
The CD27+Treg and CD27-Treg subsets both clearly showed suppression of naïve 
alloreactive CD4+CD25- T cells (Fig. 4+5). This suggests that these Treg subsets  
are of potential interest for (donor) antigen-specific immunotherapy especially in 
non-primed patients. In case of primed patients, as well as in T cell mediated auto-
immunity, it is crucial to prevent memory and ongoing T cell responses. To study 
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the potential of the Treg subsets to suppress ongoing T cell responses, Treg were 
titrated and added to a MLC co-culture suppression assay at day 0, 2 or 3 after the  
start of the culture. In contrast to CD27-Treg, only CD27+Treg suppressed ongoing 
T cell responses (Fig. 6A). Likewise, to study the capacity of Treg subsets to sup-
press memory T cell responses, MLC co-culture suppression assays were conducted 
with allogeneically primed CD4+ memory responder T cells and target stimulator 
PBMC, and titrated numbers of Treg (Fig. 6B). Both subsets were able to suppress 
memory T cell proliferation, but as compared to CD27-Treg, CD27+Treg were more 
potent suppressors (Fig. 6B). 
 
DISCUSSION 
Immunosuppressive naturally occurring CD4+CD25+ Treg are considered an impor-
tant cell source to be used in immunotherapy to prevent transplant rejection and 
autoimmunity. For clinical Treg immunotherapy, it is likely that high numbers of 
cells will be needed. Importantly, it is currently recognized that Treg are particu-
larly effective when they have specificity for their target antigen(s) 9,11-14. Hence, 
the availability of target antigen-specific Treg is advantageous, as it not only ap-
pears highly effective, but also reduces the number of cells needed for immuno-
therapy. Peripheral blood contains limited numbers of naturally occurring 
CD4+CD25+ Treg that show broad antigen reactivity. Hence, for antigen-specific 
immunotherapy with CD4+CD25+ Treg, the induction, expansion, and selection of 
target antigen-specific Treg is necessary. Large-scale ex vivo expansion of human 
CD4+CD25+ Treg by stimulation with anti-CD3 and anti-CD28 mAb coated beads 
and high dose IL-2 (100 U/ml or more) has successfully been established 21,31. This 
polyclonal, non-antigen-specific, expansion increases the total number of Treg, but 
leaves the frequency of putative antigen-reactive Treg unaltered 21. The latter is 
also clear from our own CFSE experiments showing that polyclonal stimulation with 
anti-CD3 mAb and IL-2+IL-15 provoked cell division in almost all CD4+CD25+ T 
cells, while alloantigen stimulation and IL-2+IL15 only drove a small proportion of 
the CD4+CD25+ pool, the antigen-specific cells, into cell division. Here we ex-
ploited this feature, by culturing freshly isolated CD4+CD25+ Treg with alloantigen 
and IL-2+IL-15 as stimulant, in combination with a CD27/CFSE based purification 
protocol, and demonstrated the isolation of alloantigen-specific Treg from the Treg 
pool. To our knowledge this is the first study that demonstrates an ex vivo protocol 
for induction, selection, and expansion of antigen-specific Treg from ex vivo cul-
tures conducted with freshly isolated CD4+CD25+ Treg. 
Recently, using conventional responder CD4+ T cells, a CFSE-cell sorter based ap-
proach proved successful to separate alloantigen-reactive and non-alloreactive T 
cells based on cell division 34.  The sorted divided CFSElow CD4+ population, in con-
trast to the non-dividing CFSEbright T cells, responded vigorously upon alloantigen 
rechallenge in a secondary MLC 34, indicating that the antigen-experienced primed T 
cells indeed resided in the dividing CFSElow population. We here demonstrate, that a 
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comparable approach permits isolation of potent alloantigen-specific Treg. More-
over, cell-sorter isolation based on CFSE intensity combined with the expression of 
CD27 enabled selection of antigen-specific CD27+ and CD27- Treg subsets, both of 
which are putative candidates for antigen-specific immunotherapy. 
F I G U R E  6  
Both CD27+Treg and CD27-Treg subsets suppress antigen experienced memory CD4+ T 
cells, whereas only CD27+Treg suppress ongoing T cell responses. 
A. Titrated amounts CD27+Treg and CD27-Treg 
subsets (X-axis, Log scale) were added at 
day 0, 2 or 3 of MLC consisting of a total of 
5x104 CD4+CD25- naïve original responder T 
cells and 5x104 γ-irradiated (30Gy) freshly 
isolated original stimulator cells. Relative 
suppression was calculated according to the 
following equation; %-suppression= (1- (3H-
incorporation co-culture/ 3H-incorporation 
control MLC) x 100%) and is expressed at 
the Y-axis. 
B. Titrated numbers of CD27+Treg and CD27-
Treg subsets (X-axis, Log scale) were added 
to MLC co-culture suppression assays con-
sisting of a total of 1x104 antigen experi-
enced memory CD4+ responder T cells, gen-
erated by repetitive target alloantigen-
specific stimulation of CD4+CD25- cells, and 
fresh γ-irradiated (30Gy) target alloantigen 
stimulator cells (5x104). CD27+CD4 and 
CD27+CD4 control cells were included. Prolif-
eration is shown at day 3 of the cultures. 
One representative experiment out of 3 is 
shown.  
 
The antigen-specific Treg subsets described in this studies showed highly potent 
suppressor-effector function, with 50% inhibition achieved at Treg:Tresp ratio’s of   
1:50 to 1:500  for CD27-Treg and CD27+Treg subsets, respectively. These effector-
suppressor effects are far more potent than what has previously been reported for 
either freshly isolated human CD4+CD25+ 15-17,35, CD4+CD25high Treg33  (50% inhi-
bition at Treg:Tresp ratio’s of 1:1 up to 1:10), or for large-scale polyclonally ex-
panded Treg (50% inhibition at Treg:Tresp ratio’s of 1:1 up to 1:32) 21,31.  
Our antigen-specific purification procedure includes multiple antigen-specific expan-
sion cycles. With each expansion cycle profound enhancement of effector-
suppressor potential occurred, which is best exemplified by a reduction in 50% in-
hibitory effector-target ratio’s of 1:5 for freshly isolated CD4+CD25+ Treg (data not 
shown), 1:20 after one allogeneic expansion cycle, up to 1:50-1:500 after 
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CD27/CFSE-based cell sorting and antigen-specific expansion.  Although an increase 
in suppressor potential can be the result of pre-activation 18,31, we here show that 
the enrichment and purification of target antigen-specific Treg strongly contributes 
to the formation of a highly potent effector-suppressor population. 
Very recently, Godfrey et al. 31 and Hoffmann et al. 21 demonstrated large-scale ex-
pansion (100-2800 fold expansion, respectively during a one month culture period) 
of freshly isolated human CD4+CD25+ Treg after polyclonal stimulation with bead-
coupled anti-CD3 and anti-CD28 in the presence of high dose IL-2. After expansion 
both groups found a CD62L+CD27+ CD4+CD25+ Treg population that expressed 
CTLA intracytoplasmatically. Interestingly, using our alloantigen-induced protocol 
and CD27/CFSE-based cell sorting approach we obtained 2 phenotypically distinct 
suppressive CD4+Treg subsets; being characterized as either CD27+CD25+CD70-
CD62L+CTLA4high or CD27-CD25-CD70+CD62L-CTLA4intermediate. Since the proce-
dures to isolate fresh CD4+CD25+ Treg, used in the studies of Godfrey and Hoff-
man were highly stringent 21,31, we wondered whether our standard isolation proce-
dure might explain the observed differences. To exclude this possibility, we 
conducted experiments starting with freshly isolated highly purified flowcytometry 
sorted CD4+CD25high Treg, after allogeneic stimulation in the presence IL-2+IL-15. 
Again both a CD27+Treg and a CD27-Treg subset were obtained (data not shown).  
Treg are not defined by CD25 expression per se. We here show that upon in vitro 
activation of freshly isolated naturally occurring Treg, next to a CD25+ population 
also a CD25- suppressive subset emerges. Also, in allograft tolerance 36 as well as 
in autoimmune 37 animal models, both CD4+CD25+ as well as  CD4+CD25- sup-
pressive Treg populations could be isolated. In vivo the CD4+CD25+ Treg appeared 
about 10 fold more potent than the CD4+CD25- Treg 36. For clarity, the CD4+CD25- 
subset only showed regulation when derived from tolerant animals after antigen ex-
perience 36. Also, in an in vivo experimental SCID model to study colitis both 
CD25+ and CD25-Treg protected mice from colitis and showed suppression in vitro; 
25+ Treg appeared 5 times more potent as compared to 25- Treg 38. In concert with 
these findings, in our study the CD25+ CD27+Treg subset was approximately 10 
times more potent in suppression than the CD25- CD27-Treg subset. Be that as it 
may, the fact that CD25- Treg proved suppressive in vivo also promotes the use of 
ex vivo generated alloantigen-specific CD25- CD27-Treg, next to, or in combination 
with CD25+ CD27+Treg for immunotherapy. 
The characteristic elevated level of CD27 expression crucially distinguished between 
alloantigen activated naturally occurring CD4+CD25+ Treg and activated 
CD4+CD25- T cell populations.  In contrast, such as reported previously 39, most of 
the freshly isolated CD4+CD25- T cells lost expression of CD27 upon stimulation. As 
the CD27+Treg population in particular showed extremely high suppressive potential, 
we here addressed the question of whether CD27 are required for effector-
suppressor function and showed that this is not the case.  Cellular interactions be-
tween CD27-CD70 are of importance in controlling expansion, survival, and/or ef-
ISOLATION  OF  ALLO-SPECIF IC  HUMAN REGULATORY  T CELLS 
 
 
169 
fector cell differentiation in T cell and B cell biology 40-42. Possibly, the expression 
of CD27 plays a role in homeostasis of CD27+Treg. 
CFSE-based cell selection requires a cell-sorter, which is not available in every 
laboratory. Therefore we analyzed the possibility of isolating the Treg subsets by 
virtue of their typical reciprocal expression of CD27high and CD70 by means of mag-
netic beads, which is available in many laboratories. To this end we first demon-
strated by using a cell sorter that Treg subset isolation solely based on CD27 ex-
pression pattern also resulted in antigen-specific CD27+Treg and CD27-Treg subsets. 
Cursory examination of a magnetic bead approach combined with anti-CD27 and 
anti-CD70 mAb also enabled purification CD27+Treg and CD27-Treg. However, to obtain 
pure cell populations the magnetic bead approach should be optimized. 
In transplantation, control of immunity by Treg likely takes place in the lymphoid 
organs 43 and at the graft site 44. Hence for successful Treg-cell therapy it is im-
perative that the ex vivo generated Treg migrate to these sites. The migratory 
properties of T cells are controlled by adhesion molecules such as CD62L integrin β1 
and β7 family members and chemokine receptors, like CCR7 45-47. These molecules 
mediate lymphocyte attachment to tissues and endothelial cells and promote 
transmigration to secondary lymphoid organs and extra vascular spaces 46,47. 
CD27+Treg expressed CD62L, the β1 (CD29) and β7 integrin family members, while 
the chemokine receptor CCR7 (data not shown) was only marginally expressed. CD27-
Treg were devoid of CD62L and CCR7, but did express high levels of β1 and β7 in-
tegrins. Although little is know about the in vivo trafficking characteristic of ex vivo 
generated Treg, the differences in Treg migration receptor pattern described in our 
study suggests that these cells might function at distinct sites. 
Summarizing, the efficacy of Treg-based immune therapy critically depends on anti-
gen-specificity of the Treg 13,14. Therefore we developed a CD27/CFSE cell sorter 
based ex vivo culture procedure to induce, select, and expand alloantigen-specific 
Treg starting with freshly isolated CD4+CD25+ Treg. This approach enabled selec-
tion and expansion of two highly suppressive subsets of multipotent alloantigen-
specific Treg. The availability of antigen-specific Treg subsets with high suppressor 
potential will likely reduce the total number cells needed for immunotherapy. This 
will facilitate the implementation of antigen-specific Treg therapy in transplantation, 
thereby guiding permanent graft survival, and even tolerance without the need for 
life-long non-specific immunosuppressive drugs 
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SUMMARY AND DISCUSSION 
8.1 General 
T cells play a crucial role in the rejection of transplanted cells and organs. Prevent-
ing these so called alloreactive T cells from responding determines the success of 
transplantation. Currently, immunosuppressive drugs are used in the clinic to inhibit 
the response of alloreactive T cells. Unfortunately, these immunosuppressive drugs 
also prevent mandatory T cell responses needed in case of invading pathogens and 
tumor cell development. Thus, these immunosuppressive agents act in a nonanti-
gen-specific way. The ultimate goal in transplantation research is the development 
of donor specific immunosuppressive therapies that will eventually result in toler-
ance for the allograft. Especially in rodent models various successful experimental 
approaches have been described leading to transplantation tolerance 1,2. The proc-
ess by which transplantation tolerance is established is a multiple step and multi-
faceted process that is still under investigation, which is often classified in two 
stages; an induction and a maintenance phase. Hence, immunological tolerance is 
most likely the result of early immunological mechanisms that facilitate graft accep-
tance as well as long-term mechanisms, which create an immunoregulatory state 
that actively opposes T cell mediated allograft immunity. There is accumulating evi-
dence that peripheral depletion of these aggressive alloreactive T cells is crucial in 
the induction phase of transplantation tolerance 3,4, while maintenance of peripheral 
transplantation tolerance is for large part regulated by self-perpetuating immu-
noregulatory mechanism such as regulatory T cells that keep allo aggressive T cells 
in check 3,5. 
It is very likely that the development of immunoregulatory mechanisms is an inte-
gral part of the (allo) immune response itself. This was exemplified by the genera-
tion of suppressor cells from animals that were rejecting their grafts, cells isolated 
from these animals and adoptively transferred to naïve animals prolonged graft sur-
vival 6. However, in most cases the development of immunoregulatory mechanisms 
will be dodged by the superior outgrowth of the high frequency of allo-aggressive T 
cells 7. This implies that for transplantation tolerance to settle, deliberate genera-
tion or facilitation in the immediate early phase of transplantation is needed in or-
der to shift the balance between allo-aggressive and immunoregulatory T cells. In a 
simplistic view immunosuppressive therapies aiming at the induction of transplanta-
tion tolerance should focus on a balance shift towards regulatory T cells (Treg).  
Such a condition might be reached by therapeutic interventions that selectively re-
duce the alloreactive effector T cell pool and / or that facilitate the allo specific Treg 
pool (Figure 1). Immunosuppressive drugs or costimulation blockade are well known 
for their inhibitory potential to prevent expansion of the allo-aggressive T 
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cell pool (Figure 1). In addition, some of these immunosuppressive agents led to 
cell death of the alloreactive T cell pool 3,4. These immunosuppressive protocol shift 
the balance towards functional dominance of the naturally occurring CD4+CD25 
Treg (Coenen et al, Transplantation 2004, in press). Alternatively, adoptive Treg 
cell therapy with ex vivo generated and expanded donor specific Treg might serve 
to create a balance shift towards Treg, thereby preventing the remaining alloreac-
tive T cells from rejecting the graft. Eventually this might result in transplantation 
tolerance. Evidence obtained in several animal models underlined the therapeutic 
potential of regulatory T cells 8-13. 
Currently it is recognized that Treg are particularly effective when they have speci-
ficity for their target antigen(s) 12,14-17. Hence, the availability of target antigen-
specific Treg is advantageous, as it not only appears highly effective, but also re-
duces the number of cells needed for immunotherapy. Hence, clinical therapy with 
Treg will require the ex vivo generation and expansion of sufficient numbers of an-
tigen-specific Treg with retention of their effector-suppressor function.  
 This thesis focuses on immunosuppression by costimulation blockade and the gen-
eration and expansion of donor specific Treg with the intention to be used as anti-
gen specific immunosuppressive tools in the induction and maintenance of clinical 
transplantation tolerance. 
F I G U R E  1  
Clinical transplantation tolerance might be established by therapeutic approaches 
that shift the balance between aggressive and immunosuppressive regulatory T cell 
towards immunoregulation. 
A balance shift towards Treg might be 
reached by immunotherapy with ex-vivo gen-
erated donor specific Treg and / or by inhib-
iting the clonal expansion of alloreactive ef-
fector T cells. Costimulation blockade 
inhibits the expansion of alloreactive effector 
T cells and facilitates the generation of Treg 
as well. 
 
Immunotherapy with ex vivo generated Treg. 
Recipient derived T cells are cultured with do-
nor-MHC expressing APC. In this way donor 
specific Treg are generated (see this thesis). 
These Treg are of potential interest for donor 
specific Treg immunotherapy at the time of 
transplantation. 
Costimulation blockade, 
Treatment with mAb directed against 
CD40 and CD86 or the anti-
CD40/CD86 fusion protein are poten-
tial tools to establish a balance shift  
towards Treg. (see this thesis) 
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Additionally, as new clinical therapeutic approaches will most likely be implemented 
in the presence of conventional immunosuppressive agents, the compatibility of 
currently used immunosuppressive drugs and costimulation blockade was subject of 
study. In fact, immunosuppressive drug might be needed early after transplantation 
to control the aggressive alloreactive T cell pool. 
 
8.2 Costimulation blockade mediated immunosuppression facilitates 
transplantation tolerance 
A productive T cell response requires both T cell receptor stimulation (signal 1) and 
costimulation via CD28-CD86/CD80 and the CD40L-CD40 costimulatory pathways 
(Signal 2). In the absence of the second signals, especially the lack of CD28 signal-
ing, T cells are hampered in their proliferative response and become anergic, a 
state of non responsiveness that plays an important role in transplantation toler-
ance 8,18. In addition, CD40 and CD40L mediated cell-contact between CD4+ and 
CD8+ T cells is important in the induction of cytolytic potential in activated CD8+ T 
cells. Likewise, we demonstrated that the inhibition of the CD40 and CD40L path-
way affects the induction of alloantigen specific cytotoxic CD8+ T cells 19 (Chapter 
2) and also facilitated the induction of Treg in animal models 20. Most importantly, 
we were able to show that costimulation blockade resulted in regulatory Treg that 
showed linked suppression of naive T cells after antigen specific TCR stimulation 
19(Chapter 2). Linked suppression is helpful in spreading of the non-
responsiveness and might contribute to the maintenance of a tolerance. In vivo, 
simultaneous blockade of both the CD28-CD80/CD86 and CD40L -CD40 pathways 
proved synergistic in preventing acute and chronic transplant rejection in rodent 
and non-human primate transplant models 4,21-24. Combined blockade of both 
costimulatory pathways at the time of transplantation reduced the alloreactive T-
cell pool, and in some studies donor specific tolerance was obtained 4,25-27.  
The success of this kind of therapy leans on two major pillars, specific reduction of 
the alloreactive T cell pool and facilitation the induction and establishment of anti-
gen specific Treg. 
 
8.3 The anti CD40-CD86 fusion protein 
From many experimental animal studies it is clear that combined blockade of both 
CD40-CD40L and CD80/CD86-CD28 co-stimulatory pathways provides better results 
than the separate components. We believe that clinical implementation of two sepa-
rate antagonist mAb, such as anti-CD40 and anti-CD86 mAb, for a single treatment 
is unattractive. It is highly unlikely that two experimental molecules (anti-CD40 and 
anti-CD86) that first have to be developed separately can be combined in clinical 
studies within the coming years. Since only the anti-CD40 mAb have been tested in 
phase I/II study in Chron’s disease, it will take many years to first obtain approval 
for the separate mAb, where after combination studies can only start. Therefore, we 
generated a single bi-specific anti-CD40/CD86 fusion protein that successfully com-
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bines the activity of the anti-CD86 and anti-40 mAb this. Most importantly this fu-
sion protein provides a direct and fast entrance into clinical transplantation (Chap-
ter 3). We demonstrated that like the combined use of anti-CD40 and anti-CD86 
mAb this fusion protein prevented both CD40 and CD86 mediated functional activ-
ity. Moreover it inhibited both clonal expansion of alloreactive T cells as well as the 
induction of alloreactive CD8+ T cells. Importantly the fusion protein induced aner-
gic antigen-specific regulatory T cells. All these features are crucial components in 
transplantation tolerance. As compared to the single use the anti-CD40 or anti-
CD86 mAb, the fusion protein showed an increased inhibitory potential. Therefore 
we propose that this fusion protein is of great value for fast clinical application in 
tolerance induction regimens that focus on the combined blockade of both CD40-
CD40L and CD86-CD28 pathway. As the fusion protein selectively blocks CD86, in 
contrast to CTLA4-Ig that blocks both CD80 and CD86, CD80 remains available for 
CTLA-4 signaling which provides inhibitory signals 28-31 and might be important for 
long term allograft survival and tolerance induction 32-34. 
 
8.4 Ex vivo expansion of Treg 
In recent years, various animal studies have indicated that immunotherapy by ex 
vivo induced Treg or ex vivo manipulated naturally occurring Treg might result in 
antigen specific immunosuppression and tolerance induction 10-13,35-37. For clinical 
Treg therapy with human immunosuppressive Treg, the expansion of these cells 
while preserving their (preferentially antigen specific) suppressive potential is a 
prerequisite 38. 
Most Treg, either induced or naturally occurring, are anergic by nature 39. T cell an-
ergy is defined as T cell (non)-hyporesponsiveness following antigenic stimulation, 
which is reversed upon antigenic stimulation in the presence of exogenously added 
IL-2 (19 and chapter 2). We and others demonstrated partial or complete reversal 
of anergy in case of induced and naturally occurring Treg in both mice and men af-
ter TCR stimulation in the presence of T cell growth factors (19,40-44 and chapters 
2,4 and 7). This implies that anergic Treg are expandable. Indeed, successful ex 
vivo expansion of human and mouse naturally occurring CD4+CD25+ Treg by TCR 
stimulation in the presence of T cell growth factors (TCGF) was demonstrated in our 
own laboratory (19,44 and Chapter 7) and that of others 12,42,43,45. In addition, we 
showed that TCGF expanded naturally occurring Treg become antigen adapted and 
thus resulted in donor antigen specific Treg (Chapter 7). These ex vivo expanded 
Treg retained their suppressor function 19,44 (Chapters 2, 5 and 7). Similar obser-
vations were made by others both in vitro 40,41,46,47 and in vivo 10-12. All together 
this implicates that anergic Treg are expandable without losing their functional 
characteristics (i.e. suppressive capacity, anergic state). In addition we propose 
that the antigen used in the expansion phase critically dictates the antigen specific-
ity of these ex vivo generated Treg. 
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The receptors for this TCGF cytokine family consist of three subunits, a cytokine 
specific α-chain, and a shared common β (CD122) and γ-chain (CD132) 48,49. In our 
experiments we observed that as compared to IL-2, especially IL-15 resulted in the 
optimal expansion of induced Treg. IL-15 resulted in enhanced survival that was 
paralleled by an increased expression of the anti-apoptotic molecule Bcl-2. More-
over, IL-15 induced a distinct type of anergy characterized by hyper-reactivity to 
IL-15, resulting in improved expansion. This is likely attributed to the increased 
propensity of the IL-15 expanded cells to up regulate both α and γ chain of the IL-2 
and IL-15 receptor 44 (Chapter 4). Moreover, the combined use of exogenously 
added IL-2 and IL-15, in the presence of antigen resulted in superior proliferation 
of freshly isolated naturally occurring CD4+CD25+ Treg 43 (Chapter 7).  
Next to the expansion of Treg by the addition of exogenous TCGF, Treg expansion 
was demonstrated by stimulation with DC and Toll-like receptor stimulation 50,51. 
High numbers of dendritic cells, in contrast to macrophages and B cells, were able 
to drive proliferation of freshly isolated CD4+CD25+ naturally occurring Treg in 
mice in the absence of exogenously added TCGF 50. After several cell cycles these 
cells still retained their suppressor function. Stimulation of TLR 4 resulted in en-
hanced survival and proliferation of CD4+CD25+ Treg and promotes their suppres-
sive function 51. 
 
8.5 Linked recognition and suppression by Treg 
Antigen specific immunosuppression and tolerance induction are important goals in 
both transplantation and autoimmunity. To fulfill this goal by Treg cell therapy, the 
ex vivo induction of antigen specific Treg is crucial. To secure antigen specificity, 
the CD4+ Treg described in this thesis were either generated by alloantigen stimu-
lation of CD4+ T cells in the absence of costimulation (so-called induced CD4+ 
Treg) or by alloantigen and TCGF activation of freshly isolated naturally occurring 
CD4+CD25+ Treg (Chapters 2, 4 and 7). The induction of immunosuppression by 
both types of Treg required alloantigen specific TcR triggering. This ensures that 
suppression only takes place when cognate antigen is present and, moreover, it 
prevents random suppression by the regulatory cells. Once suppression is activated 
in Treg they might suppress T cell responses directed against other antigens, a phe-
nomenon known as bystander suppression, which might largely contribute to immu-
nosuppression by Treg in vivo 41. In an in vivo transplantation setting the alloanti-
gens presented by the APC will activate the Treg and facilitate close contact 
between Treg and effector T cells. Effector T cells that recognize antigens other 
than those recognized by the Treg will also be suppressed via so called linked sup-
pression. Although it is likely that Treg suppress effector T cells directly, as sup-
pression was mediated in the absence of APC 52,53, they might in addition ‘tolerize’ 
the APC  54-56. In such a tolerogenic microenvironment it is likely that the Treg 
might transfer a suppressive state to conventional effector cells, a mechanism 
known as infectious tolerance 5,42,43,57. Importantly, together these mechanisms are 
C H A P T E R  8  
 
 
180
crucial in the maintenance of transplantation tolerance, which in all likelihood will 
represent a very local activity 58 that would not result in general immunosuppres-
sion such as is the case for immunosuppressive drugs.  
We showed that ex vivo induced donor specific human Treg mediated linked recog-
nition 19,44 (Chapters 2 and 4). We propose that upon adoptive transfer these Treg 
they might result in linked suppression and spreading of the suppressive state to 
the recipient’s alloreactive effector T cells 42,43 eventually resulting in the induction 
and maintenance of tolerance. Thus  these findings support the clinical use of allo-
antigen-specific Treg for antigen-specific immunosuppressive therapy.  
 
8.6.1 Conventional immunosuppressive drug do not induce T cell an-
ergy but instead permit memory T cell generation 
Guided by the success of currently used conventional immunosuppressive regimens, 
it is not very likely that new therapeutic protocols in transplantation, like costimula-
tion blockade or the adoptive transfer of ex vivo generated antigen specific Treg 
will be implemented in the complete absence of these drugs. Therefore we exam-
ined the effect of currently used immunosuppressive drugs like Cyclosporin A (CsA), 
tacrolimus (FK506) and rapamycin on anti-CD40 and anti-CD86 mediated immuno-
suppression and induction of T cell anergy. 
First, we focused on the in vitro effects the immunosuppressive drugs CsA, rapamy-
cin, and FK506 solely. As expected all these drugs strongly reduced the expansion 
of naïve T cells, while in addition rapamycin resulted in activation induced T cell 
death. Neither of the drugs resulted in T cell anergy, but instead memory T cell 
generation took place (Chapter 5). Combined use of rapamycin and FK506 or ra-
pamycin and CsA ameliorates the inhibitory potential of the drugs. Especially the 
combined use of FK506 and rapamycin resulted in superior immunosuppression 
(chapter 5). Combined drug use did not affect the apoptosis inducing potential of 
rapamycin. Like single drug use, combined drug treatment did not induce T cell an-
ergy but instead resulted in memory T cells. These in vitro findings support and ex-
plain successful experimental and clinical observation of combined FK506 and ra-
pamycin use 59,60. 
The fact that memory T cell generation was not affected by conventional immuno-
suppressive agents poses a risk for memory cell mediated graft rejection to take 
place. The presence of memory T cells interfered with transplantation tolerance in 
well-established animal tolerance induction protocols 61,62. Thus it is of importance 
to control these memory T cells. Memory T cell responses are efficiently prevented 
by the persistent presence of immunosuppressive drugs like CsA, FK506 or rapamy-
cin (data not shown). However it is unlikely that these drugs will result in trans-
plantation tolerance by the induction or facilitation of anergic Treg. Alternatively, 
memory effector T cell immunity in transplantation might be controlled by costimu-
latory blockade with anti-CD40 and anti-CD86 mAb (Figure 2) and/or by antigen 
specific Treg 44 (chapter 4 and 7). Costimulation blockade impaired memory T cell 
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responses (Figure 2) and moreover resulted in T cell anergy.  In addition, we pro-
vide evidence that ex vivo induced Treg also suppressed allogeneic memory CD4+ 
and/or CD8+ T cells responses in vitro (chapter 4 and 7). In general, the sup-
pression of memory T cell responses, as compared to suppression of naive T cell 
responses, required a higher number of Treg. Therefore we feel that in case of 
Treg-base immunotherapy it is of great importance to transfer sufficient Treg cell 
numbers in order to skew the immunological balance towards regulation. Additional 
costimulatory blockade might be helpful.  
F I G U R E  2  
Costimulation blockade inhibits memory T cell proliferation and induces anergy in 
alloreactive memory T cells 
Allogeneic memory CD4+ T cells were gener-
ated by allogeneic stimulation with irradiated 
PBMC in primary MLC. The activated cells 
were sorted and used as primed memory T 
cell in a restimulation experiment A. Res-
timulation cultures were performed in the 
absence (Control) or presence of anti-CD40 
and anti-CD-86 mAb (mAb). B. These cells 
were cultured for 7 days rested and the vi-
able cells were examined in a restimulation 
assay that was performed with allogeneic 
PBMC (Allo Ag) in the absence or presence of 
exogenous added IL-2 (10 U/ml). 
 
8.6.2 Conventional immunosuppressive drugs prevent T cell anergy 
induction via costimulation blockade 
In several experimental animal models conventional immunosuppressive drugs ab-
rogated the beneficial effect of costimulation blockade on allograft survival (Table 
1). As neither of these drugs induced T cell anergy (63, Chapter 5), we examined 
whether CsA, FK506 or rapamycin interfered in T cell anergy induced by costimula-
tion blockade with anti-CD40 and CD86 mAb. Concomitant costimulation 
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T A B L E  1  
Combined immunotherapy with costimulation blockade and immunosuppressive 
drugs. Animals were treated mAb against CD86, CD80, CD40ligand or CTLA-4Ig (CTLA4 fu-
sion protein that prevents interactions with both CD80 and CD86) to block the costimulatory 
pathway. Next to costimulation blockade, the additional use of conventional immunosuppres-
sive drugs was studied.  
Costimulatory blocking 
agent 
Transplant Drug Outcome 
Allograft survival 
Ref 
Mouse organ studies 
CTLA4-Ig + αCD40L mAb HCT  
Skin 
CsA Antagonism 21 
CTLA4-Ig Skin Rap 
CsA 
Synergism 
Synergism 
74 
HCT Rap No antagonism CTLA4-Ig + αCD40L mAb 
 CsA Antagonism 
4 
CTLA4-Ig + αCD40L mAb HCT  Rap 
CsA 
No antagonism 
Antagonism 
75 
HCT  Rap No antagonism 
 CsA Antagonism 
 MP Antagonism 
αCD40L + DST 
 MMF No antagonism 
76 
HCT Rap Synergism 77 CD40L mAb 
 CsA, FK506, 
αIL2r 
Antagonism **  
CTLA4-Ig HCT Rap CsA, 
FK506 
No antagonism 77 
Rat organ studies     
CTLA4-Ig HCT CsA No antagonism 78 
CTLA4-Ig HCT CsA Antagonism   79 
HCT 
Skin 
Rap Synergism CTLA4-Ig 
 CsA Synergism, over Rap 
80 
αCD40L mAb HCT CsA Synergism, **** 81 
Non human primate organ studies 
Kidney FK506 Antagonism αCD40L mAb 
 MMF + 
MP***  
Antagonism  
82 
αCD80 + αCD86 mAb Kidney CsA 
Steroids, MP 
No antagonism 
No antagonism 
83 
Mouse bone marrow transplantation / Mixed chimerism studies 
BMT 
Skin 
Rap Synergism αCD40L mAb 
 CsA No antagonism 
84 
CTLA4-Ig + αCD40L mAb BMT Rap, MP, 
FTY720, MMF 
CsA, FK506 
No antagonism 
Antagonism 
85 
**  At multiple anti CD40L doses no antagonism 
***  Corticosteroids Metylprednisolone Prednisone 
**** Transplantation tolerance 
Heterotopic cardiac transplantation (HCT), Bone marrow transplantation (BMT). 
SUMMARY  & DISCUSSION   
 
 
183 
blockade and treatment with any of these immunosuppressive drugs caused near 
total immunosuppression of human T cells that was characterized by the lack of 
proliferation and cytokine production (e.g. IL-2, IFNγ and IL-10). In addition we 
showed that  
these drugs prevented the induction of T cell anergy (Chapter 7) . In contrast to, 
CsA and FK506, rapamycin facilitated the T cell apoptosis. Apparently the induction 
of anergy, which requires early T cell signaling events 64-67, is prevented by the ac-
tion of these immunosuppressive agents. Therefore we investigated whether prior 
to the administration of immunosuppressive agents an immunological time frame is 
required to establish T cell anergy. Induction of T cell anergy by anti-CD40 and 
anti-CD86 mAb needed approximately 5 days of in vitro culture. Addition of CsA, as 
opposed to the use of rapamycin and FK506, after induction of T cell anergy did not 
abrogate the anergic state. These data strongly support the Window of opportunity 
for immunological engagement (WOFIE)-hypothesis of Calne 68, which states that 
immunological engagement of donor MHC and recipient T cells is required in the 
early post transplantation period to actively induce transplantation tolerance 69. 
Thus timing and selection of immunosuppressive regimen is crucial in the outcome 
of T cell anergy. 
 
8.7 Naturally occurring CD4+CD25+ Treg, induction and selection of 
alloantigen-specific Treg. 
Naturally occurring CD4+CD25+ are important for homeostasis of the immune sys-
tem and are of great interest for Treg therapy in transplantation 39, autoimmunity 
39,70 and allergy 71. Human naturally occurring CD4+CD25+ are anergic and show 
cell-cell contact dependent suppressive capacity upon TCR stimulation. Naturally 
occurring CD4+CD25+ Treg facilitate T cell anergy induction in CD4+CD25- T cells 
as well as the induction of Treg by costimulation blockade in mice 53,72. We demon-
strated that the induction of human CD4+ Treg by costimulation blockade also re-
quired the presence of naturally occurring Treg 44(Chapter 4).  
Infusion of either freshly isolated or ex vivo antigen adapted naturally occurring 
CD4+CD25+ Treg prevented GVHD after BMT in mice 10-13. Interestingly in a recent 
report, it was shown that naturally occurring Treg specifically prevented CD4+ 
driven GVHD while leaving the CD8 mediated graft-versus-tumor response intact 13. 
These groundbreaking studies are at the base for clinical adoptive Treg cell therapy 
in transplantation. Of great interest is the recent observation that the success of 
Treg-based immunotherapy in vivo in both transplantation and autoimmunity mod-
els critically depends on the antigen-specificity of the Treg. 12,14-17,73. Therefore, 
clinical Treg-based therapy would be further energized by the availability of anti-
gen-specific Treg. Selection and ex vivo expansion of adapted Treg would be a pre 
in Treg therapy. For selection of Treg subsets we believe it is crucial to recognize 
that the naturally occurring CD4+CD25+ Treg population is heterogeneous.  
In chapter 7 we describe an ex vivo CFSE cell sorter based isolation method for 
human alloantigen-specific Treg. To this end, freshly isolated CD4+CD25+ Treg 
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were labeled with CFSE and stimulated with (target) alloantigen and IL-2+IL-15. 
The alloantigen-reactive dividing Treg were characterized by low CFSE content and 
could be subdivided by virtue of CD27 expression. CD27/CFSE cell sorter based se-
lection of CD27+ and CD27- cells resulted in two highly suppressive antigen-specific 
Treg subsets. Each subset suppressed naïve and antigen-experienced memory T-
cells, and importantly, CD27+Treg also suppressed ongoing T-cell responses. Thus, 
this isolation procedure enables induction, expansion, and especially selection of 
highly suppressive antigen-specific Treg subsets, which are crucial in antigen-
specific Treg-based immunotherapy. 
 
8.8 Synthesis 
First of all we demonstrated that costimulation blockade resulted in a donor specific 
Treg-pool. We showed that this could be achieved by either two separate mAb 
against CD86 and CD40, but also with a biochemically constructed anti-CD40/CD86-
fusion protein. We were able to select and expand the Treg and showed that after 
expansion these Treg retained their functional suppressive properties. 
Since clinical implementation of Treg will likely take place under the cover of cur-
rently used immunosuppressive drugs we evaluated the effects of rapamycin, FK506 
and CsA on costimulation blockade induced anergic Treg. First we showed that in 
our human in vitro model these drugs do not result in T cell anergy, but instead al-
lowed activation that results in the generation of memory T cells.  Next, we found 
that these immunosuppressive agents abrogated the induction of T cell anergy via 
costimulation blockade. However, when anergy was established, prior to drug treat-
ment, CsA, in contrast to FK506 or rapamycin, left the anergic state intact. With 
respect to clinical implementation of costimulation blockade strategies to induce 
transplantation tolerance, these findings imply that first a window for immunologi-
cal tolerance induction should be established before immunosuppressive drug 
treatment is started. 
Next, we showed that human naturally occurring CD4+CD25+ Treg were required in 
the induction of anergic regulatory T cells by costimulation blockade. This prompted 
us to study the induction of antigen-specific Treg using human naturally occurring 
CD4+CD25+ Treg subset in detail. To induce, select, and expand alloantigen-
specific Treg starting with freshly isolated CD4+CD25+ Treg we developed a 
CD27/CFSE cell sorter based ex vivo culture procedure. This approach enabled se-
lection and expansion of two highly suppressive subsets of multipotent alloantigen-
specific Treg. The availability of antigen-specific Treg subsets with high suppressor 
potential will likely reduce the total number cells needed for immunotherapy. This 
will facilitate the implementation of antigen-specific Treg therapy in transplantation, 
thereby guiding permanent graft survival, and even tolerance without the need for 
life-long non-specific immunosuppressive drugs 
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Transplantatie van een donor orgaan of weefsels is vaak de laatste mogelijkheid om 
een falend orgaan of andere ernstige aandoening te genezen. Het grote probleem 
bij donor orgaan transplantatie is de afstotingsreactie door het immuun systeem 
van de ontvanger.  
Bij de afstoting van een getransplanteerd orgaan spelen met name witte bloedcellen 
zoals T en B lymfocyten (T cel en B cel) een belangrijke rol. Hoewel antilichaam 
producerende B cellen zeker een rol spelen in transplantatie, richten de studies in 
dit proefschrift zich met name op T cellen.  
T cellen hebben een sturende rol in de immunologische afstoting van een getrans-
planteerd orgaan. Er bestaan verschillende groepen effector T cellen;  T helper cel-
len (CD4+ T cel) bieden hulp aan de verschillende onderdelen van  afweersysteem  
en cytotoxische T cellen (CD8+) die het ware toxisch zijn en het donor orgaan di-
rect aanvallen. Lijnrecht tegenover de effector cellen staan de immunoregulatoire 
suppressor T cellen die ervoor zorg dragen dat immuunreacties door bijvoorbeeld de 
effector T cellen niet uit de hand lopen. In dit proefschrift staan de suppressor T 
cellen centraal. 
Ontvanger T cellen worden geactiveerd door weefselantigen, de zogenaamde ‘Hu-
man Leucocyte Antigens” HLA-moleculen, die aanwezig zijn op het donor orgaan. T 
cellen die reageren op HLA-moleculen van een ander individu worden allo-reactieve 
T cellen genoemd. Iedere persoon heeft een bepaalde HLA typering, hoe beter de 
ontvanger en de donor qua HLA typering op elkaar lijken des te kleiner is de kans 
op een immuunrespons door de ontvanger. De T cellen van de ontvanger herkennen 
de donor HLA-moleculen met hun T cel receptor. Deze eerste herkenning (Signaal 
1) zet de T cel op scherp, volgen er na deze eerst herkenning costimulatoire signa-
len (Signaal 2) dan zal de T cel compleet geactiveerd raken en vervolgens gaan de-
len en functioneel actief worden.  
Vandaag de dag worden organen zoals donor nieren met redelijk groot succes ge-
transplanteerd. Dit succes is met name te danken aan de ontwikkeling van immuno-
suppressieve medicijnen die in de meeste gevallen de celdeling van allo-reactieve T 
cellen remmen. Helaas werken de meeste immunosuppressiva niet-specifiek en on-
derdrukken zij ook T cel immuun responsen die gericht zijn tegen pathogenen zoals 
virussen. Daarnaast vertoont de overgrote meerderheid van de immunosuppressiva 
nadelige bijwerkingen, zoals nierschade, bloeddruk problemen en een verhoogd risi-
co op het ontwikkelen van tumoren. Het is dus van cruciaal belang een immunosup-
pressieve therapie te ontwikkelen die donor (HLA) specifiek is en waarbij zo weinig 
mogelijk of liefst geen immunosuppressieve medicijnen meer nodig zijn. Indien 
transplantatie van een donor orgaan kan worden bewerkstelligd in complete afwe-
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zigheid van immunosuppressieve medicijnen, is er sprake van transplantatie tole-
rantie. 
Transplantatie tolerantie wordt voor een belangrijk deel bepaald door de balans 
tussen agressieve alloreactieve T cellen en alloreactieve suppressor T cellen. Teveel 
agressieve effector T cellen zal leiden tot transplantaat afstoting. Voldoende sup-
pressor T cellen daar in tegen, verhoogd de kans op transplantatie tolerantie. Mani-
pulatie van de balans tussen effector T cellen suppressor T cellen is dan ook van 
groot belang bij de ontwikkeling van nieuwe immunosuppressieve therapieën die er 
op gericht zijn donor specifiek transplantaat tolerantie te bewerkstelligen.  
Het algemene uitgangspunt in het huidige proefschrift is een omslag in de balans 
tussen agressieve en suppressor T cel populaties te genereren zodat transplantatie 
tolerantie kan ontstaan. Dit zou enerzijds kunnen plaats vinden door de activatie en 
groei van de effector T cellen te remmen en anderzijds door het aantal suppressor T 
cellen te verhogen via immuun celtherapie met suppressor cellen die in het labora-
torium gekweekt zijn. Dit laatste betekent dat er voorafgaand aan de transplanta-
tie, in het laboratorium en dus buiten het lichaam (ex-vivo),  immunoregulatoire 
suppressor T cellen gegenereerd moeten worden die afkomstig zijn van de ontvan-
ger en die hun remmende werking alleen kunnen uit oefenen indien zij in contact 
komen donor HLA-moleculen. Het genereren van ontvanger immunoregulatoire T 
cellen die specifiek HLA moleculen herkennen van de donor, zogenaamde donor 
specifiek regulatoire T cellen staat centraal in dit proefschrift.  Het ligt voor de 
hand dat de klinische toepassing van regulatoire T cellen grote hoeveelheden cellen 
vereist, en het is dus van belang dat deze in het laboratorium gemaakt en opge-
kweekt kunnen worden. Daarnaast zal de klinische toepassing van dit soort nieuwe 
cellulaire therapieën gestart worden in aanwezigheid van bestaande immunosup-
pressieve protocollen, om elk risico op transplantaat afstoting te voorkomen. Daar-
om zijn  in dit proefschrift de volgende vragen gesteld; I.) is het mogelijk  om sup-
pressor cellen ex vivo te laten expanderen met behoud van donor-specifieke 
suppressor functie en II.) hebben immunosuppressieve drugs een effect op regula-
toire T cellen. 
Hoofdstuk 2 beschrijft zowel de reductie van alloreactieve effector cellen alsmede 
de inductie  van regulatoire suppressor T cellen. Met behulp van antilichamen ge-
richt tegen costimulatoire moleculen CD40 en CD86 wordt voorkomen dat T cellen 
het zogenaamde signaal 2 ontvangen. Het gevolg is dat effector T cellen niet goed 
kunnen groeien en er geen cytotoxische T cellen geïnduceerd worden. Bovendien, 
leidt de costimulatoire blokkade tot regulatoire T cellen. Deze regulatoire T cellen 
vertonen geen groei na activatie, echter wanneer er groeifactoren zoals interleuki-
ne(IL)-2 worden toegevoegd dan zijn deze cellen wel instaat tot groei. Deze eigen-
schap wordt aangeduid als T cel anergie en speelt een belangrijke rol bij transplan-
tatie tolerantie. Daarnaast remmen deze cellen groei van effector T cellen, en 
kunnen dus beschouwd worden als suppressor cel. Dus, door costimulatie blokkade 
wordt de balans tussen effector en suppressor T cellen zodanig gewijzigd dat deze 
doorslaat richting suppressor cel. 
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Het gebruik van meerdere antilichamen tegelijkertijd voor één klinische toepassing 
is niet erg aantrekkelijk omdat er voor iedere component afzonderlijk tijdrovende 
en kostbare primaten studies noodzakelijk zijn. Bovendien dienen dit soort studies 
ook uitgevoerd toe worden voor de combinatie therapie. Voor een snelle klinische 
introductie van een costimulatie blokkade protocol waarin zowel CD40 en CD86 de 
therapeutisch target zijn, is de biochemische constructie van een fusie-eiwit dat de 
eigenschappen van zowel het anti-CD40 en anti-CD86 mAb herbergt een pre. In 
hoofdstuk 3 wordt de constructie en functie van een CD40/CD86 fusie-eiwit be-
schreven. Dit fusie-eiwit bleek functioneel vergelijkbaar met het effect dat  de twee 
gecombineerde antilichamen vertonen. Het is te verwachten dat dit CD40/CD86 fu-
sie-eiwit de klinische introductie van een gecombineerd anti-CD40 en anti-CD86 
therapie bespoedigt. 
Hoofdstuk 4 beschrijft de ex-vivo expansie (groei) van regulatoire CD4+ T cellen 
die zijn geïnduceerd door costimulatie blokkade. Met name is het verschil tussen de 
groeifactoren IL-2 en IL-15 is bestudeerd. IL-15 bleek superieur; IL-15 resulteerde 
in een betere groei van de regulatoire T cellen die bovendien een hoger suppressie-
ve capaciteit vertoonde dan wanneer IL-2 werd gebruikt. De toename in groei door 
IL-15 was te verklaren door een verhoogde celdeling en overlevings capaciteit. IL-
15 is dus een potentiële groeifactor in de ex-vivo expansie van regulatoire T cellen 
voor toekomstig regulatoire T cel immunotherapie in transplantatie.  
Hoofdstuk 6 beschrijft het effect dat hedendaags klinisch gebruikte immunosup-
pressieve drugs hebben op immunoregulatoire T cellen die geïnduceerd zijn met 
costimulatie blokkade. Ten eerst werd het immunosuppressieve effect van de drugs 
rapamycine, cyclosporine A (CsA) en Tacrolimus (FK506) alleen of in combinatie ge-
evalueerd in het door ons gebruikte experimentele systeem (hoofdstuk 5). Geen 
van deze drugs resulteerde in T cel anergie. Vervolgens hebben we uitgezocht of 
het mogelijk is T cel anergie te induceren door costimulatie blokkade in aanwezig-
heid van de genoemde immunosuppressiva. Geen van de  bestudeerde drugs staan 
de inductie van T cel anergie door costimulatie blokkade toe. Het is dus belangrijk 
om eerst T cel anergie te induceren alvorens de behandeling met drugs te starten. 
In het laatste geval bleek alleen CsA de T cel anergie ongemoeid te laten.  
Met het oog op klinische gebruik van costimulatie blokkade om transplantatie tole-
rantie te induceren is het van groot belang het gebruik van conventionele immuno-
suppressiva uit te stellen zodat de inductie van tolerantie eerst plaats kan vinden. 
Bovendien blijkt het type drug bepalend of T cel anergie gehandhaafd blijft. 
Het T cel immuunsysteem wordt in balans gehouden door een juiste verhouding 
tussen effector T cellen en natuurlijk voorkomende regulatoire CD4+CD25+ sup-
pressor T cellen. (CD4+CD25+ Treg). Deze natuurlijk voorkomende CD4+CD25+ 
Treg bleken cruciaal in het genereren van regulatoire T cellen door costimulatie 
blokkade (Hoofdstuk 5).  
In hoofdstuk 7 laten we zien dat de natuurlijk voorkomende CD4+CD25+ Treg bij 
uitstek geschikt zijn voor ex-vivo manipulatie en voor toekomstig gebruik als donor 
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specifieke immunotherapie. Activatie van vers geïsoleerde CD4+CD25+ regulatoire 
T cellen afkomstig van de ontvanger met donor HLA-moleculen en T cel groeifacto-
ren leidt er toe dat de CD4+CD25+ Treg die het donor HLA-molecuul herkennen 
specifiek gaan groeien. Er treed dus expansie en selectie op van donor(HLA)-
specifieke CD4+CD25+ Treg. Wij hebben een methode ontwikkeld om donor(HLA)-
specifieke regulatoire T cellen te isoleren en te expanderen. Tijdens het ontwikkelen 
van deze methode kwamen we tot de ontdekking dat er twee duidelijke verschillen-
de subsets van regulatoire T cellen aanwezig zijn die te onderscheiden zijn door de 
aan- of afwezigheid van CD27 oppervlakte marker.  Hoewel beide regulatoire sub-
sets hoge suppressieve capaciteit hebben bleken met name de CD27+ regulatoire 
cellen heel erg krachtig, terwijl de CD27- subset een betere groei capaciteit heeft. 
De mogelijkheid om donorspecifieke regulatoire T cellen te isoleren is van groot be-
lang voor donorspecifieke immunotherapie met regulatoire T cellen.  
De generatie, selectie en expansie van immunosuppressieve regulatoire T cellen zo-
als beschreven in dit proefschrift, is een eerste stap op weg naar een donorspecifie-
ke regulatoire T cel gemedieerde immunotherapie. Hopelijk zal het gebruik een der-
gelijke donorspecifieke therapie er toe leiden dat het levens lange gebruik van 
aspecifieke immunosuppressieve drugs kan worden verminderd, en indien er sprake 
is van transplantatie tolerantie kan worden gestopt. 
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